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ABSTRACT OF DISSERTATION

UNDERSTANDING ABSORPTION, SUPERSATURATION, AND DRUG
ACTIVITY IN SOLUTION: WORKING TOWARDS DEVELOPING A MORE
BIORELEVANT MEDIA
With the looming dominance of poorly water-soluble chemical entities within the
pharmaceutical pipeline, the pharmaceutical industry has leaned on the use of supersaturating drug delivery systems (SDDSs) to achieve efficacious concentrations within
the gastrointestinal fluids. SDDSs aim to achieve concentrations in solutions greater
than the solubility of the lowest energy crystalline form. However, the generation of
supersaturated solutions of active pharmaceutical ingredients (APIs) creates a strong
crystallization potential, which is undesirable.
In product development, supersaturating products often fail in Phase I and Phase
II clinical trials due to poor oral bioavailability and a lack of in-vivo efficacy. Preclinical testing exists as a filter for product failures; regardless, product failures still
occur in the clinical stage of product development leading to delays or cancellations
of novel treatments. This disconnect between pre-clinical performance testing and
in-vivo outcomes highlights the lack of understanding of the in-vivo oral absorption
process of APIs from supersaturated solutions. The pharmaceutical industry would
greatly benefit from identifying critical factors associated with the safe and efficacious
delivery of pharmaceutical products to patients in need.
Currently, in-vitro dissolution testing remains the most commonly used technique
to evaluate product performance. One salient variable to dissolution testing is the
dissolution media itself. Maintenance of supersaturation is believed to be part of
the complex mechanism by which SDDSs enhance the oral bioavailability of poorly
soluble drugs. Studies have shown that the dissolution of SDDS is highly dependent
on the media used. The implications of endogenous materials such as bile acids and
phospholipids on oral absorption have been studied and accounted for in commercial
formulations of simulated gastrointestinal (GI) fluids. However, the impact of mucin,
the main glycoprotein in mucus, in solution has been neglected, which results in
studying product performance without fully characterizing all the variables.
Mucin is the main component of mucus gels lining the entirety of the gastrointestinal tract, and significant quantities are expected to be found within GI fluids.

Several recent studies have shown the impact of mucin on the permeation of lipophilic
compounds, indicating the potential for interactions with such molecules. Therefore,
it is expected mucin may stabilize supersaturated solutions of poorly water-soluble
compounds via similar interactions.
Overall, this dissertation aims to probe the impact of mucin as a solution component capable of stabilizing supersaturation:
1. The inclusion of mucin into in-vitro media to achieve an improved biorelevance
is explored and evaluated as a potential reason as to why the in-vitro dissolution
characteristics of ketoconazole do not match that within in-vivo systems. The
sensitivity of the in-vitro examination method to seed crystals is also evaluated
as a potential confounding factor in in-vitro examinations.
2. A 17β-Estradiol (E2) and polysorbate 80 (PS80) micelle system was used to
probe the increases in permeability to the diffusion of nano-scale particles through
the aqueous boundary layer (ABL). Coupled with diffusion coefficient determination of a model nano-scale species via NMR, a mathematical model was
developed to accurately predict the permeability increases due to increases in
effective diffusivity due to the nano-scale shuttling of E2 through the ABL.
3. The ability of mucin to stabilize supersaturated solutions is evaluated in the
context of its ability to reduce the thermodynamic activity, or the driving force
for crystallization, of several model drugs: 17β-estradiol, nifedipine, and bicalutamide. The flux of these model drug compounds is evaluated in the absence
and presence of mucin using horizontal diffusion cells. A decrease in the flux of
API in the systems containing mucin relative to the systems in the absence of
mucin indicates a reduction of thermodynamic drug activity.
KEYWORDS: Supersaturation, Absorption, Particle-Drift, Mucin, Speciation,
Poorly-water soluble drugs
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Chapter 1
Introduction: Fundamental Thermodynamics of Supersaturated Solutions

The growing prevalence of poorly-soluble drug candidates within the pharmaceutical
pipeline, where current estimates cite that as many as 70% of new chemical entities
(NCEs) in the pharmaceutical development pipeline are characterized as Biopharmaceutics Classification System (BCS) Class II compounds [6, 7], necessitates the development of a deep understanding of the solution-state properties of supersaturated
solutions. When delivered orally, drug molecules must first dissolve within the gastrointestinal environment for permeation and absorption to occur [8]. Unfortunately,
BCS Class II or more specifically, drugs characterized as having a poor aqueous solubility and high permeability characteristics in its most stable crystalline form, lack
a strong driving force for absorption [9, 10, 11]. Traditionally, the development of
BCS class II compounds has been a risky undertaking due to the recurrent drop-outs
of such compounds during development due to the inability to achieve efficacious
exposures in vivo [12].
With the development of of modern supersaturating drug delivery systems (SDDSs)
such as cocrystals [13, 14, 15, 16, 17], inclusion complexes [18, 19, 20], lipid formulations [21, 22], and amorphous solid dispersions [23, 24, 25, 26] it is possible to achieve
concentrations in solution significantly surpassing that of the solubility of the most
stable crystalline form. Thus the developability of such compounds becomes feasible
as the dose/solubility ratio is decreased (Figure 1.1). However, the maintenance of
supersaturation becomes a task that is difficult to predict, especially in the in-vivo
system.
The overall objective of the work presented within this dissertation is to present
a comprehensive overview of recent advances in the understanding of the underlying
mechanisms of the physical stability of supersaturated solutions. An in-depth discus-
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Figure 1.1: The Developability Classification System. NCEs residing in the green
area are unlikely to exhibit major oral bioavailability issues, and have the best devlopability potential. As we move closer towards the red region, compounds begin to
exhibit higher Dose-Solubilty ratios and lower permeability values, leading to poor
development potential in the most stable crystalline form. Those in the yellow region
may exhibit dissolution rate limited bioavailability, which can often be compensated
by particle size reduction. Those situated in the red area are solubility limited and
generally require SDDS such as co-crystallization, amorphous solid dispersions or lipid
formulations.
sion of nucleation, crystal growth, and solution-state speciation in the presence and
absence of specific solution components will be separately and systemically evaluated.
Additionally, novel technologies and theories in the field of supersaturation stability
in solutions incorporating mucin will also be discussed. Furthermore, we will also
highlight the influence of nano-scale speciation on the permeability and absorption of
APIs.
1.1

Solubility

Solubility is a phase equilibrium in which the chemical potential (µ) of each component is equal, where in equilibrium conditions the chemical potential of the active
Xtal
pharmaceutical ingredient (API) in solution (µsoln
AP I ) and in the crystalline solid (µAP I )

2

are equivalent [1].
precipitation

ÐÐÐÐÐÐÐ⇀ µXtal
µsoln
AP I ↽ÐÐÐÐÐÐ
AP I
dissolution
Upon the dissolution of an oral drug product, three potential scenarios may occur:

A. Undersaturation

Xtal
µsoln
AP I < µAP I

B. Saturation

Xtal
µsoln
AP I = µAP I

C. Supersaturation

Xtal
µsoln
AP I > µAP I

In the under-saturated case (A) the solution still has the capacity to solubilize the
API as the chemical potential of the API in solution is less than that of the crystalline
solid. The system attempts to reach equilibrium by dissolving more of the crystalline
solid into solution. This condition is often targeted for dissolution limited products
and formulators introduce solubilizing or complexing agents to reduce the chemical
potential of the API in solution so as to drive dissolution.
1.1.1

Crystalline Solubility

The crystalline solubility of an API is often defined as the thermodynamic equilibrium
between the crystalline solid and the solvent media [1]. In that case, within an ideal
solution, the partial molar free energy of both the crystalline solid (GXtal
AP I )and the
dissolved solute (Gsoln
AP I ) within the saturated media must be equivalent.

soln
GXtal
AP I = GAP I

(1.1)

The dissolution process can be described as the sequential disruption of the crystal
lattice and mixing of solutes within the solvent [1]. However, to describe the system

3

at equilibrium the free energy of the API is considered to be the sum of the free
energy of a supercooled liquid of the API and the free energy associated with mixing
of the API within the solvent. To this end, the following equation can be defined

SCL
mix
∆Gsoln
AP I = ∆GAP I + ∆GAP I

(1.2)

In general, the Gibbs free energy (∆G) can be described as a sum of its enthalpic
and entropic contributions:

∆Gi = ∆Hi − T ∆Si

(1.3)

where ∆Hi is the enthalpy of species i, ∆Si is the entropy of mixing of species i,
and T is temperature. The solubility of a crystalline solid is strongly dependent on the
physiochemical properties of the crystalline material to be dissolved. Physiochemical
properties such as melting temperature and the ability of the crystalline solid to
interact with the solution are often of primary importance.
With the mixing of the dissolved API throughout the solution, the entropy is
always expected to increase as the dissolution and mixing process allows for greater
volumes accessible to the solute and solvent. The entropy of mixing of an ideal
solution for two components, API (solute) and B (solvent) can be written as:

∆Ssoln = ∆Smix = −R(xAP I ln xAP I + xB ln xB )

(1.4)

where R is the universal gas constant and xAP I and xB are the mole fractions
of solute and solvent, respectively. Due to the non-unity values of mole fractions,
both terms in right-most side of Eq. 1.4 are expected to be negative, leading to
positive entropic values. In regular solutions where the API is solvated, the entropic
contributions are often similar to what is observed in ideal solutions. However, in
certain cases there may be an increase in the order of molecules in solutions compared
4

to ideal solutions as the solvation process maximizes the enthalpic interactions and
creates a certain degree of ordering of API and solvent molecules. Therefore, a reduced
entropy of mixing can be observed compared to that of an ideal mixture.
In ideal mixing conditions (∆Hmix = 0), the Gibbs free energy of mixing can be
described as:

∆Gideal
mix = −T ∆Smix = RT (xA ln xA + xB ln xB )

(1.5)

The partial molar free energy of mixing of the solute with an ideal solvent is given
by

∆Gideal
mix,A = RT ln(xA )

(1.6)

Substituting Eq. 1.6 into Eq. 1.2 gives

SCL
∆Gsoln
AP I = ∆GAP I + RT ln xAP I

(1.7)

Inserting Eq. 1.7 into Eq 1.1 and rearranging gives

R ln xAP I =

GSCL ∆Gm
GXtal
AP I
− AP I =
T
T
T

(1.8)

where ∆Gm represents the free energy difference associated with the disruption of
the solid API crystal lattice
Differentiating Eq. 1.8 with respect to xAP I and applying the Gibbs-Helmholtz
equation
δ(∆Gm /T ) −∆Hm
=
δT
T2

5

(1.9)

results in the following equation
δR ln xAP I −∆Hm
=
δT
T2

(@T )

(1.10)

The enthalpic contributions of solubilization on Gibbs free energy are expressed
as:

∆Hsoln = ∆Hf + ∆Hmix

(1.11)

where ∆Hf represents the enthalpic energy required to break intermolecular bonds
within the crystal lattice, and ∆Hmix represents the enthalpy of mixing that is associated with the interaction between the solute and solvent molecules. The enthalpy
of mixing is attributed to the relative strength of interactions between solute-solute,
solvent-solvent, and solute-solvent molecules. In cases where the solute-solute &
solvent-solvent interactions are more preferable than solvent-solute interactions, a
positive enthalpy of mixing (∆Hmix > 0) is observed. In cases where the solute-solvent
interactions are preferred over the solute-solute & solvent-solvent interactions, a negative enthalpy (∆Hmix < 0) of mixing is observed. In an ideal solution, there is no
preference in interaction and the enthalpy of mixing is zero (∆Hmix = 0)
For simplicity the ideal solution is considered, leading to the following equation:

∆Hsoln = ∆Hf

(1.12)

The dissolution of a crystal requires the disruption of the crystal lattice via interactions between the solute and solvent. According to Kirchoff’s Law, the enthalpy of
an irreversible process such as the disruption of the crystal lattice at temperature T
can be described as the sum of the enthalpies of three reversible processes: (1) heating of the solid to its melting temperature, Tm , (2) melting the solid at its melting
point, and cooling down the liquid back to its original temperature T (Figure 1.2).
6
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Figure 1.2: Energetics of the conversion of a solid to a hypothetical liquid. Adapted
from Ref [1]
Representing that summation as a function of the heat capacities CpC & CpL of the
solid and liquid, respectively the following equation is obtained:

@T
= −CpC (Tm − T ) + ∆Hm + CpL (Tm − T )
∆Hm

(1.13)

where the first term in that equation, −CpC (Tm − T ), is the enthalpy used during
heating of the crystal, ∆Hm is the enthalpy used during the melting process, and
CpL (Tm − T ) is the enthalpy released while cooling the melt.
The version of the Gibbs-Helmholtz equation presented in Eq. 1.10 relates the
change in the Gibbs Energy, or in this case the solubility, as a function of temperature.
Integrating Eq. 1.10 with respect to R ln XAP I yields Eq. 1.14

R ln

Xtal
T −∆H @T
XAP
m
I
ideal
=
R
ln
X
=
δT
∫T
AP I
L
2
T
XAP
m
I

(1.14)

which describes the crystalline solubility as the mole fractional solubility ratio of
Xtal
L
the crystalline solid (XAP
I ) and the liquid (XAP I ). Since an ideal solution is assumed

in the derivation of Eq. 1.14 the mole fractional solubility ratio of the crystalline solid
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ideal
and the liquid solute, this ratio is often referred to as the ideal solubility (XAP
I ).

Combining Eqs. 1.13 & 1.14 and integrating yields

ideal
R ln XAP
I = −∆Hm

Tm − T
Tm
Tm
Tm − T
Tm − T
− CpC
+ CpC ln
+ CpL
− CpL ln
Tm T
T
T
T
T

(1.15)

which describes the ideal solubility as a function of temperature and the heat capacities, CpC & CpL , of the crystalline solid and liquid forms of the solute, respectively.
Simplifying Eq. 1.15 yields

ideal
R ln XAP
I = −∆Hm

Tm − T
Tm − T
Tm
− ∆Cpm
− ∆Cpm ln
Tm T
T
T

(1.16)

where ∆Cpm represents the heat capacity difference between the solid and liquid
forms of the solute.
Most pharmaceutical systems, however, exhibit non-ideal behavior. In non-ideal
solutions, the solute-solute, solute-solvent and solvent-solvent bond energies are not
identical. Under these conditions, the solute properties are influenced by interactions
with the solvent. In non-ideal conditions, the enthalpy of mixing is non-zero and
to account for this difference, a correction factor, γ, is incorporated. The activity
coefficient, γ, is a unitless number that reflects the non-ideality of mixing.

ideal
R ln XAP
I = −∆Hm

Tm − T
Tm
Tm − T
− ∆Cpm
− ∆Cpm ln
− ln γ
Tm T
T
T

(1.17)

It is to be noted that true equilibrium is only achieved when the dissolved API is in
equilibrium with the most stable crystalline form of the API. Many pharmaceutical
compounds exhibit crystalline polymorphism which may impact the solubility observed [27]; however the solubility of higher energy polymorphs are often metastable
and will, over time, tend towards the lowest energy crystalline form [28]. The topics
of polymorphism, solvates, and hydrates are out of the scope of this project and the
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interested reader is referred to the following reviews [29, 30, 31].
1.1.2

Supersaturation

Often the goal with poorly water-soluble drugs of substantial lipophilic character
is to increase the amount of freely-soluble drug molecules in solution relative to its
crystalline solubility. By exceeding the chemical potential of the API in solution
Xtal
relative to the chemical potential of the most stable crystalline solid (µsoln
AP I > µAP I ),

one obtains a supersaturated solution. The chemical potential of a substance can be
defined in terms of the drug’s activity, ai

µi = µ0i + RT ln ai

(1.18)

ai = γi Ci

(1.19)

where activity is defined as

By combining Equations 1.18 & 1.19 we get the following equation describing the
fundamental supersaturation within a supersaturated solution

∆µAP I

S
γAP
CAP I
aSAP I
= −RT ln C = −RT ln C I
aAP I
γAP I Ceq

(1.20)

where R is the gas constant, T is temperature, aSAP I and aC
AP I are the activities
S
C
of drug in the supersaturated state and equilibrated states, γAP
I and γAP I are the

activity coefficients in the supersaturated and equilibrated states, C is the concentration of drug in solution, and Ceq is the equilibrium solubility of the drug in a given
media.
As supersaturation is often defined relative to the saturated solution, the concentration of drug within a supersaturated solution is often simply expressed as a
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supersaturation ratio (SR)

SR =

soln
γAP
I ⋅ CAP I
Xtal
γAP
I ⋅ Seq

(1.21)

However, as most pharmaceutical solutions exhibit non-ideal behavior, care must
be taken when defining supersaturation simply as the ratio of the amount of solubilized drug in solution and the crystalline solubility. True supersaturation is a function
of the activity of drug in solution and not the total amount of drug solubilized in solution. Therefore, activity coefficients must be considered as is shown in Eq. 1.21.
1.1.2.1

Amorphous Solubility.— There exists an upper limit to supersaturation, the

amorphous solubility limit, whereby any successive addition of solute into solution
yields the formation of solute-rich and solvent-rich phases [24, 32, 33, 34]. Due to
the poorly soluble nature of many of the lipophilic compounds designated for development within supersaturating formulations, the upper limit of supersaturation
becomes significant, as it defines the maximum activity of the API in solution. By
understanding the amorphous solubility, coupled with the crystalline solubility, formulators can understand how much supersaturation is possible which then informs
the design space possible for supersaturating formulations. Therefore, it has become
critical to quantitatively predict and measure the amorphous solubility of a drug
candidate.
Several authors have explored the energetics advantage of amorphous material over
its crystalline solids; however, Murdande et al. were one of the first to most closely
predict the amorphous solubility in aqueous solutions [32]. The equation defined by
Murdande et al. is as follows

CAmorphous = Ceq ⋅ exp [−I(a2 )] ⋅ exp (

∆Gc→a
)
RT

(1.22)

where Camorphous is the amorphous solubility, Ceq is the crystalline solubility,
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∆Gc→a is the free energy difference between the crystalline and amorphous forms,
and I(a2 ) is the activity of the amorphous solid saturated with water, which can be
estimated from water sorption isotherm data.
The estimation of amorphous solubility using Eq. 1.22 has been shown to accurately predict experimentally determined amorphous solubility values with an narrow
error range [32]. Several groups have made slight refinements to the amorphous solubility equation first proposed by Hancock and Parks [24]; however, following the
introduction of the I(a2 ) term by Murdande et al. minimal improvements to predictions have been made. Most of the error in the amorphous solubility calculations
have been largely attributed to the error in determining ∆Gc→a [35].
1.2

Crystallization & Phase Separation

A supersaturated system is a system which is not in equilibrium. In supersaturated
systems the chemical potential of the API in solution exceeds the chemical potential
of the most stable crystalline form.

Xtal
µsoln
AP I > µAP I

To achieve equilibrium, several phase transformations can take place; however,
the most common phase transformation for supersaturated solutions is crystallization.
Crystallization is the process by which molecules localize and organize to form clusters
or nuclei, and the molecules within nuclei contain a long range order composed of
a repeating unit structure [27]. Following the formation of such crystalline nuclei,
subsequent molecules can integrate within the crystalline lattice formed by nuclei
leading to crystal growth. A supersaturated solution will proceed to crystallize until
equilibrium is achieved.
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However, not all degrees of supersaturation are the same, as it has been observed that some supersaturated systems in the absence of nuclei do not crystallize.
Therefore, there exists a certain region where supersaturation is a metastable state,
as shown in Figure 1.3. This indicates that nucleation is a pre-requisite for crystallization. Therefore the crystallization process can be separated into two distinct
processes: nucleation and crystal growth.
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Figure 1.3: A) Solubility-Supersolubility diagram. B)Concentration vs. time profile of a hypothetical dissolving solute resulting in supersaturation and consequent
crystallization. The line with points labelled A-D in the Solubility-Supersolubility
diagram corresponds to concentrations in the Concentration versus time profile in
(B).

1.2.1

Nucleation Theories

There is a strong desire within the pharmaceutical industry to control the crystallization process such that crystal properties such as crystal structure, shape, and size
distribution can be designed. Since nucleation is a prerequisite for crystallization,
understanding the nucleation process has become a focal point for understanding
crystal properties, such as crystal structure and size distribution. Many theoretical
models have been proposed to describe the nucleation process; however, an accurate
12

understanding of the process is lacking, with most crystallization design being done
on an empirical level.
The difficulty of studying and understanding nucleation stems from the lack of
high-resolution techniques to characterize nuclei, as nuclei range from 100-1000 atoms
in size [2]. Furthermore, nuclei are transient species which rapidly form and re-dissolve
in solution. Due to the miniscule size and extremely short lifetimes of nuclei, their
structures may not be easily characterized. The lack of concrete characterization of
nuclei, have led many to propose several theoretical models of nuclei formation along
with the energetics associated with nuclei formation.
1.2.1.1

Classical Nucleation.— The main tenant of the classical nucleation theory

(CNT) is that all molecules within a nucleus are organized within a crystalline lattice
upon its formation [2]. It is the simplest and oldest accepted working theory of
nucleation. According to the theory, there exist two free energy contributions to the
nucleation process, surface free energy (∆GS ) and volume free energy (∆GV ) (Figure
1.4). The surface free energy is defined as the energy penalty due to the formation
of a new phase; it is typically a positive value and is proportional to surface area of
clusters. Volume free energy is the decrease in free energy due to the formation of
a growing cluster and is the main driving force for nucleation. Volume free energy
is also defined as a function of the degree of supersaturation present in the system.
Assuming spherical clusters, the sum of the two free energies can be described as
∆Gnuc = − (

4πrp3
) kB T ln(SR) + 4πrp2 σ
3vm

(1.23)

where rp is the radius of the cluster, vm is the molecular volume, and σ is the
surface energy. The first term represents the volume free energy contributions and
the second term represents the surface energy contributions.
As shown in Figure 2, the formation of a nucleus is a kinetic process whereby a
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Figure 1.4: Free energy diagram associated with the homogeneous nucleation of a
sphere of radius r
free energy barrier must be overcome prior to the formation of crystals. To determine
the magnitude of the free energy barrier the derivative of Equation 1.6 can be taken
with respect to rp and solved for rp when ∆Gnuc is at a maximum. Upon solving, the
following equations describing the critical size of a nucleus (rcrit ) and the free energy
barrier (∆Gcn ) are obtained.

r∗ =

∆G∗ =

2σvm
kB T ln (SR)

(1.24)

2
16πσ 3 vm
3 [kB T ln (SR)]

(1.25)

The utility of the CNT is that it approaches the nucleation process through a
thermodynamic perspective accounting for macroscopic properties of the solution.
According to the CNT, the primary nucleation rate per volume per time (J) can be
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expressed as

J=

2
dNn
16πσ 3 vm
= A exp
3
2
dt
3 [kB T ] ln (SR)

(1.26)

where Nn is the number of nuclei per unit volume and A is a pre-exponential
factor accounting for the rate of attachment of molecules to the critical nucleus.
The above equation describes homogeneous nucleation, or spontaneous formation
of nuclei in solution. However, in most cases heterogeneous nucleation, or nucleation
on surfaces, is most common and relevant for pharmaceutical systems. According
to the CNT, an apparent surface energy term, σ ′ , is introduced to account for the
difference in surface energy giving

J=

3
2
16 π σhet
vm
dNn
= A exp
3
2
dt
3 [kB T ] ln (SR)

(1.27)

The limitations of classical nucleation theory have been widely reported by several
authors, and many cite its inability to predict the kinetics of crystallization processes
as it major limitation [2, 36, 37]. Recent innovations in analytical high-throughput
methods have given researchers the ability to more accurately measure nucleation
rates of chemical species in a controlled environment [38]. As a result, many authors
are beginning to argue that nucleation is not properly rationalized using a one-step
classical theory mechanism, and a two-step nucleation mechanism may better rationalize the nucleation process.
1.2.1.2

Two-Stage Nucleation.— Contrary to the CNT, the Two-Stage Nucleation

theory posits that the phase separation of supersaturated solutions into locallized
clusters devoid of long-range order occurs prior to the formation of crystal nuclei
[2, 37, 38]. The two-step nucleation mechanism is described as having drug molecules
proceed through three distinct states: 1) a homogeneous solution, 2) high density
clusters, and 3) ordered crystalline phases (Figure 1.5). The transitions between
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states 1 & 2 and 2 & 3 are described by kinetic rate constants k1 and k2 , respectively.
As with kinetic processes, each transition is defined by a free energy barrier of its
own. Where ∆G0C represents the transition between 1 & 2 and ∆G∗2 represents the
transition between states 2 & 3. The two-step nucleation method has been shown to
accurately describe the nucleation process for several proteins and has been proposed
to be applicable to organic molecules as well [39]. The two-step mechanism model
as derived by Vekilov, still incorporates thermodynamics properties of the system,
but the model is extended to incorporate thermodynamic variables describing each of
the different states [40]. The two-step nucleation model describing the rate of nuclei
formation (J) as derived by Vekilov is as follows
∆G∗

J=

k2 C1 T exp(− kB T2 )

(1.28)

∆G0

η1 (C1 , T )[1 + UU01 exp( kB TC )]

where C1 is the concentration of the crystallizing solute in the high-density cluster phase, η1 is the viscosity of the solution within the clusters,

U1
U0

is the ratio of

the temperature-independent rate constants for the forward and reverse transitions

Two-Step
Nucleation Model

k1

k2

Classical
Nucleation Theory
(CNT)

kG

knuc

Figure 1.5: Schematic highlighting the framework behind the two-step nucleation
model and the classical nucleation theory. Adpated from Ref. [2]
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between states 1 & 2.
Several groups have reported an improved accordance of experimental observations with the two-stage nucleation model when compared to the CNT [41, 42, 43].
With more modern and high-resolution experimental methods, it was found that
the isolation of high density clusters, was better achieved with more complex and
higher molecular weight molecules as the transition to the organized crystals was
rate-limiting due to the high degree of conformational flexibility [42]. This observation supported the two-step model and showed that, in some cases, the organization
step of high-density clusters is rate-limiting.
1.2.2

Crystal Growth Theories

Crystal growth only can occur in the presence of a crystal nuclei substrate. There
exist many proposed mechanisms for crystal growth; however, adsorption layer theories have become the most widely accepted theories describing how crystals grow
in solution [44, 43]. The adsorption layer theories suggest that adsorption of solute
molecules onto the crystal face occurs in a layer by layer process following the formation of a stable crystal nucleus. However, the process by which those layers form are
less agreed upon, as two competing theories (1) step-growth and (2) birth and spread
have been proposed as plausible mechanisms for crystal growth.
In the step-growth theory, molecules are proposed to attach at the highest energy
"kink" sites, and continue in a linear step-wise fashion, forming monoatomic layers
along the crystal face [45]. The birth and spread mechanism proposes that nuclei form
at the edges or randomly along the crystal faces, creating kink sites, and monolayer
growth proceeds radially across the surface of the crystal from the nuclei [46]. The
kink sites are preferred sites of integration within the crystal lattice as they provide
attaching molecules with a greater number of bonds to neighboring molecules than
if they were to attach anywhere else along the crystal. However, from the molecules
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contained within the crystal lattice, molecules at kink sites are more likely to redissolve. The kink density, or the amount of kinks present per unit length is often
a main driver for the crystal growth rate. As a result, the crystal growth rate can
be modified by either blocking kink sites or by creating new kinks [47]. Figure 1.6
illustrates the integration process.
(b)

(a)

Figure 1.6: Schematics demonstrating the a) step-growth and b) birth and spread
mechanisms of crystal growth
Although there may be two differing mechanisms proposed, the overall kinetics of
the rate of crystal growth (RG ) can be described using the following equation [44]:

RG = kG A(Cb − C ∗ )g

(1.29)

where kG is the growth rate coefficient, A is the crystal surface area, Cb is the
bulk concentration, C ∗ is the crystalline solubility, and g is the overall growth order.
In cases where the diffusivity of the drug molecule in aqueous media is much
smaller than that of the rate of the integration of molecules within the crystal lattice
Equation 1.29 can be simplified to

RG = kd A(Cb − CI )

(1.30)

where kd is the diffusion-limited growth rate coefficient, A is the crystal surface
area, CI is the concentration at the crystal-liquid interface.
Crystal growth is the result of two sequential processes, (1) the diffusion of drug
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to the crystal surface and (2) the integration of the drug into the crystal lattice. In
certain cases, it is possible that the rate of integration within the crystal lattice outpaces that of the diffusion of drug molecules from the bulk solution to the crystal
surface, resulting in a diffusion-limited crystal growth process. Furthermore, a concentration gradient can develop, which results in a lower concentration of drug found
at the crystal-water interface than in the bulk solution.
1.2.3

Spinodal Decomposition

In certain cases, phase separation can occur as a result of spinodal decomposition.
This is often the case for complex molecules where entropic constraints can limit the
rate of crystal formation [48]. Spinodal decomposition is the spontaneous separation
of a solution of two or more components into two distinct phases without nucleation.
The two resulting phases are distinguished by differing chemical compositions and

µW

Metastable

Spinodal
Decomposition

µAPI

ΔGmix

Metastable

µ*API

µ*W

physical properties.

API

XAPI-W

X*API-W

X*W-API

XW-API

W

Figure 1.7: Free energy of mixing as function of the composition of two liquids with
a miscibility gap. API represents the drug and W represents water
A free energy of mixing (∆Gmix ) versus composition diagram is presented in
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Figure 1.7 for two partially miscible liquids. The extremes of the x-axis represent
pure API as a supercooled liquid (API) and pure water (W). Minima in ∆Gmix
is observed at compositions of XAP I−W or XW −AP I . These minima in ∆Gmix are
called binodal points or concentrations of coexistence as the chemical potential of
both species are equivalent in at each composition. Mixing of solution components is
thermodynamically favored up until the compositions denoted by the binodal points.
Any further addition of API or water into the solution to generate compositions
between the binodes are considered to be thermodynamically metastable, and the
decomposition into two phases, a drug-rich phase and drug-lean phase, will only
occur following the nucleation and growth of the new phase.
Spinodal decomposition occurs when solutions are sufficiently supersaturated.
This phenomenon occurs when the composition of the solution exceeds the inflection
2

Gmix
= 0) between the binodes in the ∆Gmix versus composition diagram.
points ( δ δX
2

These points of inflection are called the spinodal points, beyond which the the solution
will spontaneously and uniformly phase separate without the formation of nuclei.
Some examples of spinodal decomposition with pharmaceutical relevance is the
formation of liquid droplets at high supersaturation levels [33, 49, 50, 51, 52]. Several authors have observed the formation of non-crystalline nanoparticles following
the introduction of highly concentrated solutions of organic compounds into aqueous
media [33, 49, 50]. Leading some to propose that the amorphous nanoparticles were
formed by the spinodal decomposition of the solution into drug-rich and drug-lean
phases due to the rapid change of solution composition following the introduction of
the highly-concentrated solution. The process of liquid-liquid phase separation has
been closely tied to the definition of amorphous solubility as the spinodal point represents an equilibrium point between the two phases below which one phase exists
and above which two phases develop [51, 52]. However, it is expected that the introduction of more components into solution will impact the composition of phases and
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the free-energies associated with those phases [48, 53].
Impact of Solution Contents on Drug Solubilization

1.3.1

Apparent Solubility

Species

Sum of Concentrations

Micelle-Bound
Drug

Neutral

Unbound Neutral
Drug

Unbound

Unbound Charged
Drug

Unbound + Micelle-bound

Drug-Rich Colloids

Apparent Concentration

Undissolved Solids

Dose Concentration

1.3

Figure 1.8: Description of potential drug species in solution contributing to the total
apparent solubility in solution. Adapted from Ref [3]
The solubility of an API represents the maximum amount of dissolved API in a
given solvent in the presence of a crystalline solid. The solubility is a consequence
of the thermodynamic equilibrium between the crystalline solid and unbound drug
in solution. This solubility value is a constant for a given solvent and temperature,
and only represents the dissolved mass attributed to the unbound neutral drug. An
apparent increase in the solubility of an API can be observed due to ionization,
binding to proteins, or complexation with other solution components [1]. That is, an
API may exist in solution as distinct species (i.e. neutral, ionized, micelle bound, and
complexed API).
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The total dissolved mass of an API in solution can be described as a sum of the
total component species:
Ns

Mj = ∑ Aij Xij

(1.31)

j=1

where Aij is the stoichiometric coefficient yielding the number of moles of component j in species i; Xij is the activity of the species i of component j; and Ns is the
number of API species present in solution. This impact of speciation on the apparent
solubility of an API in solution is highlighted in Figure 1.8.
1.3.2

Thermodynamic Drug Activity

Ultimately, it is the freely dissolved or unbound neutral drug that drives the absorption and precipitation processes for aqueous systems, and the introduction of
solubilizing species into solution may reduce the amount of drug available for absorption or precipitation. The unbound neutral drug is often defined as the drug’s
thermodynamic activity (α). Rather than develop complex filtration or separation
methods to determine α or unbound drug concentration in solutions containing solubilizing excipients, it is simpler to determine thermodynamic drug activity, α, via
flux measurements [54, 55]. The thermodynamic drug activity, α, is expressed in
concentration units and represents the reduced chemical potential of the API in the
presence of solubilizing species. The activity of an API is related to the total API
concentration in solution via a proportionality constant termed the activity coefficent,
γ. The activity coefficient of component j is defined as the ratio of the activity of the
component, to its mole fraction solubilized in solution [54, 56].

γj =

αj
Xj

(1.32)

Therefore, in the absence of speciation to forms other than unbound neutral drug,
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the activity of a component will be equivalent to its mole fraction solubilized yielding
an activity coefficient of unity. However, through ionization or the inclusion of solubilizing solution components the activity of a component will be less than its mole
fraction, yielding a γ < 1.
1.3.3

Complexation and Its Effect on Activity

A variety of formulation excipients can be utilized to increase the solubilizing capacity
for a specific drug compound. A majority of the techniques rely on the formation of
complexes. Complexes are distinct solution species composed of a substrate and a
ligand joined via relatively weak intermolecular forces such as hydrogen bonds, van
der Waals forces, electrostatic interactions, dipole interactions, or hydrophobic interactions [1]. Some of the most common complexes are inclusion complexes such
as cyclodextrin, whereby the small molecules are often stabilized in the cavity of
supramolecular cyclic structures. However, complexes can be the result of the partitioning of drugs into aggregates of molecular additives [1]. Examples of such aggregates include micelles [1], polymeric aggregates[25], and surfactant and polymeric
aggregates (i.e., beaded-necklace model) [57, 58, 59]. All of which can potentially
increase the apparent solubility of a drug molecule in solution, however, the thermodynamic activity may be detrimentally impacted.
Gastrointestinal fluids have been observed to solubilize larger amounts of drug
when compared to purely aqueous media [60, 61]. The presence of solubilizing species
such as bile acids, lipids, and proteins within the human gastrointestinal (GI) fluids
provide GI fluids with a greater solubilizing capacity than would be observed in
simple aqueous buffers [62]. Therefore, complexes may inherently exist in solution
when examining the thermodynamic activity of drugs within the GI fluids.
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1.4

Impact of Solution Contents on Nucleation of Crystals

Classical nucleation theory can not predict the the effect of solution components on
nucleation rates, and the ability of solution components to inhibit nucleation has been
highly contested although there has been evidence to support the nucleation inhibition capabilities of certain solution components [38, 63, 64]. The two-step nucleation
process, however, provides a framework to understand the potential influence that
solution components may have on the rate of nucleation. Work by Pons Siepermann
et al., evaluated the nucleation of 3-nitrophenol in the presence of a dilute weakly
hydrogen-bonding solute, 3-aminobenzoic acid [38]. It was observed that in the presence of the weakly hydrogen-bonding solute that the nucleation induction times, or
the time to which a nuclei is detected, is prolonged in the presence of the additive.
Similar observations have been made in the systems containing complexing agents
[65]. Using the framework for nucleation outlined by the two-step nucleation model,
it is expected that additives with sufficient interaction strength can interact with
the concentrated clusters and limit the mobility of the supersaturated solute. This
reduction of mobility limits the rate to which the supersaturated solute reorganizes
within the clusters to form a crystal lattice. Although most of the work examining the
impact of solution additives on nucleation have been conducted using small molecule
additives it is expected that the similar effects can be seen with larger molecular additives such as polymers. Recent work by Lu et al. demonstrated the propensity of
bile salts found naturally in gastrointestinal fluids in reducing the rate of nucleation
of telaprevir [66]. Interestingly, different bile salts exhibited different extents of nucleation inhibition of telaprevir, which could be dependent on the types of interactions
between the bile salt and drug molecule.
Not all additives, however, increase supersaturation stability. Molecules with amphiphilic characteristics have been observed to increase the rate for nucleation [67].
This has been hypothesized to be a result of the decrease in solution surface tension,
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leading to a reduced free energy barrier to the formation of crystal surfaces. According to Eq. 1.25 the free energy barrier to nucleation is directly proportional to surface
tension to the third power. Therefore, small changes in surface tension can dramatically impact the nucleation rate. Surfactants are often used as formulation excipients
to improve processing and care must be taken to understand how such excipients may
impact the crystallization propensity of products where supersaturation is important.
1.5

Impact of Solution Contents on Crystal Growth

The stabilization of supersaturated solutions can be accomplished through the introduction of polymeric additives as crystal growth inhibitors [68, 69]. This is caused by
the ability of certain polymers to adsorb onto crystal faces and slowing the integration
of further molecules within the crystal lattice. However, the extent a certain polymer
may adsorb onto a crystal depends on the physiochemical properties of the API and
polymer [68].
Adsorption is an entropically unfavored process, as polymers within solution become constrained to crystal surfaces thereby reducing the degrees of freedom available
to it. However, it is possible that the enthalpic contributions derived from replacing
the solvation shell may sufficiently reduce free energy and lead to spontaneous adsorption, as polymers may interact with the crystal surface via electrostatic, hydrophobic,
and hydrogen bonding interactions [70]. Overall, the crystal adsorption process is a
balance between the polymer-solvent and polymer-crystal interactions. A more effective crystal adsorption process is achieved when the polymer-crystal interactions
are favored over polymer-solvent interactions. In this case, a free energy minima is
achieved through the replacement of high-energy polymer solvent interactions with
polymer-crystal interactions.
A polymer’s effectiveness in inhibiting crystal growth is more than whether or not
the adsorption process is favorable, as it also depends on its ability to completely
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completely cover the surface of the crystal [71, 72]. Work by Ilevbare et al. and
Schram et al. have shown that the most effective polymers exhibited mild hydrophobic
character, where polymers at the extremes of the hydrophobicity spectrum, exhibited
weak crystal growth inhibition characteristics [68, 73]. It is likely that hydrophilic
polymers will prefer solubilization within the aqueous media, yielding minimal crystal
surface adsorption. However, the introduction of extremely hydrophobic polymers
into aqueous media would result in the formation of dense globules or aggregates. It
is likely that these globules form as a result of the polymer achieving a conformation
that minimizes the interaction with the surrounding aqueous environment. Therefore,
all of the hydrophobic moieties in the polymer structure would most likely be hidden
from interacting with the crystal surface. Further investigations of this conformation
effect by Ilevbare et al. demonstrated an increased polymer effectiveness in polymers
which were in a more extended conformation in solution [72]. Interestingly, it was
found that conformation plays a stronger role than the degree of adsorption as it
was found that for the same polymer system, a greater effectiveness was observed in
an extended conformation even though the condensed conformation adsorbed to a
greater degree. Similar observations were made by Schram et al. where more crystal
surface coverage was observed via AFM in conditions that yielded polymers in a more
extended conformation [71].
1.5.1

Endogenous Material

The ability to inhibit crystal growth is not reserved solely for polymers, as it has
been found that certain bile salts, found naturally within the human gastrointestinal
fluids, may also inhibit crystal growth [74, 66, 75]. Work by Chen et al. was one of the
first examinations of monomeric bile acids and their effectiveness in crystallization
inhibition [74]. At surfactant concentrations below the CMC, sodium taurocholate
(STC) was noted to slow down solution crystallization of a group of structurally
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diverse active pharmaceutical ingredients (APIs). Two other bile salts, sodium glycocholate (SGC) and sodium glycodeoxycholate (SGDC), were also revealed to be
effective crystallization inhibitors for celecoxib and nevirapine in monomer form.
Further examination of a series of different bile salts at a concentration below their
CMC in supersaturated solutions of a variety of different compounds found that most
bile salts are capable of inhibiting crystallization [66, 75]. However, the extent of
inhibition varied amongst the bile salts, indicating the absence of interchangeability
in the context of crystallization inhibition. Zeta potential analyses were performed
on seed crystals of telaprevir in the absence and presence of several bile acids below
their CMC, and it was found that the addition of bile salts lead to the development
of an increased negative charge of about 5-6 fold [75]. Since bile salts are negatively
charged at neutral pH it is suggested that this change in zeta potential may be due
to the adsorption of bile salts onto the surfaces of seed crystals.
1.6

Implication of Speciation on Permeation

1.6.1

Barriers to Absorption

Bulk Fluid

1.17 mm

Water Boundary Layer

0.285 mm

Loosely Adhered Mucus

0.015 mm

Firmly Adhered Mucus

ABL

Epithelial Cells

Figure 1.9: Schematic highlighting the in-vivo barriers to absorption. The mucus
layer is often assumed to be an Aqueous Boundary Layer (ABL) due to mucus’s 95
wt% composition of water
The desire to increase the solubility of poorly-soluble drug compounds or maintain supersaturation stems from the need for increased exposure within the systemic
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circulation. However, the human body has developed a series of barriers to control
the body’s exposure to environmental toxins and pathogens [76, 77]. A schematic of
the barriers found within the GI lumen is highlighted in Figure 1.9. There exists two
distinct mucin layers, a firmly and loosely adhered mucus layer. The firmly adhered
mucus layer contains mucin glycoproteins which are anchored into the cell membranes
of the epithelial layer. Although there has been limited literature evaluating the impact of the mucus layers on permeability, the mucus layer is often assumed to be an
aqueous boundary layer (ABL) due to mucus’s 95 wt% composition of water [78].
A main issue with poorly water-soluble drugs is that they tend to have strong
lipophilic character. Due to this lipophilic character the membrane transport often
outpaces the solution transport of drug to membrane surfaces. This difference in
transport rates results in the formation of a concentration gradient from the bulk
solution to the membrane surface, where the thickness of the concentration gradient
depends on the hydrodynamic conditions of the system.
1.6.2

Permeability

The mass transport of an API across a boundary can be described by Fick’s first law
of diffusion, where the flux (J) of an API through the gastrointestinal (GI) lumen
depends on the permeability coefficient (P ) of the API through the GI wall and
the activity (aAP I ) of the API in solution within the luminal side of the GI tract
(assuming sink conditions)[79]:

J = P ∗ aAP I

(1.33)

This relation demonstrates the impact of increasing API supersaturation, where
the diffusive flux of the API increases linearly with increasing supersaturation. The
permeability coefficient defined in Eq. 1.33 is often defined as an effective permeability or the sum of permeabilities, when considering complex barriers with multiple
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layers with distinct physiochemical properties. However the main barrier separating
the gastrointestinal lumen from the systemic circulation is the epithelial cell layer.
Drug molecules may either permeate through the spacing between cells (paracellular
transport), which is typically reserved for more hydrophilic molecules, or through the
cells themselves (transcellular transport) [78]. For most poorly water-soluble drug
compounds, transcellular transport is the primary mode of absorption through the
gastrointestinal lining.
Permeability is the inverse of the resistivity to transport, which means that since
paracellular and transcellular transport are parallel processes we are able to sum the
two permeabilities to get an overall epithelial permeability. Same considerations can
be placed on diffusional and water convection transport through the ABL; however,
since permeation through the ABL and epithelial cell lining occur in series, their reciprocals must be summed to get the inverse of the effective permeability. The following
equation can be used to describe the effective permeability of the gastrointestinal
barrier:

Pef f =

PE
1
Ppara +Ptrans

1
+ PABL

(1.34)

where Ppara , Ptrans , and PABL are the permeabilities through the paracellular &
transcellular routes, and the ABL. The values of Ppara & Ptrans are often experimentally determined or estimated using empirical equations correlating observed permeability in cell monolayers or artificial membranes.
In cases where a solid membrane is used, Eq. 1.34 becomes

Pef f =

PE
1
Pmem + 2 PABL
1

(1.35)

where Pmem represents the permeability of the species of interest across a given
membrane.
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1.6.3

Particle-Drift Effect

For BCS Class II compounds, characterized by poor aqueous solubility and high
lipophilic permeability, permeability through the aqueous boundary layer (ABL) is
often the rate-limiting step for absorption. Due to the high lipophilic permeability
of BCS Class II compounds, membrane transport often outpaces the solution transport of drug to membrane surfaces. This difference in transport rates results in the
formation of a concentration gradient from the bulk solution to the membrane surface, where the thickness of the concentration gradient depends on the hydrodynamic
conditions of the system. However, it has been reported that the addition of micelles
may improve the overall mass transport of drug molecules across the ABL, resulting in
increased local drug activity at the membrane surface [80, 81, 82, 83, 84]. Similar observations have been made in systems containing other colloidal species [3, 85, 86] and
in systems containing an excess of crystalline drug [87]. The term “particle-drifting”,
coined by Sugano, describes this phenomenon in systems containing excess nanocrystalline particles drifting into the mucus and water boundary layers[87]. However,
the term particle-drifting is often used more generally to the describe the drifting of
all sub-micron particles crystalline or non-crystalline.
ABL

ABL

Bulk Fluid

Membrane

Bulk Fluid

API-Loaded Micelle
Freely Dissolved API Molecule

Figure 1.10: Schematic demonstrating the horizontal diffusion cell setup used for flux
experiments
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1.6.3.1

Mathematical Models Accounting for Particle-Drifting.— If we consider an

experimental setup similar to that of Figure 1.10, the effective permeability, Pef f , can
be expressed as a function of two components: membrane (Pmem ) and ABL (PABL )
permeability. From Figure 1b, it is apparent that unbound drug must first traverse
one ABL and subsequently cross the membrane and ABL on the opposite side. For
simplicity, it is assumed that the ABLs on either side of the membrane are equivalent.
Since these events occur in series, the equivalent permeability is equal to the inverse
of the sum of the reciprocal permeabilities, as shown in Eq. 1.35.
In the case of a system containing particles capable of drifting through the ABL,
drug molecules can transverse the ABL as either unbound or nano-scale species. The
ability of an API to associate with nano-scale species provides it with another path
to permeate the ABL, resulting in a nano-modified effective permeability (Pef f,nano ).
Since these two processes occur in parallel, the ABL permeability can be described as
a sum of the unbound (PABL,u ) and nanoparticle (PABL,nano ) permeabilities through
the ABL (Eq. 1.36).

Pef f,nano =

1
1
Pmem

+ PABL,u +P2ABL,nano

(1.36)

Simplification of Eq. 1.36 is possible if it is assumed that (PABL ≪ Pmem ) for the
slow stirring conditions
The modified permeability can be estimated by the following function, as determined by Stewart and Grass [86].

Pef f,nano ≈ Pef f (1 +

Dnano ⋅ Cnano
)
Du ⋅ Cu

(1.37)

where Dnano and Du represent the diffusion coefficients of the nano-particulate
species and unbound drug, respectively. Cnano and Cu represent the concentrations
of the nano-particulate species and unbound drug, respectively. By rearranging Eq.
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1.37, a particle drift factor, fP D , can be defined as the ratio of the effective permeability in the presence and absence of particle drifting species.

fP D =
1.6.4

Pef f,N ano
Dnano ⋅ Cnano
≈ (1 +
)
Pef f
Du ⋅ Cu

(1.38)

Implications on Activity Determination

The ABL is a rate-limiting barrier for many BCS class II compounds, which comprise
a vast majority of new chemical entities in the pharmaceutical pipeline [3, 88, 89, 90].
As mentioned previously, the ability for these compounds to permeate across the ABL
may be further complicated by the presence of solution species in-vivo [91, 92, 93]. The
biological gastrointestinal fluid is comprised of many endogenous materials capable of
self-associating or associating with exogenous formulation excipients. The presence
of aggregates, polymer gels, vesicles, or mixed micelle aggregates has been reported
in gastrointestinal fluids or simulations of those fluids after exposure to drug product
formulations [94, 95, 25, 96, 97, 98, 99]. Furthermore, all of these aggregates are
expected to have a diverse set of diffusivities across the ABL, where each species may
distinctly influence the observed flux.
1.7

Overview of Research

In this introductory chapter, relevant fundamental principles such as the thermodynamics of supersaturated solutions, crystallization theories, and how solution components may impact the thermodynamic or kinetic processes related to crystallization were presented. Furthermore, an in-depth description of the impact of particledrifting on the permeability of ABL-limited drugs was highlighted.
In chapter 2, important background relevant to the methodology and materials
used in the following chapters is reviewed.
Chapter 3 investigates the incongruency of in-vitro and in-vivo precipitation data
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of highly supersaturated solution of ketoconazole within the literature. An evaluation
of the inclusion of mucin within in-vitro testing media is performed to evaluate its
impact on precipitation kinetics. The precipitation kinetics were found to be much
slower in the presence of mucin than in the absence. Utilizing a simplified physiologically based pharmacokinetic (PBPK) in-silico model, coupled with the precipitation
kinetics found in the in-vitro system, an accurate prediction of the published in-vivo
precipitation data was achieved.
Chapter 4 examines the determination of the thermodynamic drug activity of an
active pharmaceutical ingredient (API) in the presence of solubilizing excipients in
cases where the aqueous boundary layer is a significant obstacle to permeation. In
cases where the hydrodynamic conditions of the bulk solutions containing API cannot be controlled and the ABL is a rate-limiting barrier to absorption, the effective
permeability and consequently the flux of the API across a barrier is a function of
the degree to which an API can form distinct nano-scale species(i.e., ionized drug,
micelle-drug complexes, drug-rich colloids, etc.). This differentiation of drug into distinct species can confound the determination of thermodynamic drug activity using
flux. An accurate prediction of flux and measure of thermodynamic drug activity in
complex media containing drug distributed into nano-scale species is achieved through
the development of a mathematical model which accounts for increases in API diffusivity due to the shuttling of API to the membrane by nano-scale species capable of
transversing the ABL.
Chapter 5 highlights the use of diffusion ordered NMR spectroscopy (DOSY) to
quantify the aqueous diffusion coefficient of micelle-bound API. The diffusion coefficient determined in this study was a key parameter within the mathematical model
describing the improvement in permeability due to the drifting of micelle-bound API
through the ABL. It was found that the diffusion coefficient is inversely proportional
to the degree of API supersaturation in solution as it is expected that the size of mi-
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celles increases with increasing degrees of incorporation at higher supersaturations.
Chapter 6 probes deeper into the potential interactions between mucin and lipophilic
and poorly-soluble compounds. Evidenced by the stabilization of supersaturated solutions of poorly-soluble API, it is expected that mucin may depress the thermodynamic
activity of the API through the formation of complexes leading to a weakened driving
force for crystallization. The tendency for mucin to form complexes with API is evaluated using flux methods highlighted in chapter 4. The outcome of those experiments
showed that mucin does not significantly depress the thermodynamic drug activity
in solution. Therefore, it is hypothesized that mucin must interact to reduce either
nucleation or crystal growth kinetics in solution.

34

Chapter 2
Methods and Materials

2.1

Horizontal Diffusion Cell Models

The concurrent in-vivo dissolution and absorption processes are often explored invitro through the use of diffusion cells. The evaluation of permeation through the
use of diffusion cells is to, at least qualitatively, capture the potential in-vivo dynamics of these systems. The use of diffusion cells as a model to describe permeation
phenomenon must adhere to the following model assumptions [3]:
1. Drug transport through the aqueous boundary layer (ABL) and the membrane
is described by Fick’s laws of diffusion.
2. The diffusion coefficient of the drug is not a function of concentration in the
medium explored.
3. Drug transport via convection (i.e., bulk fluid flow) across the membrane can
be neglected for the hydrodynamic conditions studied.
4. The ABL is a theoretical boundary representing the development of a concentration gradient near the membrane surface due to fast membrane transport
relative to solution transport.
5. The flux observed is characterized by unidirectional transport across each barrier in series from the well-mixed, bulk aqueous donor medium to the receiver
medium.
6. The instantaneous concentration profile within each diffusion layer resembles a
steady-state (pseudo steady-state approximation).
7. The thickness of each diffusion layer is constant with time for a given experiment.
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8. The partitioning of drug into the membrane is unaffected by medium components.
9. The concentration of drug in the receiver medium is much less than that in the
donor medium.
10. Colloid-associated drug is in equilibrium with the unbound drug in solution.
11. The integrity of the membrane is conserved for the duration of the experiment.
If the listed assumptions are valid, the absorption profiles of model active pharmaceutical ingredients (APIs) can be mathematically described by the following version
of Fick’s first law (Eq. 2).

J=

V dC
∗
= Pef f ∗ aD,solution
A dt

(2.1)

The rate of drug absorption, represented as flux (J), is a product of the effective permeability (Pef f ) and the drug solution thermodynamic activity (aD,solution ).
Experimentally, volume (V), membrane surface area (A), and the change in drug concentration as a function of time ( dC
dt ) can be measured to calculate the flux across a
membrane.
2.2
2.2.1

Nuclear Magnetic Resonance (NMR) Spectroscopy
Theory

The fundamental property that allows for the detection of NMR signal is the presence
of a nuclear spin in atomic nuclei. The spin values of a given nuclei (I) are dependent
on its mass number and atomic number and can yield values of 0,

1
2,

1, 1 12 , etc.

Through the application of an external magnetic field (B0 ) to an atomic nucleus, it is
possible to influence its magnetic moment (µ). The magnetic moment of an atomic
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nucleus can be defined by the following equation:
γIh
2π

µ=

(2.2)

where h is the Planck’s constant and γ represents the gyromagnetic ratio.
Upon the application of a magnetic field, the nuclear moments will orient themselves, however, only distinct orientations are available for a given nucleus depending
on its spin. For a nucleus of spin I, 2I + 1 orientations are possible. The magnetic
spin quantum number (mI ) describes the orientation of the nuclear moment and can
have values of −I, −I + 1, ..., I − 1, I. For example, a nucleus with spin

3
2

will have mI

values of − 23 , − 21 , 21 , 23 . The energy describing this interaction is defined as follows:

E=

γh
mI B0
2π

(2.3)

The energy required to transition the nuclear moment from one quantum orientation to another is defined as

∆E =

γ h B0
2π

(2.4)

This transition is achieved through the application of radiation of at a specific
frequency (∆E = hv) which according to Eq. 2.4 is

v=

γ B0
2π

(2.5)

where v represents the Larmor frequency or the frequency at which resonance is
achieved. For most nuclei this resonant frequency often lies within the radio-frequency
region (ca. 100-1000 MHz) using standard magnetic field strengths of (2.35-23.5
Tesla).
Through the application of a radio frequency pulse at or above the resonant fre-
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quency of a given nuclei, it then becomes possible to excite a nucleus to a higher
energy state. However, the extent to which that excitation occurs is defined by a
Boltzmann distribution of nuclei within distinct quantum states. Let us consider the
excitation of a nucleus from one low energy and more thermodynamically favorable
state (α) to a high energy state (β). The transition from β → α will resort in an
emission of energy as the nucleus relaxes from a higher energy state to a lower energy
condition. According to a Boltzmann distribution the population of nuclei in the α
(Nα ) and β (Nβ ) states can be described as follows
Nβ
∆E
γ h B0
= exp (
) = exp (
)
Nα
kB T
2 π kB T

(2.6)

Following the excitement of nuclei, the precession of the net magnetization results
in an alternating current which can be measured. The evolution of the alternating
current with time represents the NMR signal. The signal or free induction decay
(FID) is collected in the time domain and then subjected to a Fourier transformation
to give rise to the NMR spectrum.
2.2.2

The Chemical Shift

The utility of nuclear magnetic resonance (NMR) spectroscopy lies in its ability to
distinguish certain resonances attributed to specific nuclei. This distinct "fingerprint"
in NMR resonance is attributed to the electronic environment in which a nuclei is
situated. When a molecule containing the nucleus of interest is placed under a magnetic field, the electrons surrounding the nucleus serve to shield it from the externally
applied field. Therefore, the magnetic field that the nucleus experiences is different
that what is externally applied, leading different non-chemically equivalent nuclei to
precess at distinct frequencies.
The chemical shift, δ, is defined as the ratio of the difference between the magnetic field a nucleus experiences and the applied field over the applied magnetic field.
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However, it has been common to describe the chemical shift as the difference between
the magnetic fields experienced by a sample and reference nucleus divided by the the
field experienced by a reference material

δ=

(Bref − Bsample )
× 106 ppm
Bref

(2.7)

In the NMR spectrum chemically distinct nuclei are often revealed as well separated peaks, where the x-axis is commonly expressed in terms of chemical shift having
the units of parts per million (ppm). The utility of defining chemical shift according to Eq. 2.7 is that it allows for the definition of chemical shift independent of
the strength of B0 . For the characterization of

13 C

and 1 H nuclei, tetramethylsilane

(TMS) is used as the standard reference.
2.2.3

Solvent Suppression Techniques

Often analytes of interest are diluted in non-deuterated solvents, where protons
present in solvent molecules may confound the interpretation of NMR spectra, as
strong signals resulting from solvent resonances may overlap with the resonance of
the solute of interest or in certain cases cause baseline distortions. As a result, a
plethora of solvent suppression techniques have been developed to address this issue.
Of all the techniques, presaturation has become a standard and widely used technique
due to its simplicity.
The presaturation technique employs two distinct pulses. First, a long (seconds),
low power (mW), and selective 45-90° pulse is applied, which effectively saturates
the resonance at a desired frequency range. A non-selective 90° pulse then follows
to excite all of the remaining resonances for detection. The impact of any solvent
resonances on the resulting spectra is significantly reduced, leading to an improved
Signal-to-Noise ratio (S/N) for solute resonances.
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2.2.4

Diffusion Ordered Spectroscopy (DOSY)

The random Brownian motion of molecules or sub-micron particles can be described
by the Stokes-Einstein equation:

D=

kB T
6 π η rH

(2.8)

where kB is the Boltzmann constant, T is the temperature, η is the dynamic viscosity of the solution, and rH is the hydrodynamic radius of the molecule assumed
to be a spherical particle. It is expected that molecules or particles of sufficiently
different molecular size would exhibit different diffusion coefficients within the same
media. Applying this concept within NMR spectroscopy, it becomes possible to resolve certain molecules within a mixture according to their diffusion coefficients.
The differentiation of NMR signals based on their diffusion coefficient is called
Diffusion Ordered Spectroscopy (DOSY). DOSY has found widespread applications
within the pharmaceutical industry, especially in the identification and quantification
of compounds following chemical synthesis and purification steps.
90°

180°
𝞣

𝞣
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𝚫
𝛿

G
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g

g

Figure 2.1: Schematic showing a simple DOSY pulse sequence
To measure the diffusivity of molecules within solution using DOSY NMR, a
series of radio-frequency pulses coupled with magnetic field gradients are applied to
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molecules of interest. A general scheme of the pulsed field gradient spin-echo used
for measuring diffusion is highlighted in Figure 2.1. Nuclei are first excited with a
90° radio-frequency pulse to flip the orientation of spins and then dispersed using a
magnetic field gradient pulse. The strength of the magnetic field exists as a gradient
along the length of the NMR tube, or z-axis. As a result of this magnetic field gradient,
nuclei are exposed to distinct magnetic field strengths based on their z-axis position.
The molecules are then given time (T ) to diffuse within the NMR tube, following
which, a 180° radio-frequency pulse is applied to invert the dispersed magnetization.
This inversion of spins is followed by an equivalent, but opposite gradient pulse which
should cancel out the impact of the first magnetic field gradient, i.e. "refocusing". In
the absence of diffusion within the time between the two gradient pulses, the signal
intensity should be equivalent if acquisitions were made following the 90° and 180°
radio-frequency pulses. However, in the presence of diffusion, the signal intensity is
reduced as molecules which had diffused along the z-axis are exposed to a different
magnetic field strength than what was intially applied. Therefore, the gradient pulse
is unable to effectively "refocus" or return nuclei back to their initial states, and some
signal is lost. Figure 2.2 provides an schematic representation of the effects on spins
following the application of a gradient pulse.
The diffusion coefficient, D, is derived from a fit of signal intensity, S, according
to the Stejskal-Tanner formula:
δ
2
S = S(0) exp [− (γ g δ) D (∆ − )]
3

(2.9)

where S(0) is the intensity in the absence of a gradient pulse, γ is the gyromagnetic ratio, δ is the gradient duration, g is the strength of the gradient, D is the
diffusion coefficient and ∆ is the diffusion delay. A series of signals can be collected
by either varying the diffusion delay time (∆), the gradient strength (g), or the
length of gradient pulses (δ). In practice, many have found it easiest to experimen41

(a)

1st Magnetic Field
Gradient

2nd Magnetic Field
Gradient

(b)

1st Magnetic Field
Gradient

Diffusion

2nd Magnetic Field
Gradient

Figure 2.2: Effect of a magnetic field gradient pulse in the a) absence and b) presence
of diffusion. The magnetization vector a nuclei experiences is distinct along different
vertical positions in the NMR tube. A refocusing gradient pulse reverts the initial
magnetization resulting in the recovery of signal. However in the presence of diffusion,
the refocusing gradient pulse does not fully recover signal.
tally to manipulate the gradient strengths (g) while maintaining the diffusion delay
and gradient pulse lengths constant.

42

2.3

MATLAB Simbiology

In the last few years, in-silico simulation approaches have become an integral part
of drug discovery and development. Physiologically-Based Pharmacokinetic (PBPK)
Modeling is an example of such approaches. PBPK models attempt to mechanistically capture the absorption, distribution, metabolism and excretion processes of a
substance in humans and several animal species, by mapping drug movement in the
body onto a compartmental structure, using sets of differential equations.
SimBiology provides programmatic tools for modeling, simulating, and analyzing dynamic systems, through the use of the interactive drag-and-drop block diagram editors. While SimBiology is a interface within the MATLAB software, SimBiology provides a variety of user-friendly techniques to evaluate ordinary differential equation (ODE)-based models within quantitative systems pharmacology (QSP),
physiologically-based pharmacokinetic (PBPK), and pharmacokinetic/pharmacodynamic
(PK/PD) applications. The SimBiology interface provides users with the capability
to run simulations to assess target feasibility, predict drug efficacy and safety, and
identify optimal dosing schedules. Variability and parameter sensitivity can be assessed through the use of running parameter sweeps, which is integrated within the
Model Analyzer interface. In cases where models are developed to fit observed invivo data, key parameters and confidence intervals can be estimated using nonlinear
regression and nonlinear mixed-effects techniques.
2.4

Materials

As the acquisition of human mucins has been traditionally been limited, porcine
mucins have often been used as a substitute. For this study, mucin from porcine
stomach (PGM type III, 0.5-1.5 % bound sialic acid, partially purified powder) was
used to understand the potential for interactions with poorly-water soluble drugs.
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Although this commercially sold mucin may not fully represent the mucin types found
within the human intestines, the overall structure is similar. The use of porcine mucins
to model the human mucins has been widely studied and validated. The structure of a
general mucin glycoprotein along with the potential sites of interactions are displayed
in Figure 2.3.
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Figure 2.3: Generic structure of a mucin glycoprotein. Specific residues and the
potential intermolecular interactions with such residues are highlighted. Adapted
from Ref. [4]

44

Chapter 3
Improved Predictability of the Precipitation Profiles of Weakly Basic
Drugs in the Small Intestine Through the Use of Biomimetic Fluids
Incorporating Mucin

3.1

Introduction

The expanding prevalence of poorly water-soluble drugs (PWSDs) within the pharmaceutical pipeline [6, 7] has driven a concerted effort in understanding supersaturation within the gastrointestinal lumen. Strategies such as the use of cocrystals
[13, 14, 15, 16, 17], inclusion complexes [18, 19, 20], lipid formulations [21, 22], and
amorphous solid dispersions [23, 24, 25, 26] have become standard techniques to
achieve increased concentrations within the intestinal fluid than would otherwise be
found using the most stable crystalline form. In-vitro models have been increasingly
been used to rank order formulations to accelerate product development [100, 101].
Therefore, it has become highly desirable that in-vitro testing methods accurately
predict the in-vivo behavior. Furthermore, the early estimation of the in-vivo potential of an active pharmaceutical ingredient (API) to be delivered as a supersaturating
formulation becomes crucial, as decisions on the continuation of the development of
drug candidates are made as early as possible using limited data [102]. Consequently,
simple predictive tools and models have been sought to quickly probe potential drug
product outcomes before dedicating significant resources to a single compound.
The gastrointestinal tract is a complex system to model. Many models have
been developed to mimic the gastrointestinal absorption process [103, 104, 105, 106,
107, 108, 109, 110, 111, 112]. Variations in pH [113, 114, 115], gastric transit time
[116, 117, 118], surface area [119], and mucus content [77] can all lead to differences
in API absorption. In certain cases, poorly water-soluble candidates are weak bases
with pH-dependent solubility, and in some instances, the dissolution of an API in the
stomach and its consequent transfer to the small intestinal lumen can generate super45

saturation [120, 121, 116, 122]. This phenomenon is primarily due to the variability
in pH along the human gastrointestinal tract (GIT) [114]. That is to say, within the
stomach’s acidic environment, weakly basic drugs have higher solubility [114]. As
the dissolved API progresses through the GIT, the pH increases and tends towards
more neutral values, decreasing solubility for weakly basic APIs [123]. Regardless of
how supersaturation is generated, for compounds where supersaturation is required
to reach efficacious doses within the in-vivo system (i.e. poorly water-soluble compounds), it is important to understand the stability of supersaturated solutions and
how it may impact its overall absorption.
There have been several attempts to predict the in-vivo performance of poorly
water-soluble drugs using in-vitro testing coupled with in-silico models [124, 125,
126, 127, 128, 129, 130, 131, 132, 133]. However, many of these attempts fail to
consider the significance of luminal precipitation, as API supersaturation is often
short-lived. In supersaturated solutions, the API exists in a higher energy state, and
thermodynamics dictates that the API will always revert to its most stable crystalline
form to maximize its strong intermolecular interactions with itself [24]. Formulation
excipients such as polymers, surfactants, or complexing agents are often used to hinder those intermolecular interactions, thereby limiting the formation of nuclei or the
diffusion of molecules to growing nuclei [73, 134, 69, 68].
Attempts to predict product performance utilizing in-vitro precipitation methods
often result in contradicting observations [115, 135]. In a study by Carlert et al.,
two formulations of a poorly water-soluble and weakly-basic compound, AZD0865,
were evaluated in 114 healthy human subjects across four clinical studies [135]. The
bioavailability and the pharmacokinetics of the two formulations in clinical studies
were linear and dose-proportional, with no evidence of intestinal precipitation. Within
that same study, the precipitation kinetics were evaluated in-vitro using three distinct precipitation models within FaSSIF media. Surprisingly, all the in-vitro models
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suggested significant precipitation of AZD0865 would occur in-vivo, which strongly
contrasted with the clinical studies. In a second study, the intestinal precipitation of
mebendazole, a BCS Class IIb compound, was evaluated in dogs following the administration of a highly concentrated solution, resulting in a supersaturation value of
20-times the crystalline solubility [136]. The authors found that very minimal precipitation occurred two hours following administration (11% of dose) in-vivo. In contrast,
in-vitro evaluations suggested that >75% of the dose would have precipitated after
10 min. In another study, Psachoulias et al. evaluated the duodenal precipitation of
ketoconazole in healthy human volunteers following the administration of an acidic
solution to generate a dose-to-solubility ratio of 164:1. Samples aspirated from the
end of the duodenum contained limited amounts of precipitation ( 12% of dose) 70
min after administration [137]. Cristofoletti et al. found that the best fits of in-silico
models to the in-vivo ketoconazole data collected by Psachoulias et al. were achieved
when slow precipitation kinetics were assumed [138]. However, it has proved difficult
to achieve similar kinetics in-vitro as are observed in-vivo for ketoconazole, as in-vitro
attempts have grossly overestimated precipitation [5, 139].
The apparent disconnect between in-vitro and in-vivo precipitation suggests the
failure to account for a factor within in-vitro models which may play a significant role
within the in-vivo system. Studies have shown that the dissolution of supersaturating
formulations can be highly dependent on the media used [140, 141, 142]. Recent emphasis has been placed on studying and understanding the composition of the human
gastrointestinal fluid, as the utilization of more biorelevant media is understood to
achieve better correlations with in-vivo data. The implications of endogenous materials such as bile acids and phospholipids [143, 144, 74, 145, 66, 75], found natively in
the intestinal fluids have been studied and accounted for in commercial formulations
of simulated GI fluids [146]. Recently, a focus has been placed on understanding the
impact of the mucus layer on absorption. Several groups have observed a reduced dif-
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fusivity, relative to aqueous diffusivity, of APIs, nano & micro-particles, and polymers
across mucus barriers, indicating the presence of intermolecular interactions between
mucus and certain species [77, 147, 148, 149, 150, 151, 152, 153, 154]. To accurately
predict product performance in-vivo, one must consider the impact of the competing
kinetic processes of precipitation and drug absorption, where the effects of exogenous
and endogenous material can be of critical importance.
Many epithelial surfaces within the human body are lined with a mucus layer, especially the gastrointestinal epithelium. Mucin has been identified as the main component of mucus, imbuing mucus with its viscoelastic properties. Mucin is defined
as a long polymeric glycoprotein containing heavily O-glycosylated proline, threonine, and serine-rich tandem repeats (PTS domains)[155]. The presence of negatively
charged glycosylated functional groups such as sialic acid and sulfonate groups and
non-glycosylated hydrophobic residues have led some to suggest mucin may interact
with lipophilic molecules via electrostatic, hydrogen-bonding, or hydrophobic interactions [4].
It is argued that a significant amount of mucin can be found in the intestinal
fluids due to the high turnover rate of the intestinal mucus lining (47-270 minutes)
as determined in rats [156]. Using fluorescence and UV-vis spectroscopic techniques,
Butnarasu et al. were able to identify the complexation of mucin with several model
lipophilic compounds and found that the binding energies associated with the complexation suggested that the lipophilic molecules established weak intermolecular interactions with mucin [4]. In another study by Yeap et al., mucin stabilized supersaturated solutions of carvedilol approximately 5-fold longer than buffer [157]. In the
same study, mucin was found to prolong the supersaturation of piroxicam for >24
hours. In summary, the presence of an interaction between mucin and several model
lipophilic drug molecules suggests that mucin may have a marked impact on not only
dissolution but potentially on precipitation as well. Therefore, the absence of mucin
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from biorelevant media may lead to pre-clinical testing methods where product performance is evaluated without fully characterizing all the variables, which may impact
dissolution in-vivo.
This study aimed to investigate the likely mechanisms behind the poor correlation between in-vitro and in-vivo precipitation kinetics of a weakly basic and poorly
water-soluble drug ketoconazole at high degrees of supersaturation utilizing a simple
pH-shift precipitation model coupled with in-silico modeling. The influence of the
inclusion of mucin within biorelevant media on the inhibition of crystallization is explored to evaluate the observed discrepancy between in-vitro and in-vivo data. The
precipitation kinetics observed from in-vitro experiments were then extrapolated and
translated into in-silico simulations. The in-silico simulations were then compared
to published in-vivo data evaluating the extent of ketoconazole precipitation in the
duodenum.
3.2
3.2.1

Materials and Methods
Chemicals and reagents

Ketoconazole (M W = 531.43, lot 2HA0302) was purchased from Spectrum Chemical
Mfg. Co. (Gardena, CA). Simulated Intestinal Fluid (SIF) powder was obtained
from Biorelevant.com Ltd. (Surley, UK). Mucin from porcine stomach (PGM type
III, 0.5-1.5 % bound sialic acid, partially purified powder), maleic acid, hydrochloric
acid, sodium hydroxide, and sodium chloride were all sourced from Sigma Aldrich Co.
LLC (St. Louis, MO). Acetonitrile, potassium dihydrogen phosphate, and potassium
phosphate dibasic were supplied by VWR International (Radnor, PA). Dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific (Fair Lawn, NJ). Deionized water
was obtained from a MilliQ water purification device (Milli-Q Synthesis, Millipore,
Bedford, MA).
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3.2.2
3.2.2.1

Methods
Preparation of the dissolution media.— A modified Fasted State Simulated

Intestinal Fluid (FaSSIF) was used to evaluate the precipitation of ketoconazole invitro using a biorelevant methodology. Specifically, a FaSSIF-V2 buffer containing
1 mg/mL of mucin was used in this study. The composition and preparation of the
simulated intestinal fluid have been described previously [158, 159]. In short, a buffer
(pH = 6.5) was prepared with NaCl, NaOH, and maleic acid. The SIF powder was
then dissolved in the buffer. Mucin was then introduced to the solution by sonication
for 2-5 min and allowed to equilibrate for 1 hour prior to use. The addition of mucin
to FaSSIF-V2 had no impact on the pH of the media, which was maintained at
pH = 6.5. Other media examined within this study includes FaSSIF-V2 without the
added mucin.
3.2.2.2

Crystalline Solubility Determination.— Crystalline solubility of ketocona-

zole was determined by placing an excess of crystalline drug into glass vials containing either buffer, FaSSIF-V2, buffer containing 1 mg/mL of mucin, or FaSSIF-V2
containing 1 mg/mL of mucin. The buffer used in this study contained maleic acid,
NaCl, and NaOH in the concentrations found in FaSSIF-V2. The pH of the four
media examined within this study was varied to yield media at pH = 6.5, 6.3, 5.6, 4.2.
The vials containing excess crystalline ketoconazole were agitated using a vial rotator in an incubator at 37 °C for 72 hours. Following the 72 hour equilibration, the
O
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Figure 3.1: Chemical structure of ketoconazole
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equilibrated suspension was centrifuged (4,000 × g, 7 min, 37 °C). The supernatant
was then removed using a glass syringe with a stainless-steel luer-lock tip and filtered
through a 0.45 µm polyvinylidene difluoride (PVDF) filter. The first 3 mL of the
filtrate were discarded, and 200 µL of the remaining filtrate was sampled and diluted
1:4 with acetonitrile. Samples from solutions at pH = 4.2 were diluted 1:8 to ensure
the concentration of the injected sample is within the linear region of the HPLC
calibration curve. All solubility measurements were performed in triplicate.
3.2.2.3

Selection of An Appropriate HCl Concentration to Completely Dissolve Ketoconazole.—

The complete dissolution of ketoconazole was evaluated in solutions of HCl at varying
concentrations: 0.02, 0.025, 0.03, 0.04 N. Twenty-five milligrams of ketoconazole was
introduced into several volumetric flasks containing 5 mL of acidic solutions of varying HCl concentration to generate a 5 mg/mL concentration of ketoconazole, which
is equivalent to the maximum concentrations used in the 50 mL dosing solution by
Kambayashi et al. [5]. The solutions containing ketoconazole were mixed using a
SpinbarTM micro stir bar (VWR International, Radnor, PA). The solutions were allowed to stir at room temperature, and were visually inspected for the presence of
undissolved crystalline material.
3.2.2.4

In vitro precipitation testing.— In vitro precipitation testing was conducted

at 37 °C ± 0.2 °C using a USP 2 paddle dissolution apparatus (VK 7000, Agilent,
Santa Clara, CA) with a 50 rpm paddle revolution rate. A gastric dumping model
was employed to mimic the in-vivo oral dosing process evaluated by Psachoulias et al.
[137]. A series of 50 mL “dosing” solutions containing various amounts of dissolved
ketoconazole: 175, 200, 225, and 250 mg, were prepared in both 0.02N and 0.025 N
HCl. The introduction of the 50 mL “dosing” solution to 450 mL of the FaSSIF-V2 +
Mucin solution indicated the start of the experiment. For these studies, all FaSSIF-V2
solutions contained 10% higher sodium taurocholate and lecithin concentrations than
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standard FaSSIF-V2. Also, the FaSSIF-V2 + Mucin media contained 1.1 mg/mL
of mucin such that the final mucin concentration, upon dilution, is 1 mg/mL. The
final sodium taurocholate and lecithin concentrations in the 500 mL precipitation
media are 3 mM and 0.2 mM, respectively. Following the addition of the “dosing”
solution, samples were taken at 5, 10, 15, 20, 30, 40, 50, and 60 min. 5 mL samples
were taken from the precipitation media using a glass syringe with a stainless-steel
luer-lock tip at the above-mentioned times. The 5 mL samples were filtered using a
0.45 µm polyvinylidene difluoride (PVDF) syringe filter (Tisch Scientific, Cleves, OH)
and placed into test tubes. A 200 µL sample of the filtered solution was immediately
diluted 1:4 with acetonitrile to avoid further precipitation of ketoconazole prior to
HPLC analysis. The diluted samples were then centrifuged (4000 × g, 2 min, 37°C)
to remove as much mucin as possible before analysis via HPLC. All experiments were
performed in triplicate.
3.2.2.5

Analytical method for the quantification of drug concentration.— The sam-

ples from the crystalline solubility and in-vitro precipitation experiments were analyzed using a Dionex Ultimate 3000 high-performance liquid chromatography (HPLC)
system equipped with a photodiode array (Thermo Fisher Scientific, Waltham, MA)
to determine the concentration of ketoconazole in solution quantitatively. An injection volume of 30 µL was introduced through a Hypersil GOLD C18 column (4.6
mm internal diameter, 100 mm length, 2.1 µm particle size, Thermo Fisher Scientific,
Waltham, MA). The mobile phase consisted of acetonitrile and 20 mM Potassium
Phosphate buffer (pH = 6.8) in a 50:50 v/v ratio, and it was pumped isocratically
at a flow rate of 0.75 mL/min. The detection wavelength was set at 240 nm for
the quantification of ketoconazole. A retention time of approximately 6 minutes was
obtained. A calibration curve (R2 = 0.999) between 1 µg/mL and 75 µg/mL was
developed to determine ketoconazole concentrations in solution.
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3.2.2.6

Evaluation of solid precipitates.— In a similar setup used for the in-vitro pre-

cipitation testing, the acidified ketoconazole solutions were introduced to FaSSIF-V2
solutions to evaluate the solid precipitates generated following ketoconazole supersaturation. Immediately after the addition of the 50 mL dosing solution to the 450
mL of FaSSIF-V2 media, a 50 mL sample was taken and centrifuged (37 °C, 4122
× g, 10 min). Another sample was extracted one hour after the introduction of the
acidified ketoconazole solution and similarly centrifuged. After centrifugation, the
supernatant was carefully poured out of the tube so that any precipitated material
remained in the centrifuge tube. This process yielded a few milligrams of solid precipitates, which were then used for crystallinity evaluations via powder X-ray diffraction
(PXRD) analysis. Samples were only collected from experiments in which a 5 mg/mL
dosing solution was introduced. To compare PXRD profiles of the precipitates extracted from in-vitro experiments, ketoconazole, as received, was also evaluated using
PXRD.
The crystallinity of the solid precipitates generated in the in-vitro experiments was
evaluated using a Rigaku Miniflex 600 benchtop diffractometer (Rigaku Corporation,
Tokyo, Japan), equipped with a Cu Kα radiation source (40 kV × 15 mA). The samples extracted from in-vitro experiments were mounted onto Si(510) zero-background
sample holders and scanned between 5° and 40° 2θ at a scan speed of 1.0°/min and a
step size of 0.02° 2θ under continuous mode. All PXRD experiments were conducted
at room temperature.
3.2.2.7

Drug concentrations in the small intestinal lumen.— The total and dissolved

ketoconazole concentrations in the jejunum of human subjects following dosing of a
240 mL acidified solution (pH=2.7) containing either 100 or 300 mg of dissolved
ketoconazole were extracted from the literature [137]. In the referenced study, the
dosing solutions were administered to 12 healthy human subjects (10 M & 2 F) with
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a mean age of 26 years, and ages ranged from 20-38 years. For more information on
how samples were collected and analyzed, the authors refer the reader to the study
by Psachoulias et al. [137].
3.3

Results and discussion

3.3.1

Crystalline Solubility of Ketoconazole

The crystalline solubility of ketoconazole was evaluated in several different media
at four different pH at 37 °C. The solubility was examined in both FaSSIF-V2 and
buffer at pH = 6.5, 6.3, 5.6, 4.2, which closely resembles the gastrointestinal fluid and
pH variation found in the in-vivo study conducted by Psachoulias et al. [137]. Ketoconazole is a diprotic base is characterized by two pKa ’s: pKa,1 = 2.9 and pKa,2
= 6.5, which correspond to the amine and imine groups, respectively [160]. The pKa
of the imine group is very close to physiological pH values found within the GI tract,
and it is expected that the solubility would be impacted by the solution pH. The pH
values explored in this study represent the pH of FaSSIF-V2 (pH = 6.5), the pH following the addition of the acidic dosing solution in the in-vitro studies (pH = 6.3), the
reported mean pH (pH = 5.6), and the pH one standard deviation from the mean pH
of the aspirated intestinal fluids (pH = 4.2) from the in-vivo ketoconazole study. The
solubility of ketoconazole was also explored at the above pH values in both FaSSIFV2 and buffer containing 1 mg/mL of mucin. The results of the solubility analysis
are summarized in Figure 2 and Table 1. It is important to note that the solubility
defined in Figure 2 and Table 1 represents total drug solubilized, which may include
micellized or complexed API.
The crystalline solubility of ketoconazole at 37 °C in FaSSIF-V2 was found to be
12.0 ± 1.0, 12.5 ± 0.9, 33.3 ± 0.4, 255.0 ± 1.0 at pH values of 6.5, 6.3, 5.6, and 4.2,
respectively (Table 1). At all of the pH values explored, the addition of mucin in
solution significantly increased the amount of ketoconazole solubilized in the media.
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Ketoconazole
Concentration (µg/mL)
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Figure 3.2: Ketoconazole solubility observed in ( ) Buffer, ( ) Buffer + 1 mg/mL
mucin, ( ) FaSSIF-V2, and ( ) FaSSIF-V2 + 1 mg/mL mucin at various pH. Two asterisks indicate p ≤ 0.01, three asterisks indicate p ≤ 0.001, and four asterisks indicates
p ≤ 0.0001 correlated to the significance of the difference between the mean values of
ketoconazole solubility between FaSSIF-V2 media in the presence and absence of 1
mg/mL mucin
Table 3.1: Crystalline Solubility of Ketoconazole in Different Media and Various pH
Crystalline Solubility
(µg/mL)

Medium
pH = 6.5
Buffer
3.3 ± 0.6
Buffer + 1 mg/mL Mucin
5.3 ± 0.4
FaSSIF-V2
11.0 ± 1.0
FaSSIF-V2 + 1 mg/mL Mucin 20.4 ± 0.2

pH = 6.3
5.0 ± 0.4
7.0 ± 1.6
12.5 ± 0.9
20.0 ± 1.0

pH = 5.6
22.0 ± 2.0
27.0 ± 2.0
33.3 ± 0.4
49.4 ± 0.5

pH = 4.2
159.0 ± 22.0
175.0 ± 28.0
255.0 ± 1.0
296.0 ± 3.0

An unpaired t-test was conducted using Prism (ver. 9.1, GraphPad Software Inc.,
San Diego, CA) to evaluate the mean solubilities across systems and found that the
inclusion of 1 mg/mL of mucin within FaSSIF-V2 resulted in a statistically significant
increase in the solubility of ketoconazole at all of the pH values explored. It was
observed that with the inclusion of mucin in FaSSIF-V2 the solubility of ketoconazole
was 20.4 ± 0.2, 20.0 ± 1.0, 49.4 ± 0.5, 296.0 ± 3.0 at pH values of 6.5, 6.3, 5.6, and 4.2,

55

respectively (Table 1).
This observation suggests the existence of interactions between ketoconazole and
mucin which may lead to the formation of complexes in solution. Yeap et al. evaluated the solubility of weakly-basic carvedilol and weakly-acidic piroxicam, two poorly
water-soluble compounds, and found that the addition of mucin in buffer increased
the apparent solubility of piroxicam [157]. In contrast, in the same study, Yeap et al.
observed no significant impact on the apparent solubility of carvedilol. The impact of
mucin on the solubility of poorly-soluble compounds is inadequately understood, and
compounds need to be evaluated on a case-by-case basis. The difference in the ketoconazole solubilities with the addition of mucin to FaSSIF-V2 may also suggest the
presence of interactions with sodium taurocholate or lecithin, which may increase the
solubilization capacity of their respective micelles or mixed micelles. The solubility of
ketoconazole was evaluated in buffer media to isolate the interactions between mucin
and ketoconazole and avoid any potential interactions between mucin and sodium
taurocholate or lecithin. The solubility of ketoconazole in buffer was observed to be
3.3 ± 0.6, 5.0 ± 0.4, 22.0 ± 2.0, 159.0 ± 22.0 µg/mL at pH values of 6.5, 6.3, 5.6, and 4.2,
respectively (Table 1). The solubility of ketoconazole in buffer containing 1mg/mL
of mucin was 3.3 ± 0.6, 5.0 ± 0.4, 22.0 ± 2.0, 159.0 ± 22.0 µg/mL at pH values of 6.5,
6.3, 5.6, and 4.2, respectively (Table 1). Interestingly, the addition of mucin did
not have a statistically significant impact on the measured ketoconazole solubilities
(Figure 2). The lack of a significant difference in ketoconazole solubility in buffer
containing mucin suggests that mucin may interact with sodium taurocholate and
lecithin present in FaSSIF-V2, leading to an increase in its solubilizing capacity. The
mucin monomers can serve as an adsorption site of sodium taurocholate and lecithin
molecules, aiding the orientation of such molecules into hemicellar or micellar aggregates attached to the mucin structure. This is in agreement with the necklace or
bead-on-a-string model which has been widely reported in the literature [57, 58, 59].
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3.3.2

Theoretical Considerations

In an attempt to accurately capture the precipitation kinetics of ketoconazole within
the small intestines, a first-order equation is fit to in-vitro precipitation data. From
this data, first-order rate constants at several degrees of supersaturation are obtained
from fits to Eq. 1.
dP (t)
= kP ∗ (XDose − SAP I,SIF ∗ VSIF )
dt

(3.1)

The above equation describes the change in precipitated drug mass, P (t), over
time as a function of the precipitation rate constant, kP , the dose of ketoconazole,
XDose , the solubility of the API in the simulated intestinal fluid, SAP I,SIF , and the
volume of the dissolution media, VSIF . The in-vitro precipitation profiles at the
various degrees of supersaturation (XDose = 175 mg, 200 mg, 225 mg, 250 mg) were
fitted to Eq. 1 using GraphPad Prism (ver. 9.1, GraphPad Software Inc., San Diego,
CA) to obtain fitted estimates for the precipitation rate constant, kP .
It is important to note that although the in-vitro precipitation profiles can be
fitted according to the first-order rate equation, it is challenging to describe precipitation using a single parameter. In addition to the stochastic nature of crystal nuclei
formation, the extent of precipitation is often a function of the quantity, size, and
density of nuclei. Fortunately, in similar research by Kambayashi et al., they demonstrate that the parameters attributed to nuclei characteristics can be grouped into a
single function, f(C), which is dependent solely on the drug concentration, C [5].
The precipitation process within the small intestine can be described using the
following equation:
dP (t)
= f (C) ∗ (C − SAP I,SI ) ∗ VSI
dt

(3.2)

where SAP I and VSI represent the solubility of the API in the small intestines and
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the volume of the small intestinal fluid, respectively. Kambayashi et al. found that
the following exponential-growth equation could accurately describe the relationship
between the API concentration and the first-order precipitation rate constants derived
from the in-vitro experiments [5]:

kP = f (C) = k0 ∗ eβ∗C

(3.3)

where k0 and β are constants estimated by curve fitting the plot of kP vs. C
derived from in-vitro experiments with GraphPad Prism.
3.3.3
3.3.3.1

In-vitro precipitation of ketoconazole
Impact of Dosing Solution on the Precipitation Profiles of Ketoconazole.—

The in-vitro precipitation profiles of ketoconazole following the addition of a 0.02 N
HCl solution containing various amounts of dissolved ketoconazole are shown in Figure
3. The profiles observed in Figure 3 share similar kinetics to the profiles determined
in the study conducted by Kambayashi et al [5]. The profiles exhibited first-order
kinetics, and the fitted values of the first-order rate constant, kp , are 14.070, 9.299,
5.757, and 2.064 h−1 for 250, 225, 200, and 175 mg dosing conditions, respectively.
According to the fitted data (Fig S1), the k0 and β values were determined to be
k0,0.02N HCl = 0.09362 h−1 and β0.02N HCl = 10.07 mL/mg. The fitted values of the
first-order rate constant, kp , in the study by Kambayashi et al. are 38.510, 13.860,
10.470, 4.496 h−1 for 250, 225, 200, and 175 mg dosing conditions, respectively [5].
Furthermore, the k0 and β values determined from that study were 0.01095 h−1 and
16.30 mL/mg, respectively. Although the Kambayashi et al. data appear to be
significantly different from what was observed in Figure 3, the trend in the data is
very similar. The rapid precipitation of ketoconazole within 0.5 h was observed.
It is to be noted that the addition of 250 mg of ketoconazole into 50 mL 0.02 N
HCl solutions produced turbid solutions, indicating the presence of light scattering
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Figure 3.3: Precipitation250
profiles
of ketoconazole in FaSSIF-V2
N HCl solutions of 250 mg ( ), 225 mg ( ), 200 mg ( ), and 175 mg ( ) of dissolved
200 mg Dose
175 mg Dose
ketoconazole. The final pH of the media was 6.3 following the introduction of the
acidic dosing solution. The curves represent fits to the data according to the firstorder kinetic rate equation in Eq. 1.
material. Similar issues were observed with the solubilization of the 225 and 200mg
doses of ketoconazole. It is hypothesized that the light scattering material is undissolved ketoconazole crystals. Solutions of varying concentrations of HCl (0.02, 0.025,
0.03, 0.035, 0.04 N) were evaluated in their ability to completely dissolve the highest
dose examined within this study (250 mg) by dissolving 25 mg of ketoconazole within
5 mL volumetric flasks to generate an equivalent concentration as what is found in
the dosing solution used by Kambayashi et al. (5 mg/mL) [5]. The results of the solubilization study suggested the solubility of ketoconazole in 0.02N HCl was less than 5
mg/mL, which was evidenced by the presence of turbidity of solutions after overnight
mixing with a stir bar at room temperature. In the Kambayshi et al. study, the
dissolution of 250 mg of ketoconazole within 50 mL of the 0.02 N HCl solution should
have resulted in a 5 mg/mL ketoconazole concentration. Therefore, it is plausible
that the dosing solutions in the study by Kambayashi et al. contained undissolved
ketoconazole.
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In contrast, all solutions containing an HCl concentration greater than 0.02 N
yielded transparent solutions, suggesting the presence of undissolved ketoconazole in
the 0.02 N HCl solutions. The precipitation kinetics observed in Figure 3 and in the
study by Kambayashi et al. were probably affected by the presence of undissolved
crystalline ketoconazole, which effectively seeded the solution and accelerated the
precipitation kinetics. Therefore, the difference in values of kp , k0 , and β determined
in this study when compared to the study by Kambayashi et al. could be attributed
to the size or number of the crystalline material in solution, which would impact the
overall kinetics of precipitation observed.
A second examination of the precipitation of ketoconazole in FaSSIF-V2 was performed using a 0.025 N HCl dosing solution to ensure the complete dissolution of all
doses of crystalline ketoconazole. Care was taken in selecting a low HCl concentration
that would not impact the final pH of the FaSSIF-V2 media. The pH of the media
following the addition of the 0.025 N HCl acidic dosing solution was 6.26, where the
addition of the 0.02 N HCl solution lowered the pH to 6.3. It is not expected that
the final pH difference between the two dosing solutions would significantly affect the
precipitation profiles. Figure 4 highlights the observed precipitation profiles following
the addition of the 0.025 N HCl dosing solution containing 225, 200, and 175 mg
of dissolved ketoconazole. The resulting precipitation rate constants kp for initial
amounts of the drug (225, 200, and 175 mg) in 500 mL of FaSSIF-V2 were 4.272,
1.604, and 1.212 h−1 , respectively (Figure S2). Fitting the rate constants with Eq.
3 the resulting fitted values are k0,0.025N HCl = 3.55 × 10−3 h−1 and β0.025N HCl = 15.73
mL/mg (Figure S2). When comparing the precipitation profiles in Figures 3 and 4,
it is apparent that there is a significant difference in the precipitation kinetics. The
first-order precipitation rate constants determined are 54 %, 80 %, and 41 % lower
when compared to the 225, 200, and 175 mg profiles in Figure 4, respectively. The
difference in the first-order precipitation rate constants across different ketoconazole
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doses highlights the impact of the dosing solution. It is unlikely that the difference in
the final pH of the media can explain the difference in precipitation kinetics; therefore, it is highly probable that the presence of undissolved crystalline ketoconazole

Dissolved Ketoconazole (mg)

affected the precipitation kinetics observed.
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0
0.0
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Figure 3.4: Precipitation profiles of ketoconazole in FaSSIF-V2 after dumping of 0.025
N HCl solutions of 225 mg ( ), 200 mg ( ), and 175 mg ( ) of dissolved ketoconazole.The final pH of the media was 6.26 following the introduction of the acidic dosing
solution. The curves represent fits to the data according to the first-order kinetic rate
equation in Eq. 1.
Another point of observation from Figure 4 is a plateau in dissolved ketoconazole immediately following the introduction of the 0.025N HCl dosing solution at all
conditions. Regardless of how much ketoconazole is added into solution, the plateau
appears immediately after dosing and at the same concentration. It is hypothesized
that immediately following the introduction of the dosing solution into the FaSSIFV2 media, the solution undergoes spinodal decomposition resulting in the formation
of phase-separated drug-rich colloidal species. Once this occurs, the concentration of
freely solubilized API in solution remains constant and can be observed as a plateau
in the precipitation profile. However, the phase-separated drug-rich colloidal species
are metastable and have a propensity to crystallize out, and once that occurs, the
61

plateau in concentration can no longer be maintained.
Interestingly, the precipitation profile of ketoconazole following the addition of
the 0.025N HCl solution containing 250mg of ketoconazole displays a plateau that is
maintained for greater than one hour (Figure 5). Figure 5 highlights the influence of
the filter cutoff used during the preparation of samples for analysis, where samples are
filtered using either a 0.45 µm, 0.22 µm, or 0.02µm filter. What is surprising about
the profiles in Figure 5 is that ketoconazole appears to remain supersaturated for the
time course of the experiment. In contrast, the precipitation profile at a lower starting
dose of 225mg appears to reach the crystalline solubility after 0.5 h (Figure 4). At
a higher degree of supersaturation or a higher initial dose, the precipitation kinetics
is expected to be faster than at a lower initial dose. This confounding observation
is likely a consequence of sample preparation. The amount of crystal nuclei formed
is directly related to the degree of supersaturation achieved in solution. With higher
degrees of supersaturation the probability of nuclei formation increases, leading to
a larger number of nuclei formed relative to lower degrees of supersaturation. With
more sites available for the supersaturated species to integrate within the crystal
lattice, the mean size increase of nuclei during crystal growth is minimal. In cases
of low supersaturation, the supersaturated species have fewer crystal growth sites,
which results in larger crystals. Therefore, it is hypothesized that within the 250
mg profile, the crystals present throughout the experiment are much smaller than
what the 0.45 µm filter can remove. Only until the 0.5 h mark, some of the nuclei
become sufficiently big enough to be filtered out with the 0.02 µm filter. Before
quantifying ketoconazole within samples, samples are diluted 1:4 with acetonitrile to
avoid crystallization after sampling. Therefore, any crystalline material which was
not filtered could be redissolved following the dilution of the sample with acetonitrile,
leading to the apparent plateaus in concentration observed in Figure 5. Due to the
inconsistencies within this dosing condition, the precipitation parameters extracted
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from this profile are excluded from any further analyses within this study.
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Figure 3.5: Precipitation profiles of ketoconazole in FaSSIF-V2 after dumping of
0.025 N HCl solutions containing 250 mg of dissolved ketoconazole, where samples
are filtered with 0.45 µm ( ), 0.22 µm ( ), 0.02 µm ( ) filters. The final pH of the
media was 6.26 following the introduction of the acidic dosing solution.

3.3.3.2

Impact of Mucin on the Precipitation Profiles of Ketoconazole.— The pres-

ence of exogenous and endogenous material has been shown to either inhibit or promote nucleation and crystal growth [38, 63, 64, 65, 66, 67, 68, 69, 74]. Cellulosic
polymers, such as HPMC and HPMC-AS, which share compositional similarity to
mucin, are potent crystallization inhibitors. The effectiveness of a given solution
component as a crystallization inhibitor is believed to be a function of the strength of
the intermolecular interactions between the material and the supersaturated species.
Although there is limited literature evaluating the exact mechanism of the crystallization inhibition for several polymers and endogenous material, there exists a consensus
that hydrophobic, hydrogen-bonding, and ionic interactions may play a role.
To probe the impact of mucin on the precipitation kinetics of ketoconazole, an
in-vitro precipitation experiment was performed. Figure 6 shows the in-vitro precipitation profiles of ketoconazole introduced via a 0.025N HCl solution to FaSSIF-V2
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containing 1 mg/mL of mucin. More rapid rates of precipitation were observed with
higher doses of ketoconazole. This relation between supersaturation and precipitation
kinetics is expected as with higher degrees of supersaturation, the smaller the activation energy for nucleation becomes, leading to faster precipitation kinetics. Overall,
all the precipitation profiles followed first-order kinetics (Eq. 1). The resulting precipitation rate constants, kp , in 500 mL of FaSSIF-V2 containing 1mg/mL mucin
were 1.332, 0.818, 1.290, and 1.034 h−1 corresponding to ketoconazole doses of 250,
225, 200, and 175 mg, respectively. According to Figure S3, the differences between
the profiles are rather minimal, indicating the strong propensity for mucin to reduce
precipitation kinetics. Fitting the data in Figure S3 to Eq. 3, the k0 and β values
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were determined to be 0.7978 and 0.7925, respectively.

250
200
150
100
50
0
0.0

0.5

1.0

Time (h)
mg Dose
225 mg containing
Dose
Figure 3.6: Precipitation250
profiles
of ketoconazole in FaSSIF-V2
1 mg/mL
of mucin after dumping of 0.025 N HCl solutions of 250 mg ( ), 225 mg ( ), 200 mg
200 mg Dose
175 mg Dose
( ), and 175 mg ( ) of dissolved ketoconazole. The final pH of the media was 6.26
following the introduction of the acidic dosing solution.The curves represent fits to
the data according to the first-order kinetic rate equation in Eq. 1.
The presence of mucin within FaSSIF-V2 resulted in slower precipitation kinetics
of ketoconazole when comparing the profiles observed in Figure S3 to those observed
in Figure 4. The first-order precipitation rate constants derived from Figure S3 are
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80%, 25%, and 12% lower in the media containing mucin than the profiles without
mucin for the 225, 200, and 175 mg doses, respectively.
To understand the impact of mucin on the precipitation kinetics of ketoconazole
with the presence of undissolved crystalline material within the dosing solution the
same in-vitro precipitation experiment was conducted using a 0.02 N HCl dosing
solution. Figure 7 shows the in-vitro precipitation profiles of ketoconazole in FaSSIFV2 containing 1 mg/mL of mucin following the introduction of a 0.02 N HCl acidic
solution containing various amounts of dissolved ketoconazole. The resulting precipitation rate constants kp for initial amounts of the drug (250, 225, 200, and 175
mg) in 500 mL of FaSSIF-V2 were 14.070, 9.299, 6.911, and 1.099 h−1 , respectively
(Figure S4). Fitting the rate constants with Eq. 3 the resulting fitted values are
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k0,0.025N HCl = 0.1004 h−1 and β0.025N HCl = 9.941 mL/mg.
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Figure 3.7: Precipitation 250
profiles
ketoconazole in FaSSIF-V2
containing 1 mg/mL
of mucin after dumping of200
0.02
HCl solutions of 250
), 225 mg ( ), 200 mg
mgNDose
175mg
mg( Dose
( ), and 175 mg ( ) of dissolved ketoconazole. The final pH of the media was 6.3
following the introduction of the acidic dosing solution. The curves represent fits to
the data according to the first-order kinetic rate equation in Eq. 1.
When the 0.02N HCl dosing solution containing undissolved ketoconazole is used,
there is no apparent impact on the precipitation kinetics of ketoconazole when compared to the profiles in Figure 3, except for in the 175 mg dosing condition where
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there is a 53% reduction in the rate constant. It is expected that complete dissolution
of the 175 mg dose occurs within the 0.02N HCl solution. Suppose the diffusion of
supersaturated species to mucin molecules and the formation of the intermolecular
interactions are not allowed to occur prior to crystallization. In that case, it is unexpected that mucin will significantly impact precipitation kinetics. The lack of a
significant change is speculated to result from the fast crystal growth kinetics and
localized supersaturation resulting from the dumping method.
3.3.4

Evaluation of solid precipitates from in-vitro precipitation experiments

An apparent discrepancy between the form of the precipitated material exists between the material sampled from in-vitro and in-vivo evaluations of ketoconazole
precipitation in the literature. In the in-vivo study conducted by Psachoulias et al.,
the precipitated material sampled from within the duodenum was found to be amorphous by powder X-ray diffraction (PXRD) [137]. Studies conducted in-vitro using a
three compartmental drug transfer setup have found the precipitated material to be
crystalline via PXRD analyses [161]. This discrepancy might lend itself as a potential factor playing a role in the contradictory observations found in-vivo and in-vitro.
However, the hydrodynamic conditions used in the referenced study may influence
precipitation as well. Nonetheless, within this study, the presence of an amorphous
precipitate shortly after the introduction of the dosing solution is suggested by the
plateau in concentration in Figures 3.5 & 3.7, agree with the in-vivo observations.
Precipitates were extracted from solution using ultracentrifugation and analyzed
for crystallinity using PXRD to evaluate the nature of the precipitated material following the introduction of the 0.025N and 0.02N HCl dosing solutions. Figure 8 displays
the powder X-ray diffraction patterns of the solid material collected immediately following the introduction of a 0.025N HCl dosing solution containing the highest dose
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of ketoconazole explored within this study, 250 mg, of dissolved ketoconazole into b)
FaSSIF-V2 media and d) FaSSIF-V2 media containing 1 mg/mL mucin. The PXRD
analysis suggests that the solid precipitates immediately following the introduction
of the dosing solution are partially amorphous with minimal crystalline content, indicating that the plateau in concentration is due to the presence of drug-rich colloidal
species rather than crystal nuclei. Furthermore, it is to be noted that no significant
differences can be observed between the PXRD patterns of precipitates in FaSSIF-V2
media in the presence and absence of mucin.
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Figure 3.8: Powder X-ray diffraction patterns of ketoconazole precipitates following
the introduction of a 0.025N HCl dosing solution. (a) KCZ reference material (used
for preparing the administered solutions and measuring equilibrium solubilities); (b)
a partially amorphous pattern that refers to the precipitate collected immediately following the introduction of 250 mg of ketoconazole into FaSSIF-V2; (c) a crystalline
pattern referring to the precipitate collected one hour after the introduction of 250
mg ketoconazole to FaSSIF-V2; (d) a partially amorphous pattern that refers to the
precipitate collected immediately following the introduction of 250 mg of ketoconazole
into FaSSIF-V2 + 1 mg/mL mucin; (e) a crystalline pattern referring to the precipitate collected one hour after the introduction of 250 mg ketoconazole to FaSSIF-V2
+ 1 mg/mL mucin; (f) mucin reference material.
An evaluation of crystallinity was also conducted on the precipitated material
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one hour after introducing the dosing solution. PXRD patterns c) and d) show
strong crystalline peaks indicating crystallization has occurred. In Figure 5, it was
suggested that crystals within the FaSSIF-V2 media following the introduction of 250
mg of ketoconazole were too small to be filtered by the 0.45 µm filter, leading to
the observed plateau in ketoconazole concentration. The PXRD pattern in Figure 8c
indicates the presence of crystalline material, which validates that hypothesis.
A similar analysis was performed on the solid precipitates collected immediately
following the introduction of a 0.02N HCl dosing solution containing 250 mg of ketoconazole into b) FaSSIF-V2 media and d) FaSSIF-V2 media containing 1 mg/mL
mucin (Figure 9). The PXRD patterns suggest that all of the solid material collected
during the in-vitro precipitation experiment were predominately crystalline. These
observations are consistent with previous assumptions that the 0.02N HCl dosing
solution contained undissolved crystalline ketoconazole, where the presence of such
crystalline material led to the difference in precipitation kinetics observed in Figures
3 & 4.
3.3.5

In-silico modelling and simulation of ketoconazole precipitation in
the small intestinal lumen

The total, dissolved, and precipitated concentrations of ketoconazole in the small intestinal lumen were predicted using an in-silico drug absorption model constructed
using the Simbiology interface within MATLAB software (ver 9.9, Mathworks, Natick, MA). The in-silico drug absorption model was constructed similarly to other
drug absorption models found in the literature. In summary, the in-silico model is
composed of three compartments: the stomach, the small intestine, and the central compartment. The quantity of the drug species within these compartments is
impacted by gastric emptying, intestinal emptying, permeation, and precipitation
processes (Figure 10).
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Figure 3.9: Powder X-ray diffraction patterns of ketoconazole precipitates following
the introduction of a 0.02N HCl dosing solution. (a) KCZ reference material (used
for preparing the administered solutions and measuring equilibrium solubilities); (b)
a partially amorphous pattern that refers to the precipitate collected immediately following the introduction of 250 mg of ketoconazole into FaSSIF-V2; (c) a crystalline
pattern referring to the precipitate collected one hour after the introduction of 250
mg ketoconazole to FaSSIF-V2; (d) a partially amorphous pattern that refers to the
precipitate collected immediately following the introduction of 250 mg of ketoconazole
into FaSSIF-V2 + 1 mg/mL mucin; (e) a crystalline pattern referring to the precipitate collected one hour after the introduction of 250 mg ketoconazole to FaSSIF-V2
+ 1 mg/mL mucin; (f) mucin reference material.
By utilizing the fitted parameters describing the precipitation kinetics in the presence of mucin as determined from in-vitro experiments, it is possible to correlate
those observations to what is predicted to occur within the small intestine in-vivo.
In the study by Psachoulias et al., the 240 mL dosing solutions containing dissolved
ketoconazole were dosed directly into the upper antrum of the stomach. This model
assumes that the whole dosing solution is available as a bolus dose within the stomach,
and no lag-time exists. The emptying of the gastric contents after dosing is assumed to
follow first-order emptying kinetics and can be described by an 8.3 h−1 rate constant,
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Figure 3.10: In-silico model structure for predicting total, dissolved, and precipitated
ketoconazole concentration in the small intestinal lumen. Adapted from Ref [5].
which corresponds to a half-life of approximately 5 min. The initial fluid volume
of the stomach is assumed to be 250 mL following the introduction of the dosing
solution, where the resting fluid volume of the stomach is 10 mL.
For simplicity, any metabolic effects on the ketoconazole concentration are neglected within this model. It is assumed for the model explored that the elimination
of ketoconazole from the small intestine is solely dependent on the small intestinal
emptying rate. The emptying of contents from the small intestine is assumed to follow first-order emptying kinetics, which can be described by a rate constant of 7.22
h−1 , which corresponds to a half-life of 0.096 h. The small intestinal transit time is
reported in the literature to be 4.6 h for fluids; however, in the study by Psachoulias
et al., solutions were dosed in the upper antrum of the stomach, and samples were
aspirated at the ligament of Treitz. Therefore, absorption is only evaluated for the
length of the duodenum. The duodenum has been reported to be 20-25 cm long, and
the length of the entire small intestine is estimated to be around 600 cm long. Therefore, the study by Psachoulias et al. explores ∼ 4% of the length of the small intestine.
70

Assuming the small intestinal emptying rate is constant throughout the entirety of
the small intestine, it is expected that the duodenal emptying time is approximately
0.19 h, which corresponds to the estimated duodenal emptying rate of 7.22 h−1 . The
initial fluid volume of the small intestine is assumed to be 10 mL.
The absorption of ketoconazole to the systemic circulation is assumed to be predominately dependent on the permeation through the small intestinal membrane.
Therefore, ketoconazole absorption through the stomach epithelium is neglected. The
permeation rate through the small intestinal membrane can be described with the following equation:
dMcc (t)
= Pef f ∗ SAP I,SI ∗ C
dt

(3.4)

where Mcc (t) is the mass of drug permeated into the central compartment from the
intestinal lumen at time t, and Pef f is the effective permeability constant. For most
weakly basic and poorly water-soluble drugs, the aqueous boundary layer (ABL) often
limits the effective permeability. Ketoconazole is a weakly basic drug categorized
as a BSC class IIb compound, indicating ketoconazole’s high affinity for biological
membranes and poor aqueous solubility. In similar cases, the effective permeability
constant is accurately described by the drug’s permeability through the ABL.
Diffusion through the ABL, adjacent to the intestinal epithelial membrane, limits
the intestinal permeation of highly lipophilic drugs. Because ABL permeation can
be modeled as a simple diffusion process in a water layer, ABL permeability (PABL )
is represented by the diffusion coefficient and the thickness (δ) of the ABL (7). The
diffusion coefficient was assumed to be accurately captured by the Stokes-Einstein
equation for small, spherical molecules:

PABL =

D
kB T
1
=
∗
δ 6πηR δ
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(3.5)

where kB is the Boltzmann constant, 1.38 × 10−23 J/K, T is the temperature in
kelvin, η is the viscosity of the ABL, and R is the molecular radius. The ABL viscosity is assumed to be equivalent to the viscosity of water (0.6922 mPa⋅s at 310.15
K). It is also assumed that δ = 50 µm accurately describes the thickness of the ABL
surrounding the small intestinal epithelium. The molecular radius of a ketoconazole
molecule was determined to be 10.115 Å, measured using the measure distances tool
in Mercury software (ver. 3.1, Cambridge Crystallographic Data Center (CCDC),
Cambridge, UK). The resultant value for the effective permeability, Pef f , of ketoconazole determined using Eq. 5 at 37 °C through a 50 µm thick ABL was estimated
to be 6.49 × 10−4 cm/s. The duodenum is 20-25 cm in length with a mean diameter
of 24.8 mm. The surface area of the duodenum is estimated to be 156 cm2 , assuming
the shape of the duodenum to be a simple cylinder.
3.3.6

Prediction of duodenal precipitation of ketoconazole

The goal of this work is to to predict and model intestinal drug precipitation of
ketoconazole accurately. In-vivo precipitation data of ketoconazole from within the
human duodenum was extracted from the literature. To accurately model the kinetic
processes of absorption, precipitation, and elimination, the simple physiologicallybased pharmacokinetic (PBPK) model defined in Figure 10 was coupled with the
precipitation parameters derived from the in-vitro precipitation profiles collected in
Figures 3, 4, 6, and 7, and other parameters defined in Table 2.
Figure 11 shows the predicted total, dissolved, and solid concentrations of ketoconazole in the duodenum, as well as in-vivo data extracted from the literature. The
a) and b) components of Figure 11 represent the ketoconazole profiles following the
introduction of 100mg and 300mg of ketoconazole, respectively. In Figure 11a, the
predicted dissolved and total ketoconazole concentrations do not appear to match up
very well with the observed in-vivo data. In this instance, the model overestimates
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Table 3.2: Parameter Values Used in the In-Silico Drug Absorption Model to Simulate
Ketoconazole Precipitation in the Small Intestinal Lumen
Parameter

Value

VStomach,t=0
VSmallIntestine,t=0
k0,(0.02N HCl)
k0,(0.025N HCl)
k0,mucin,(0.02N HCl)
k0,mucin,(0.025N HCl)
β(0.02N HCl)
β(0.025N HCl)
βmucin,(0.02N HCl)
βmucin,(0.025N HCl)
kempty
kelim
Pef f
SA
SAP I,SI,@pH=6.3
SAP I,SI+M uc,@pH=6.3
SAP I,SI,@pH=5.6
SAP I,SI,@pH=4.2

250 mL
10 mL
0.0936 h−1
3.55 × 10−3 h−1
0.1004 h−1
0.7978 h−1
10.07 mL/mg
15.73 mL/mg
9.941 mL/mg
0.7925 mL/mg
8.3 h−1
7.22 h−1
6.49 × 10−4 cm2 /s
156 cm2
0.0125 mg/mL
0.02 mg/mL
0.0333 mg/mL
0.255 mg/mL
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Figure 3.11: Predicted total ( ), dissolved ( ), and precipitated ( ) concentrations of ketoconazole (KCZ) in the small intestine following (a) 100 mg and (b)
300mg dosing. Simulations generated using the precipitation kinetics derived from
the 0.025N HCl dosing conditions. Observed total ( ) and dissolved ( ) KCZ concentrations were extracted from literature.
the exposure of ketoconazole within the duodenum and fails to model the in-vivo data
accurately. When the dose of ketoconazole is increased to 300 mg, the in-silico model
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overestimated precipitation and underestimated the exposure of dissolved ketoconazole within the duodenum. This discrepancy between the predicted and observed
data may be attributed to the failure to accurately capture the precipitation kinetics
using the parameters derived from the system containing solely FaSSIF-V2.
Interactions between mucin and solubilizing components within FaSSIF has been
suggested by increases in solubility, as shown in Figure 2. These interactions may
serve to stabilize supersaturated solutions of ketoconazole within the in-vivo system.
The in-silico model is coupled with the precipitation parameters derived from the
in-vitro precipitation kinetics containing 1 mg/mL of mucin to evaluate the potential
implications of mucin on intestinal precipitation. Figure 12 highlights the predicted
and observed in-vivo ketoconazole concentrations within the duodenum. A better
prediction of the 100 mg observed data is observed in Figure 12a. This improvement
could be attributed to the slight increase in solid content observed when comparing
Figures 11a & 12a, where small amounts of precipitation contributed to the decreases
in total and dissolved ketoconazole. When the amount of ketoconazole dosed is increased to 300 mg, the model prediction appears to fit the data very well. The almost
overlapping values of total and dissolved ketoconazole concentrations in the observed
in-vivo data set suggest the absence of extensive crystallization. Interestingly, the
model simulations utilizing the precipitation parameters defined by the in-vitro precipitation study using 0.025 N HCl dosing solutions can capture the precipitation
behavior of ketoconazole reasonably well, even at high degrees of supersaturation.
Simulations incorporating the fitted parameters from the system dosed with the
0.02 N HCl solution were conducted to evaluate the degree of discrepancy between
the precipitation kinetics determined from the 0.02 N HCl dosing solution containing
crystalline ketoconazole and the 0.025 N HCl dosing solution. Figure 13 shows the
predicted ketoconazole precipitation data simulated in these conditions. It is difficult
to distinguish the differences between the simulated data at the two dosing conditions.
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Figure 3.12: Predicted total ( ), dissolved ( ), and precipitated ( ) concentrations of ketoconazole (KCZ) in the small intestine following dosing of a) 100 mg and
b) 300 mg of ketoconazole to FaSSIF-V2 media containing 1 mg/mL mucin. Simulations generated using the precipitation kinetics derived from the 0.025N HCl dosing
conditions. Observed total ( ) and dissolved ( ) KCZ concentrations were extracted
from literature.
Both data sets show a similar overestimation of ketoconazole precipitation within the
duodenum. However, according to Figure 14, the addition of mucin into FaSSIF-V2
while introducing ketoconazole with the 0.02 N HCl dosing solution shows a distinct
difference from what is observed in the 0.025 N HCl dosing solution system. In
contrast, the simulated data in Figure 14 does not accurately fit the observed invivo data as well as the data in Figure 12 and more closely resembles the behavior
exhibited in Figure 13, where no mucin is present. In the systems where the 0.02
N HCl solution is used, the sensitivity to solution components capable of reducing
crystallization is reduced due to the presence of undissolved crystalline ketoconazole.
Due to the high degrees of supersaturation, the crystal growth rate is speculated to
be of much greater magnitude than the rate of the diffusion of API to mucin and
vice-versa, leading to the lack of distinguishing features between Figures 13 & 14.
To more quantitatively compare the observed and predicted data sets collected
within this study, the area under the curves (AUCs) of the data sets were calculated.
Table 3 summarizes the calculated AUCs and the fractions precipitated attributed to
the systems explored within this paper. Only 5% and 15% precipitation was observed
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Figure 3.13: Predicted total ( ), dissolved ( ), and precipitated ( ) concentrations of ketoconazole (KCZ) in the small intestine following (a) 100 mg and (b) 300 mg
dosing. Simulations generated using the precipitation kinetics derived from the 0.02N
HCl dosing conditions. Observed total ( ) and dissolved ( ) KCZ concentrations were
extracted from literature.
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Figure 3.14: Predicted total ( ), dissolved ( ), and precipitated ( ) concentrations of ketoconazole (KCZ) in the small intestine following dosing of a) 100 mg and
b) 300 mg of ketoconazole to FaSSIF-V2 media containing 1 mg/mL mucin. Simulations generated using the precipitation kinetics derived from the 0.02N HCl dosing
conditions. Observed total ( ) and dissolved ( ) KCZ concentrations were extracted
from literature.
in-vivo within the duodenum, after the oral administration of 100 and 300 mg of
ketoconazole, respectively. Although 2% and 8% precipitation was predicted within
the 100 mg system using kinetics determined from 0.025N and 0.02N HCl dosing
solutions, respectively, ketoconazole’s exposure was grossly overestimated, evidenced
by the significant difference between the AUCs of the observed and predicted data.
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Furthermore, in the 300 mg system, approximately 30% precipitation was expected
to occur, indicated by the AUC of the simulated dissolved data being significantly
less than the AUC of the observed data in either dosing solution condition. The
introduction of mucin led to improved correlations between the in-silico and in-vivo
data sets solely within the 0.025 N HCl dosing solution condition, where no change
was observed when the 0.02 N HCl dosing solution is used. Overall, the congruence
between AUCs was improved with the incorporation of mucin within precipitation
media, suggesting its influence within the in-vivo system.
Table 3.3: Observed and Predicted AUC of total and dissolved duodenal concentrations and fraction precipitated of ketoconazole.
Observed

Predicted

AUC (total)
(mg⋅h/mL)

AUC (dissolved)
(mg⋅h/mL)

Fraction
precipitated

AUC (total)
(mg⋅h/mL)

AUC (dissolved)
(mg⋅h/mL)

Fraction
precipitated

Ketoconazole
100mg

0.117

0.109

0.05

0.196
0.177

0.193
0.163

0.02
0.08

Ketoconazole
300mg

0.438

0.373

0.15

0.421
0.387

0.311
0.258

0.26
0.33

-

-

-

0.175
0.176

0.159
0.162

0.12
0.08

-

-

-

0.496
0.386

0.437
0.257

0.12
0.33

Ketoconazole
100mg
+1 mg/mL mucin

Ketoconazole
300mg
+1 mg/mL mucin

Upper values refer to the values derived from 0.025N HCl dosing solutions
Lower values refer to the values derived from 0.02N HCl dosing solutions

3.3.7

Parameter sensitivity analysis on predicted precipitation profiles in
small intestine

Ketoconazole is a weakly basic and poorly water-soluble compound whose solubility
can be largely affected by the pH of the solution in which it is solubilized. In the study
by Psachoulias et al., from which the in-vivo data used in the study is extracted, the
pH of the intestinal aspirates had a significant degree of variability. The mean and
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Figure 3.15: (a) Distribution of the ionized and unionized species of ketoconaozole as
a function of pH. (b) The total fraction of ionized ketoconazole as a function of pH.
median pH of aspirates from the end of the duodenum following the introduction of
an acidified solution containing 300 mg of ketoconazole was 5.6 and 6.0, respectively.
The standard deviation of the pH of the aspirates was 1.4, which for weakly basic
compounds could impact solubility dramatically. Ketoconazole as a diprotic base is
characterized by two pKa ’s: pKa,1 = 2.9 and pKa,2 = 6.5, which correspond to the
amine and imine groups, respectively [160].
At the pH values observed in the duodenal aspirates within the study by Psachoulias et al., it is expected that ketoconazole would primarily exist in solution as
ionized species. Figure 15 highlights the distribution of the diprotic, protic, and neutral species of ketoconazole as a function of pH. The distribution of species in Figure
15 indicates that pH may play an important role in the ketoconazole precipitation
profiles observed as the solubility of ketoconazole can vary significantly with changes
in pH. Furthermore, the crystalline solubility data highlighted in Figure 2 and Table
1 highlight the influence of pH on solubility. When considering precipitation kinetics,
the solubility could play a significant role in defining the driving force for crystallization. If the solubility is sufficiently high, it could be expected that the precipitation
kinetics could be lessened relative to the kinetics at a more neutral pH.
A parameter sensitivity analysis was conducted by adjusting the ketoconazole solubility value used within the model to consider the impact of ionization on solubility
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within the simple PBPK model used within the study. The solubility values were
adjusted to reflect the experimentally determined solubility values at various pH values highlighted in Table 1. The simulated data in Figures 16a & b appear to be
very similar to Figure 11b, suggesting the lack of a strong influence of pH within
the ketoconazole system explored. Although the pH and solubility difference between
pH = 5.6 and pH = 4.2 is rather large considering the weakly basic nature of ketoconazole, it appears that there is very little difference between the two simulated
profiles at either pH. This observation suggests that the in-vitro precipitation kinetics
vastly overestimates the precipitation kinetics observed within the in-vivo system as
solubility differences do not play a significant role. A similar analysis was conducted
on the model using the precipitation kinetics determined using a 0.02 N HCl dosing
solution to evaluate whether pH would have a similar impact on the simulations. The
data from those simulations are highlighted in Figures 17a &b. Similar to what was
observed in the simulations using the kinetics derived from the 0.025 N HCl dosing
solution, the simulated data in Figure 17a is almost indistinguishable from Figure
13b. Figure 17b is similar to Figure 17a; however, the total and dissolved simulated
data are slightly elevated.
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Figure 3.16: Predicted total ( ), dissolved ( ), and precipitated ( ) concentrations of ketoconazole (KCZ) in the small intestine following 300 mg dosing and
assuming an instestinal pH of (a) pH = 5.6 and (b) pH = 4.2. Observed total ( ) and
dissolved ( ) KCZ concentrations were extracted from literature.
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Figure 3.17: Predicted total ( ), dissolved ( ), and precipitated ( ) concentrations of ketoconazole (KCZ) in the small intestine following 300mg dosing and
assuming an instestinal pH of (a) pH = 5.6 and (b) pH = 4.2. Observed total ( ) and
dissolved ( ) KCZ concentrations were extracted from literature.
The AUCs of the data shown in Figures 16 & 17 are summarized in Table 3.6.
Across the systems, it appears that the difference in AUC and fraction precipitated
is minimal when comparing the curves attributed to pH = 6.3 & 5.6. In these systems, 20% and 33% of the ketoconazole dose are predicted to have precipitated when
considering the kinetics associated with a 0.025N and 0.02N HCl dosing solution,
respectively. The impact of pH only becomes relevant when considering the curves
associated with a pH = 4.2, where the predicted fraction precipitated decreases to
11% and 25%, respectively. Overall, pH has a negligible impact on the simulated
data sets when considering the precipitation kinetics from either dosing conditions in
FaSSIF-V2 media. The simulated data collected in this parameter sensitivity analysis suggests that changes in solubility - which in this case is a 20-fold increase from
pH 6.3 to pH 4.2 - are overshadowed by the gross overestimation of ketoconazole
precipitation kinetics in the in-vitro model containing FaSSIF-V2.
3.4

Conclusion

The accurate prediction and modeling of supersaturation and precipitation in-vivo
are important, especially when considering supersaturating drug delivery formula80

Table 3.4: Observed and Predicted AUC of total and dissolved duodenal concentrations of ketoconazole with various solubilities determined at various pH’s
Observed

Ketoconazole
300mg
0.025N HCl Kinetics

Ketoconazole
300mg
0.02N HCl Kinetics

Predicted

pH

AUC (total)
(mg⋅h/mL)

AUC (dissolved)
(mg⋅h/mL)

Fraction
precipitated

AUC (total)
(mg⋅h/mL)

AUC (dissolved)
(mg⋅h/mL)

Fraction
precipitated

6.3
5.6
4.2

0.438
-

0.373
-

0.15
-

0.421
0.422
0.442

0.311
0.313
0.344

0.26
0.26
0.22

6.3
5.6
4.2

0.438
-

0.373
-

0.15
-

0.387
0.389
0.425

0.258
0.262
0.319

0.33
0.33
0.25

tions where crystallization may severely impact product performance. The work
demonstrated here highlights the utility of a simple in-vitro pH-swing model, which
can be extended to other weakly basic and poorly water-soluble compounds. Furthermore, while many commercially available simulated gastrointestinal fluids have been
designed to mimic what is natively found in the intestinal lumen closely, many fail to
incorporate mucin. The findings in this study suggest that mucin may play a role in
stabilizing supersaturated solutions against crystallization, and its inclusion within
biorelevant media should be considered when an accurate correlation to the in-vivo
product performance is desired. Overall, the advantage of this simple approach to
evaluate product performance is that it could be used as an early assessment and
pre-screening tool to evaluate product sensitivity to precipitation.
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Chapter 4
Towards Developing Discriminating Dissolution Methods for
Formulations Containing Nano-Particulates in Solution

4.1

Introduction

Current analyses estimate that approximately 70-90% of new chemical entities progressing through the pharmaceutical pipeline are Class II compounds as defined by the
Biopharmaceutics Classification System (BCS). Specifically, those compounds with
low solubility and high permeability characteristics in its most stable crystalline form
[9, 10, 11]. When delivered orally, drug molecules must first dissolve in the gastrointestinal (GI) environment for permeation and absorption to occur. Consequently,
drugs with poor aqueous solubility or low dissolution rates lack a strong driving
force for absorption. For this reason, many BCS Class II drugs have traditionally
failed due to the difficulty in formulating products that achieve efficacious exposures
in-vivo with these compounds [12]. However, with the development of modern supersaturating drug delivery systems (SDDS) such as cocrystals [13, 14, 16, 17], inclusion
complexes [18, 19, 20], lipid formulations [21, 22], and amorphous solid dispersions
[24, 25, 26] it is possible to increase the overall amount of drug dissolved in solution
and consequently enhance bioavailability. As a result, there has been a shift in industry perspective from avoiding such risky development candidates towards acceptance.
The use of SDDS allows for the generation of drug supersaturation where the active
pharmaceutical ingredient’s (API) concentration in solution is higher than that of
the solubility of the crystalline state, resulting in an increased driving force for absorption. The mass transport of API across a boundary can be described by Fick’s
first law of diffusion, where the flux (J) of an API through the GI lumen depends
on the permeability coefficient (P ) of the API through the GI wall and the concentration (C) of the API in solution in the luminal side of the GI tract (assuming sink
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conditions)[79]:

J =P ∗C

(4.1)

This relation demonstrates the impact of increasing API supersaturation, where
the diffusive flux of the API increases linearly with increasing supersaturation. However, complexities arise since the maximum diffusive flux is limited by the spinodal
decomposition of the solution at high supersaturations, where the API begins to form
drug-rich species, which may range in size from nano-scale to micron-scale. Beyond
this decomposition point, the amount of freely solubilized API molecules remains
constant [162, 52]. Given these complexities, the observed flux may deviate from the
above equation, when an API is introduced in concentrations where dilute conditions
no longer exist. In these cases, the flux should be defined as a function of drug activity
instead of drug concentration and include the impact of particulates, which may diffuse into the ABL. Unfortunately, the measurement of thermodynamic activity is not
straightforward and, consequently, flux is often evaluated in accordance with Eq. 1.
While the use of bulk concentration may adequately estimate thermodynamic activity in certain conditions, such as dilute solutions, the application of this assumption
to describe in-vivo absorption could be erroneous [163, 164, 165]. If complex media
is considered, such as human intestinal fluids and simulated gastric fluids, the API
of interest most often does not exist in dilute conditions [166]. This deviation from
dilute conditions leads to solutions where the apparent or total drug concentration
does not represent the true driving force for absorption [167, 168]. For instance,
drug molecules may be solubilized by endogenous surfactants present in the intestinal
lumen, such as bile salts, and these molecules which become entrapped within the
endogenous micelles may not readily be absorbed via passive diffusion, compared to
those “freely-dissolved” molecules [91, 169]. Furthermore, these phenomena are not
restricted to endogenous material, as exogenous material (i.e., formulation excipients)
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has also been shown to impact drug activity in solution [163, 170, 171]. Although
“freely-dissolved” drug at the membrane surface is the main driving force for absorption, it has been observed that weakly-bound drug may have implications on the
overall permeability of drug through the aqueous boundary layer and the amount of
free-drug at the membrane surface.
For BCS Class II compounds, characterized by poor aqueous solubility and high
lipophilic permeability, permeability through the aqueous boundary layer (ABL) is
often the rate-limiting step for absorption. Due to the high lipophilic permeability
of BCS Class II compounds, membrane transport often outpaces the solution transport of drug to membrane surfaces. This difference in transport rates results in the
formation of a concentration gradient from the bulk solution to the membrane surface, where the thickness of the concentration gradient depends on the hydrodynamic
conditions of the system. However, it has been reported that the addition of micelles
may improve the overall mass transport of drug molecules across the ABL, resulting in
increased local drug activity at the membrane surface [80, 81, 82, 83, 84]. Similar observations have been made in systems containing other colloidal species[3, 85, 86] and
in systems containing an excess of crystalline drug[87]. The term “particle-drifting”,
coined by Sugano, describes this phenomenon in systems containing excess nanocrystalline particles drifting into the mucus and water boundary layers[87]. In this
work, this approach is used to describe the ability of nano-scale species in solution
to shuttle drug through the ABL and increase the overall mass transport of drug
molecules to the membrane surface.
Estradiol (E2), a poorly water-soluble compound, is used to determine the aR
in complex media containing nano-particulate species and the deviation from ideality of

γD,solution
γD,eq

in the absence and presence of a surfactant model, polysorbate 80

(PS80) is presented. The knowledge gained from the experiments detailed in this
paper will serve to provide a deeper understanding of the impact of nano-particulate
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species, derived from endogenous or exogenous material, on the absorption of APIs.
Furthermore, although the authors acknowledge that human intestinal fluid is comprised of a variety of bile salts, lipids, and aggregates, the use of a simplified model
will help to facilitate the understanding of the impact of media components within
complex systems on the absorption and performance of APIs. This work provides a
tool whereby development scientists can better understand the implications of nanoparticulate speciation on the overall performance of formulations in ways that may
better correlate in-vitro performance with in-vivo performance and therefore develop
more meaningful discriminating dissolution methods.
4.2

Theoretical Considerations

The concurrent in-vivo dissolution and absorption processes are often explored invitro through the use of diffusion cells. The intention is to, at least qualitatively,
capture the in-vivo dynamics of these systems using in-vitro tools which can mimic
in-vivo conditions (Figure 1) [172, 162, 173]. The use of diffusion cells as a model
to describe permeation phenomenon must adhere to the following model assumptions
[3]:
1. Drug transport through the aqueous boundary layer (ABL) and the membrane
is described by Fick’s laws of diffusion.
2. The diffusion coefficient of the drug is not a function of concentration in the
medium explored.
3. Drug transport via convection (i.e., bulk fluid flow) across the membrane can
be neglected for the hydrodynamic conditions studied.
4. The ABL is a theoretical boundary representing the development of a concentration gradient near the membrane surface due to fast membrane transport
relative to solution transport.
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5. The flux observed is characterized by unidirectional transport across each barrier in series from the well-mixed, bulk aqueous donor medium to the receiver
medium.
6. The instantaneous concentration profile within each diffusion layer resembles a
steady-state (pseudo steady-state approximation).
7. The thickness of each diffusion layer is constant with time for a given experiment.
8. The partitioning of drug into the membrane is unaffected by medium components.
9. The concentration of drug in the receiver medium is much less than that in the
donor medium.
10. Colloid-associated drug is in equilibrium with the unbound drug in solution.
11. The exchange of drug between the bulk fluid and colloid phase is instantaneous
12. The integrity of the membrane is conserved for the duration of the experiment.
If the listed assumptions are valid, the absorption profiles of model active pharmaceutical ingredients (APIs) can be mathematically described by the following version
of Fick’s first law (Eq. 2).

J=

V dC
∗
= Pef f ∗ aD,solution
A dt

(4.2)

The rate of drug absorption, represented as flux (J), is a product of the effective permeability (Pef f ) and the drug solution thermodynamic activity (aD,solution ).
Experimentally, volume (V), membrane surface area (A), and the change in drug concentration as a function of time ( dC
dt ) can be measured to calculate the flux across a
membrane.
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Figure 4.1: Schematic of the (a) in-vivo and (b) in-vitro boundaries to active pharmaceutical ingredient (API) absorption in the presence of nanoparticles capable of
drifting within the aqueous boundary layer (ABL).
Pef f is the effective permeability of the drug molecule through both the membrane
of interest and the aqueous boundary layers (ABLs) on either side of the membrane.
The value of Pef f is primarily dictated by the physicochemical properties of the drug
molecule, and it may be affected by the experimental conditions utilized [174, 175,
176]. A regenerated cellulose dialysis membrane was used in this study to separate
free drug molecules from both drug-rich aggregates and micellized drug molecules, as
is shown in similar systems [91, 163, 162, 54]. However, it should be acknowledged
that other drug molecules may very well have ionizable groups, may form dimers, or
perhaps might be complexed with cyclodextrin, all of which would be “recognized” as
a free drug species using the dialysis membrane, due to its 6-8 kDa molecular weight
cutoff.
For constant hydrodynamic conditions, and under the assumptions stated above,
Pef f is largely invariable, so long as the drug is chemically stable. Thus, the extent
of permeation is predominately governed by the drug’s thermodynamic activity. The
thermodynamic activity is the product of the total drug concentration CT , and the
thermodynamic activity coefficient of the drug in solution γD,solution as shown in Eq.
3.
aD,solution = γD,solution ∗ CT
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(4.3)

The activity coefficient describes the deviation from ideality of a species in solution
and serves to correlate concentration to activity. In non-ideal conditions (γD,solution ≠
1), the flux can be calculated by combining Eq. 2 and Eq. 3.

J = Pef f ∗ γD,solution ∗ CT

(4.4)

Due to the difficulty in assessing thermodynamic activity in complex media, the
drug concentration is often described in terms of a supersaturation ratio (SR), which
is the ratio between the total drug concentration, CT , and the crystalline equilibrium
solubility, Seq , as shown in Eq. 5 [177].

SR =

CT
Seq

(4.5)

However, as noted above, the total concentration may not be representative of the
true absorption driving force. Therefore, the true extent of supersaturation should
be calculated as the activity ratio (aR ), which is the ratio between the drug solution activity, aD,solution , and the drug solution activity at the equilibrium crystalline
solubility limit, aD,eq , as shown in Eq. 6.

aR =

aD,solution γD,solution ∗ cT γD,solution
=
=
∗ SR
aD,eq
γD,eq ∗ Seq
γD,eq

(4.6)

The drug solution activity coefficients of the supersaturated drug solution and the
drug solution at the crystalline solubility limit are represented as γD,solution and γD,eq ,
respectively. Note that the

γD,solution
γD,eq

term in Eq. 6, i.e., gamma ratio serves as the

correction factor for supersaturation in non-ideal conditions. Care must be taken in
interpreting this ratio since, strictly, multiple phases may exist. For instance, the
drug-rich precipitate will exist about the spinode, and the API may exist as truly
dissolved species or within the micellar structure. With these considerations in mind,
the activity ratio, Eq. 6, can be combined with Eq. 2 to yield Eq. 7, which allows
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for the calculation of aR .

aR =

aD,solution
=
aD,eq

JD,solution/P
JD,eq/P

ef f

(4.7)

ef f

In other words, the flux at any non-dilute condition can be compared to the flux
at the crystalline solubility in a surfactant-free system to attain the true extent of
supersaturation. In cases where the effective permeabilities in the conditions compared are equivalent, the activity ratio can be determined by a simple ratio of the
fluxes observed in a saturated and supersaturated solution [54]. However, in certain
instances, where nano-scale species are present in media, the effective permeabilities
exhibited by the two cases may not be equivalent. That is, in systems where drug
permeability is limited by the aqueous boundary layer, the introduction of nano-scale
solution species may serve to increase the effective diffusion coefficient, Def f , allowing for more effective movement of drug molecules across the ABL. Such cases of
non-equivalent Pef f will be explored and discussed in depth within this paper.
4.3
4.3.1

Materials and Methods
Materials

17β-Estradiol (E2) and polysorbate 80 (PS80) were purchased from Sigma-Aldrich
(St. Louis, MO). Acetonitrile, potassium dihydrogen phosphate, and potassium phosphate dibasic were supplied by VWR International (Radnor, PA). Dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific (Fair Lawn, NJ). Hydroxypropyl
methylcellulose (HPMC) K4M grade was provided by Colorcon (West Point, PA).
Deionized water was obtained from a MilliQ water purification device (Milli-Q Synthesis, Millipore, Bedford, MA) and filtered through a 0.22 µm filter (Millipak 40,
Millipore, Bedford, MA) before use. Polytetrafluoroethylene (PTFE) syringe filters
with a diameter of 13 mm (0.22 µm pore size) were purchased from Tisch Scien-
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tific (Cleves, OH). Regenerated cellulose dialysis membrane with 6-8 kDa molecular
weight cutoff (MWCO) and 70 µm thickness was obtained from Spectrum Laboratories (Rancho Dominguez, CA). Membranes were soaked in deionized water overnight,
prior to use in flux experiments. All other materials were used as received.
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Figure 4.2: Molecular structures of (a) 17β-estradiol (E2), (b) Hydroxypropyl methylcellulose (HPMC), and (c) Polysorbate 80 (PS80).

4.3.2

Crystalline Solubility Measurements

Crystalline solubility of E2 was determined by placing an excess of crystalline drug
into a glass vial containing 20 mM potassium phosphate buffer at pH 6.8 in the absence and presence of excipients. For media containing excipients, excipients were
pre-dissolved in the buffer prior to the solubility measurements. The mixture was
agitated using a vial rotator in an incubator at 37°C for 72 hours. The total drug con-
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centration and the unbound drug concentration in solution were determined utilizing
different separation techniques. For the determination of the total drug concentration, CT , samples were filtered through a 0.22 µm syringe filter. The syringe filter was
saturated by discarding the first 3 mL of the filtrate. For the determination of the
unbound drug concentration, Cu , ultracentrifugation was employed to separate any
nano-scale species in solution. Samples were spun at 100,000 RPM (451,268 g) for 4 h,
while maintaining the temperature at 37 °C, using a Sorvall Discovery M120 microultracentrifuge equipped with a fixed-angle (30°) S120-AT2 rotor (Thermo Fisher
Scientific, Waltham, MA). The selection of the parameters suitable for complete sedimentation of PS80 micelles was made using Stokes’ Law [178]. The values for the
particle density, the medium density, and medium viscosity were derived from literature [179]. Following filtration and separation, 200µL of the sample or supernatant
was sampled and diluted with an equal volume of the mobile phase. The only exception was for samples containing 1% PS80, where filtered samples were diluted 8-fold
to maintain E2 concentrations within the linear region of the HPLC calibration curve.
The concentration of E2 in samples were determined using a Dionex Ultimate 3000
high-performance liquid chromatography (HPLC) system equipped with a photodiode array (Thermo Fisher Scientific, Waltham, MA). An injection volume of 20 µL
was run through an ODS-2 Hypersil C18 column (4.6 mm internal diameter, 150
mm length, 5 µm particle size; Thermo Fisher Scientific, Waltham, MA). The mobile
phase consisted of acetonitrile and water in a 55:45 v/v ratio, and it was pumped
isocratically at a flow rate of 1 mL/min. The detection wavelength was set at 224 nm
for the quantification of 17β-estradiol. A retention time of approximately 3 minutes
was obtained. A calibration curve (R2 = 0.999) between 0.25 µg/mL and 30 µg/mL
was developed to determine E2 concentration in solution. All solubility measurements
were performed in triplicate.
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4.3.3

Amorphous Solubility Measurements

The amorphous solubility measurements were performed via a solvent shift method.
1 µL of two different stock solutions of E2 in DMSO, 1 mg/mL and 50 mg/mL, was
added into a 3 mL solution of buffer in the absence and presence of 1% w/v PS80
(both of these solutions contained 100 µg/mL HPMC to prevent E2 crystallization
over the time-scale of the experiment), respectively. Several additions of the E2 stock
solution were introduced to obtain a few points below and above the amorphous solubility. It should be noted that care was taken to ensure that the final concentration
of DMSO was less than 1% v/v. After each E2 stock solution addition, the solution was stirred at 300 RPM for 1-2 minutes, and measurement was taken using a
UV-Vis spectrometer. UV-Vis scattering was monitored using a Shimadzu UV-1800
spectrometer (Columbia, MD) at a non-absorbing wavelength of 700 nm to monitor
the formation and evolution of phase-separated aggregates. The amorphous solubility
was characterized by a sharp increase in UV absorbance due to the scattering of light
by the formation of drug-rich aggregates [51]. An aliquot of each solution was placed
under a polarized light microscope (Olympus, Waltham, MA) to confirm the absence
of birefringence. The unbound drug was then separated with ultracentrifugation using
the same conditions as described for the crystalline solubility measurements. Following ultracentrifugation, the amount of E2 in the supernatant was quantified using
the same HPLC methodologies described above. All solubility measurements were
performed in triplicate.
4.3.4

Micelle-Associated E2 Diffusion Coefficient Determination

The micelle-associated E2 diffusion coefficient (Dmic ) was measured using a routine
two-dimensional Diffusion Ordered Spectroscopy (2D DOSY) nuclear magnetic resonance (NMR) technique [180]. The measurements were conducted on a 1% v/v PS80
+ 100 µg/mL HPMC solution containing E2 at a supersaturation value of SR = 2. All
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experiments were carried out at 37 °C on a Bruker AVANCE III spectrometer with a
proton frequency of 500.13 MHz in the Biopharmaceutical NMR Laboratory (BNL)
in Pharmaceutical Sciences, Preclinical Development, MRL (Merck & Co., Inc. West
Point, PA, 19486). A DOSY sequence with the bipolar-pulsed field gradient longitudinal eddy-current delay (LED-BPP) was used [181]. To ensure the complete recovery
of the magnetization vector and efficient acquisition, a small pulse flip-angle 30° was
used rather than the 90° flip-angle in the conventional single pulse sequence. The
gradient strength was 6 G/mm with a D2 O sample as the standard. Sixteen linear
steps from 2% to 95% of gradient strength and a t2 (F2 dimension) of 2048 sampling
data points were used. The implemented diffusion time big delta (∆) and the diffusion gradient length small delta (δ) were 300 ms and 2 ms, respectively. TSP−d4
(Me3 Si−CD2 CD2 −CO2 Na) was used as the external reference for calibration purposes.
Diffusion coefficients were derived using a standard procedure of DOSY processing in
Topspin.
4.3.5

Diffusion Cell Experiments

A side-by-side diffusion cell (PermeGear, Inc., Hellertown, PA) of 30 mL volume (each
compartment) and a 32 mm orifice diameter was used to determine the flux, J, at
several supersaturated concentration conditions (Figure 1b). A regenerated cellulose
membrane (MWCO 6-8 kDa) was inserted between the two diffusion cells, coupled
with two Teflon spacer rings on either side of the membrane to ensure adequate sealing of the system. The surface area of the exposed membrane was 8.042 cm2 . Both
the donor and acceptor compartments were filled with 30 mL of 20 mM phosphatebuffered media (pH=6.8) and sealed with teflon plugs to minimize osmotic pressure
effects. The media within each cell was stirred using a Double Spinfin® alnico stir
bar at either 100 RPM or 300 RPM and maintained at 37°C. All media used for flux
experiments contained 100 µg/mL HPMC, to stabilize against crystallization through-
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out the time-course of the experiment. For experiments at SR = 1 (i.e., suspension),
the donor compartment contained an excess of crystalline drug, whereas the acceptor
compartment was filled with a blank buffered solution. A solvent shift approach,
where a highly concentrated E2 solution in DMSO (50 mg/mL) was transferred to
the aqueous buffered solution at t = 0, was used to generate different supersaturation
ratio (SR) conditions. The DMSO content in the donor compartment was kept below
1% v/v.
A 200 µL sample was taken from the acceptor compartment of the side-by-side
diffusion cells every 30 min after the start of the experiment for 6 hours, and then
diluted with an equal volume of mobile phase to minimize crystallization after sampling. Samples were then analyzed via HPLC using the same method described for
crystalline solubility determination. To study the effect of micelles drifting in the
ABL, experiments were performed similar to the method described above, except the
donor and acceptor compartments contained 1% v/v Polysorbate 80 (PS80). The
critical micelle concentration (CMC) value at 37 °C and in the presence of buffer and
HPMC was found to be similar to reported values at 25 °C (CMC ≈ 0.012 - 0.014
mM) [179, 182, 183] (Figure S1). The concentration of PS80 used in this paper is well
above its CMC, and to verify the formation of micelles in solution, Dynamic Light
Scattering (DLS) was used. DLS analysis indicated the presence of 11 nm particles,
which is consistent with literature values of the size of empty PS80 micelles [184].
Also, the concentration of PS80 in the acceptor compartment was kept the same as
that in the donor compartment to minimize osmotic pressure effects. All diffusion
cell experiments were done in triplicate.
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4.4

Results

4.4.1

17β-Estradiol Crystalline and Amorphous Solubility

The measured crystalline and amorphous solubility values of E2 at 37 °C in 20 mM
phosphate buffer (pH = 6.8) in the absence and presence of 100 µg/mL HPMC and
1% v/v PS80 is summarized in Table 1. For the the solubility determinations in this
paper, the total concentration (CT ) in solution will be referred to as the apparent
crystalline or apparent amorphous solubility, and the unbound drug concentration
(Cu ) will be referred to as the crystalline or amorphous solubility. This consideration is important in the 1% PS80 solution conditions as two distinct solubilities are
reported; one where micelles are included (CT ), and one where micelles are separated
out (Cu ).
The crystalline and amorphous solubility of E2 is found to be 2.2 µg/mL and 13.9
µg/mL in the absence of 1% v/v PS80. The addition of 100 µg/mL HPMC for the
inhibition of crystallization was found to slightly increase the crystalline solubility
values to 2.6 µg/mL. The amorphous solubility determination of E2 was conducted
with 100 µg/mL of HPMC to stabilize against crystallization over the time-course of
the experiment (i.e., no birefringence was observed).
The presence of 1% PS80 in solution served to solubilize higher amounts of drug
molecules in solution. In the presence of 1% v/v PS80, the apparent crystalline and
apparent amorphous solubility values were 60.2 µg/mL and 220.8 µg/mL, respectively.
The addition of 100 µg/mL HPMC for the inhibition of crystallization was found to
perhaps slightly increase the apparent crystalline solubility value to 62.2 µg/mL. The
amorphous solubility determination of E2 in the presence of 1% PS80 was conducted
with 100 µg/mL of HPMC to stabilize against crystallization over the time-course of
the experiment.
The micelles in the sampled solutions were separated using ultracentrifugation,
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Table 4.1: E2 crystalline and amorphous solubility values in different mediaa .
Medium
Buffer
Buffer

Crystalline Solubility

Amorphous Solubility

(µg/mL)
CT,CS
Cu,CS
2.2 ± 0.0 2.2 ± 0.0

(µg/mL)
CT,AS
Cu,AS
b
-b

SRmax =

CT,AS
CT,CS

-b

+ 100µg/mL HPMC

2.6 ± 0.1

2.6 ± 0.1

13.9 ± 1.2

13.9 ± 1.2

5.3

1% PS80

60.2 ± 1.3

4.6 ± 0.8

-b

-b

-b

1% PS80

62.2 ± 0.1 5.0 ± 1.1 220.8 ± 0.0 15.7 ± 1.7
3.5
values indicate standard deviation with n = 3
b In the absence of HPMC, E2 crystallization impeded amorphous solubility
determination
+ 100µg/mL HPMC

a Error

and the E2 concentration in the supernatant was analyzed to determine the crystalline
and amorphous solubilities. It was found that the crystalline solubility of E2 in
the presence of 1% PS80 was 4.6 µg/mL, which is about 2-fold greater than the
crystalline solubility of E2 in the absence of PS80. The addition of 100 µg/mL
HPMC for the inhibition of crystallization was found to yield a statistically equivalent
crystalline solubility in the presence of 1% v/v PS80 (5.0 µg/mL). However, the
amorphous solubility was found to be 15.7 µg/mL, which is statistically equivalent to
the amorphous solubility in the absence of PS80. This difference between Cu and CT
at the amorphous solubility limit indicates that a large fraction of E2 exists within the
micelles since the apparent amorphous solubility is 220.8 µg/mL, an approximately
14-fold difference.
4.4.2

Estradiol Diffusion Coefficients

For the determination of the micellar-associated E2 species, a two-dimensional Diffusion Ordered Spectroscopy (2D DOSY) NMR technique was used and described in
our previous study [185]. The measurements evaluated the diffusion of E2’s aromatic
protons in a 1% v/v PS80 + 100 µg/mL HPMC solution. An SR = 2 system was
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selected for diffusion coefficient determination at the midpoint of micelle saturation
as the maximum amount of E2 loading as the amorphous solubility limit is reached
at SR ≈ 3.5. The diffusion coefficient for micelle-associated E2 molecules, Dmic , as
measured by NMR, was determined to be 8.65 × 10−7 cm2 /s at 37°C.
In this work, the diffusion coefficient of the unbound API was determined using
the empirical equation derived by Avdeef relating the molecular weight of a drug
molecule to its diffusion coefficient in water at 37 °C[186].

Dmono (cm2 /s, 37°C) = 9.9 × 10−5 M W −0.453

(4.8)

An evaluation of the the empirical Avdeef equation across a series of drug-like
molecules resulted in an average error of 20%[186]. The free estradiol diffusion coefficient, Du , was estimated to be 7.8 × 10−6 cm2 /s at 37°C using Eq. 8.
4.4.3

Flux Measurements

The flux, J, in the diffusion cell experiments, was derived from the slopes of the
linear regions of the mass transport rates of E2. The flux is also derived from volumecorrected mass transport rates due to decreases in the receiver compartment volume
as a result of sampling. The flux values are also normalized against the surface area
of the membrane to give values of units (µg/min/cm2 ).
The activity, aD,solution , of E2 in the presence of 1% v/v PS80 was determined using
a calibration curve correlating the observed flux at different concentrations at and
above its crystalline solubility in buffered media containing 100 µg/mL HPMC. Two
calibration curves were developed in 20 mM phosphate buffer (pH = 6.8) containing
100 µg/mL HPMC at stirring rates of 100 & 300 RPM. A flux vs fraction of amorphous
solubility curve was generated and found to be linear (R2 = 0.9942) and (R2 = 0.9716)
for 100 & 300 RPM, respectively (Figures S2 & S3).
Figure 3 shows the activity ratios determined for the buffer systems in the absence
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Figure 4.3: Relationship between SR & Activity Ratio (aR ), (grey bar), and SR &
γD,solution
γD,crystal ( ∎, represented as “Gamma Ratio") in 20 mM phosphate buffered (pH = 6.8)
) and
solutions stirred at (a) 100 RPM and (b) 300 RPM. Also shown is aR,max (
the standard deviation error (
) based from amorphous solubility measurements
(n = 3). Error bars represent standard deviation with n = 3.
of 1% v/v PS80 utilizing the calibration curve generated at different supersaturation
conditions. Below the amorphous solubility, it is observed that SR = aR and the
gamma ratio is close to or equivalent to 1, indicating that all of the drug introduced below the amorphous solubility is readily available for absorption. Furthermore, the flux
was found to plateau above the amorphous solubility. This phenomenon is expected
since concentrations above the amorphous solubility exhibit spinodal decomposition
into drug-rich colloidal aggregates, and the concentration of molecularly dissolved or
“free” drug remains constant [51, 162, 52, 187, 188]. Since these experiments were
conducted in dilute conditions, the activity coefficient ratio is expected to be unity
up until the amorphous solubility limit. Past the amorphous solubility limit, where
dilute conditions no longer apply, it is observed from Figure 3 that the gamma ratio
becomes < 1. However, it is important to note that a second phase begins to form past
the amorphous solubility limit. Upon forming a second phase, the observed gamma
ratio becomes an apparent gamma ratio, coupling the activity coefficients of both the
free and phase-separated drug.
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Figure 4.4: 17β-Estradiol concentration observed over time in the acceptor compartment, in systems containing simple aqueous buffer stirred at 100 & 300 RPM. The
donor compartment was dosed with a) an excess of crystal solids to achieve an SR = 1
and b) a concentrated stock solution to achieve an SR = 2.
4.4.4

Influence of Stirring Rate on Flux Profiles

Flux experiments were conducted in the absence and presence of 1% v/v PS80 at
different SR under two stirring conditions, 100 & 300 RPM. Figure 4 demonstrates
the influence of the stirring conditions explored at different supersaturation conditions
in the simple aqueous buffer systems. The slopes of the mass transport rates of E2
at an SR = 1 in buffered systems stirred at 100 & 300 RPM were determined to be
1.07×10−3 and 1.78×10−3 µg/mL/min, respectively, which represents an approximately
2-fold difference (Figure 4a). The slopes of the mass transport rates of E2 in buffered
systems at an SR = 2 stirred at 100 & 300 RPM were determined to be 2.31 ×
10−3 and 7.80 × 10−3 µg/mL/min, respectively, which represents an approximately
3-fold difference (Figure 4b). In both cases, the slopes at different stirring rates were
significantly different (P < 0.0001). Moreover, the lag times are notably different for
each measured SR. At an SR of 1, the lag time was about 1 h at a stirring rate of 100
RPM and minimal (< 0.5 h) at a stirring rate of 300 RPM. At an SR of 2, the lag
time was found to be about 0.5 h at a stirring rate of 100 RPM and minimal (< 0.5
h) at a stirring rate of 300 RPM. These results reflect the influence of the stir rate
on the overall or effective permeability of E2 (Figure 4a & 4b).
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The influence of stirring conditions on the observed mass transfer profiles was also
explored in systems containing 1% v/v PS80 at various supersaturation ratios. In the
presence of 1% v/v PS80, the slopes of the mass transfer profiles at SR = 1 stirred
at 100 & 300 RPM were determined to be 1.67 × 10−3 and 2.72 × 10−3 µg/mL/min,
respectively, which represents an approximately 1.6-fold difference (Figure 5a). The
slopes were determined to be significantly different (P < 0.02) (Figure 5a). At SR = 2,
in the presence of 1% v/v PS80, the slopes of the mass transfer profiles stirred at 100 &
300 RPM were determined to be 2.62 × 10−3 and 4.12 × 10−3 µg/mL/min, respectively,
which represents an approximately 1.6-fold difference (Figure 5b). At SR = 3, in the
presence of 1% v/v PS80, the slopes of the mass transfer profiles stirred at 100 &
300 RPM were determined to be 3.63 × 10−3 and 5.38 × 10−3 µg/mL/min, respectively,
which represents an approximately 1.5-fold difference (Figure 5b). The slopes of the
mass transfer profiles stirred at 100 & 300 RPM were found to be significantly different
(P < 0.0001) at both SR = 2 and SR = 3. In the SR = 1 system, there were minimal
differences between the lag-times of the two flux profiles at 100 & 300 RPM (Figure
5a), where both profiles had a lag time < 0.5 h. The lack of a lag-time difference may
result from the particle-drifting of micellar or suspended crystals in the slow stirring
conditions, leading to a faster appearance of E2 in the acceptor cell. In supersaturated
systems containing 1 % v/v PS80, there is a distinct difference between the lag-times
and slopes at 100 & 300 RPM (Figure 5b). For experiments stirred at 100 RPM,
there was a significant lag time at both SR = 2 and SR = 3, ∼ 2.5 h and ∼ 1.5 h,
respectively. It is observed that the lag-time decreases with an increasing degree
of supersaturation, as is expected with a greater concentration gradient across the
membrane. In contrast, the experiments conducted with stirring at 300 RPM, have
minimal (< 0.5 h) lag-times, indicating that the ABL is significantly reduced.

100

(a)

(b)

Estradiol Concentration (µg/mL)

Estradiol Concentration (µg/mL)

1.2
1.0
0.8

SR = 1; 100 RPM

0.6

SR = 1; 300 RPM

0.4
0.2
0.0
0

1

2

3

4

5

6

2.0
1.5

SR = 2; 100 RPM

1.0

SR = 3; 100 RPM
SR = 2; 300 RPM

0.5

SR = 3; 300 RPM
0.0
0

1

2

3

Time (h)

4

5

6

7

Time (h)

Figure 4.5: 17β-Estradiol concentration observed over time in the acceptor compartment, in systems containing 1 % v/v PS80 stirred at 100 & 300 RPM. The donor
compartment was dosed with a) an excess of crystal solids to achieve an SR = 1 and
b) a concentrated stock solution to achieve an SR = 2.
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4.5.1

Discussion
Influence of Aqueous Boundary Layer (ABL) Thickness on Observed Flux

Ultimately, this work aims to understand the influence of nano-scale species on the
overall permeability of APIs. Nano-scale species are called out in particular since
they have diffusion rates, which may impact the overall permeability through the
ABL much more drastically than, for instance, micron-scale structures. Logically, to
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understand how the presence of nano-scale species influences overall permeability, one
must first understand the permeability in the absence of nano-scale species. Therefore,
the permeability of freely solubilized E2 and the extent to which the ABL is ratelimiting is considered first. In the most simplistic terms, the permeability of a species,
i, through the Aqueous Boundary Layer (ABL) is defined as
PABL,i =

Di
hABL

(4.9)

where Di is the diffusion coefficient of species i and hABL is the thickness of the
ABL. For poorly-soluble and lipophilic compounds, the ABL is often the rate-limiting
barrier to absorption (PABL ≪ Pmem )[3, 88, 89, 90]. However, with increasing stirring
rates, there may be a point at which the permeability of the ABL is no longer ratelimiting. In these cases, the drug’s permeability may become either membrane-limited
or a combination of ABL-limited and membrane-limited [3]. In the system explored in
this study, the increase in the stirring rate from 100 to 300 RPM is observed to have a
dramatic effect on the ABL, as evidenced by the minimal (< 0.5 h) lag times (Figure
4). At low-speed stirring conditions, the lag-time is observed to be more than an
hour, and in certain cases, lag times up to 2.5 h have been observed. However, when
the stirring rate is increased to 300 RPM, the lag-time is almost negligible (Figure
4a). This impact of the stirring rate is significant as the lag-time is directly related
to the permeability of the diffusing species and the thickness of the ABL. The ABL
forms as a result of the differences between the aqueous and membrane transport
rates of an API close to the membrane surface. The thickness of the ABL is expected
to be a result of the hydrodynamic conditions of the bulk fluid, which is why we see a
dramatic difference in lag-times in systems stirred at 100 & 300 RPM. These results
are consistent with expectations and previous reports [189, 190].
The boundary layer thickness may be estimated through the application of the
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classical Nernst-Brunner equation. This equation describes the surface dissolution
rate of solid particles controlled by the diffusion process across a stagnant aqueous
boundary layer on the solid surface (Eq. 10).

V ∗

dC Di ∗ SA
=
∗ (Cdonor − Cacceptor )
dt
hABL

(4.10)

Equation 10 may be extended to the side-by-side diffusion cells used in this study
to estimate the ABL thickness if the mass transport is rate limited by a boundary
layer. That is, extending the Nernst-Brunner equation to systems where a concentrated species in the bulk fluid permeates across the ABL towards the species deficient
side of the stagnant water layer. For the applicability of the Nernst-Brunner equation
to the diffusion cell system, certain assumptions must be made. First, it is assumed
that the permeability of the diffusing species is limited primarily by the ABL (i.e.,
PABL ≪ Pmem ), which is the case for most BCS Class II compounds such as 17βEstradiol. Also, our flux profiles in Figures 4 & 5 demonstrate a correlation between
the stirring rate and permeability, indicating a strong influence of the ABL on permeation. The regenerated cellulose membranes used in this experiment are 70 µm thick;
however, to simplify the estimation of the boundary layer thickness, it is assumed
that the barrier to transport on both sides of the membrane act as one continuous
ABL.
If these conditions are met, then

dC
dt

describes the rate of appearance of the dif-

fusing species in the acceptor compartment, V represents the volume of the media in
the acceptor compartment, Di is the diffusion coefficient of the diffusing species, SA
is the surface area of the barrier separating the donor and acceptor compartments,
hABL is the thickness of the ABL, and Cdonor & Cacceptor represent the concentration
of the diffusing species in the donor and acceptor compartments, respectively. By
reorganizing Eq. 10, it is possible to isolate, hABL , and describe the ABL thickness
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as a function of the

dC
dt

and Cdonor .

hABL =

Di ∗ SA ∗ (Cdonor − Cacceptor )
V ∗ dC
dt

(4.11)

A simpler method of determining the thickness of the ABL involves the diffusion
equation for one-dimensional motion, where the diffusion coefficient, Di , is defined
as:

Di =

⟨h2ABL ⟩
2tlag

(4.12)

Similar to Eq. 11, hABL represents the thickness of the ABL, and tlag represents
the time for the diffusing species to appear in the acceptor compartment of the sideby-side diffusion cells. By isolating the hABL term and expressing it as a function of
the lag time, tlag , the Mean-Squared Displacement (MSD) Equation is obtained [191].

hABL =

√

2Di ∗ tlag

(4.13)

Both Eqs. 11 & 13 allow for the quantification of the effects of the stirring rate on
the ABL thickness using two independent measurable parameters,

dC
dt

and tlag . Table

2 summarizes the impact of the stirring rate on the thickness of the ABL, evaluated
using both the Nernst-Brunner and the MSD equations, on the flux experiments
conducted in simple aqueous buffers, as exhibited in Figure 4. Notably, the NernstBrunner and MSD equations yield statistically equivalent values for the ABL thickness
in all cases except for the system at SR=1 stirred at 300 RPM. In this condition,
the discrepancy between the two equations can be attributed to the variability in
the measured lag-time or impacts of suspended crystalline particles in the receiver
compartment. However, it is generally observed that the stirring conditions at 100
RPM yielded ABL thicknesses of about 2 mm, while those systems stirred at 300
RPM had ABLs of approximately 500 µm thick.
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The observations are in good agreement with those made by Avdeef et al. where
the authors report ABL thickness values, evaluated for 40 compounds, ranging from
1500-4000 µm in unstirred systems separated by a PAMPA membrane [192]. Furthermore, in a study conducted by Miller & Kasting, the authors report an ABL
thickness of approximately 660 µm in a vertical diffusion cell containing parathion
and 4-Hexylresorcinol stirred at 400 RPM [193]. The diffusion coefficients of parathion
and 4-Hexylresorcinol, are similar to that of E2 (7.8×10−6 cm2 /s) and were determined
to be 7.22 × 10−6 and 9.17 × 10−6 cm2 /s, respectively at 37 °C. It is important to note
that not all systems exist with equivalent hydrodynamic conditions (i.e., diffusion coefficients, in-vitro devices, and fluids) [194, 195, 3]. Thus, it is difficult to accurately
compare ABL thickness across systems. However, the above-referenced studies utilize
similar in-vitro devices, fluids, and drug molecules.
As described above, the ABL thickness is highly dependent on the stirring rate.
For instance, the ABL thickness is reduced by a factor of 4 when the stirring rate is
increased from 100 to 300 RPM (Table 2) and “particle drift” is expected to play a
smaller role on the overall mass transport as the bulk solution becomes more accessible
to the membrane (Figure 6). The theoretical flux as predicted by Eqs. 2 or 7, with
the assumption of constant Pef f across systems, and the observed flux should match
well under these circumstances. This congruence is the case as is illustrated in Figure
Table 4.2: Summary of membrane thickness evaluations of data from Figure 4 using
the Nernst-Brunner & Mean-Squared Displacement (MSD) Equations
Lag-Time
(s)

∆C/∆t b
Barrier Thickness
SR RPM
(×10−5 µg/mL/s)
(µm)
Mean 95% CI Nernst-Brunner
MSD
100
4961 ± 648 1.79 1.28, 2.31
2386 ± 308
2784 ± 182
1
300
171 ± 341
2.95 2.70, 3.23
1445 ± 63.2
517 ± 515
100
2228 ± 875 3.85 3.39, 4.30
2222 ± 128
1865 ± 366
2
300
195 ± 78
13.0 12.3, 13.6
657 ± 16.1
552 ± 110
a Lag-Time is displayed as Mean ± SD calculated from n = 3 replicates
b The slope (∆C/∆t) is displayed as the mean of n = 3 replicates with 95%
Confidence Intervals (CI)
a
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7a when the expected or theoretical flux, determined for a given SR condition stirred
at 300 RPM using the calibration curve in Figure S3 and Eq. 2, is equivalent to the
observed flux in the system containing 1% v/v PS80 at an equal thermodynamic drug
activity. The agreement between what is observed and expected indicates that the
addition of PS80 micelles in solution has little to no impact on the permeability of E2
within the diffusion cells. In this case, the system can be described as having either
membrane-limited or a combination of ABL-limited and membrane-limited transport
[3].
Due to the lack of equivalence of SR values across different media for a given
API, a fraction of amorphous solubility term, fAS , was developed and utilized to
comparatively describe supersaturation in solution. The fraction of amorphous solubility, fAS , is defined as the ratio of the measured apparent drug concentration, CT ,
in solution and the apparent amorphous solubility of the drug in the same media,
CT,AS . Similarly, fAS is also equivalent to the ratio of the supersaturation ratio of
the solution as defined in Eq. 5, and the max supersaturation ratio, SRmax defined
by the amorphous solubility limit.

fAS =

SR
CT
=
CT,AS SRmax

(4.14)

The utility of describing supersaturation in solution in terms of fAS is that it allows
for accurate comparisons of solution activity across different media with differing
degrees of solubilization. Therefore, we can compare the flux observed in the absence
and presence of micelles at equivalent unbound drug concentration or thermodynamic
drug activities, as shown in Figure 7b. The definition of fAS relies on the equivalence
of the unbound amorphous solubility across different media types, which is consistent
with the equivalent amorphous solubility values in the presence and absence of 1%
v/v PS80 as shown in Table 1, and also consistent with work by Elkhabaz et al.
[54]. The equivalence of flux in Figure 7b supports this observation as the maximum
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Figure 4.7: Expected and observed E2 flux at various supersaturation ratios (SR) in
1% PS80 (v/v) solutions stirred at 300 RPM. Expected flux values were determined
using the flux vs. calibration curve in Figure S3 for equivalent values of supersaturation as the observed data.
flux observed occurs at the amorphous solubility limit, and by defining a fAS , we
can normalize the drug activity to that maximum value at the amorphous solubility
limit (fAS = 1). Thus, by defining the supersaturation as a fraction of amorphous
solubility, one can estimate the unbound drug concentration and, consequently, an
API’s activity in complex media.
This observation underlines the impact of conducting in-vitro experiments under
conditions that minimize the ABL thickness such that the presence of nano-scale
species does not obscure the determination of flux in complex media [54]. However, it
is argued that valuable information regarding the potential benefits gained from the
presence of nano-particulate species in solution will be lost under conditions where
the ABL thickness is minimized, which may be necessary for understanding a drug
product’s bioperformance in-vivo. This understanding becomes especially essential
when the ABL serves as a rate-limiting barrier to absorption across the GI lumen for
certain drugs. In the following section, we will highlight how nano-scale speciation can
impact an API’s permeation behavior and introduce methods to estimate permeability
mathematically through the characterization of those nano-scale species.
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4.5.2

Modelling the Elevated API Flux in the Presence of Nano-scale
Species

The complexity imbued by the presence of drifting species may confound the ability
to determine the unbound drug concentration. However, through the use of a simple
correction factor to account for the increased permeability present with nano-sized
drifting species, it is possible to accurately determine the thermodynamic activity of
API, even in complex media. This approach allows for a more in-depth understanding of the potential benefits to bioperformance in in-vivo systems where the ABL
thickness cannot be controlled.
If we consider an experimental setup similar to that of Figure 1b, the effective
permeability, Pef f , can be expressed as a function of two components: membrane
(Pmem ) and ABL (PABL ) permeability. From Figure 1b, it is apparent that unbound
drug must first traverse one ABL and subsequently cross the membrane and ABL
on the opposite side. For simplicity, it is assumed that the ABLs on either side
of the membrane are equivalent. Since these events occur in series, the equivalent
permeability is equal to the inverse of the sum of the reciprocal permeabilities, as
shown in Eq. 15.

Pef f =

1
Pmem

1
1
)
+ 2 ( PABL

(4.15)

In the case of a system containing particles capable of drifting through the ABL,
drug molecules can transverse the ABL as either unbound or nano-scale species. The
ability of an API to associate with nano-scale species provides it with another path
to permeate the ABL, resulting in a nano-modified effective permeability (Pef f,nano ).
Since these two processes occur in parallel, the ABL permeability can be described as
a sum of the unbound (PABL,u ) and nanoparticle (PABL,nano ) permeabilities through
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the ABL (Eq. 16).

Pef f,nano =

1
1
Pmem

+ PABL,u +P2ABL,nano

(4.16)

Simplification of Eq. 16 is possible if it is assumed that (PABL ≪ Pmem ) for
the slow stirring conditions explored in this paper (100 RPM). This assumption is
valid as 17β-Estradiol is classified as a BCS Class II compound, characterized by
poor aqueous solubility and high epithelial permeability[196]. Furthermore, for the
characterization of this data utilizing this simplified equation, it is assumed that the
diffusion rate of micelles through the ABL is much slower than the rate of release of
drug from micelles.
The modified permeability can be estimated by the following function, as determined by Stewart and Grass [86].

Pef f,nano ≈ Pef f (1 +

Dnano ⋅ Cnano
)
Du ⋅ Cu

(4.17)

where Dnano and Du represent the diffusion coefficients of the nano-particulate
species and unbound drug, respectively. Cnano and Cu represent the concentrations
of the nano-particulate species and unbound drug, respectively. In this experiment,
the Dnano can be estimated using the diffusion coefficient of the micelle-associated
E2, Dmic . Furthermore, the diffusion coefficient of the unbound drug is equivalent
to the diffusion coefficient of E2, as defined by the Avdeef equation in Eq. 9. The
concentration of micelles in solution was determined using an aggregation number of
60 for PS80 micelles, as reported by de Campo et al. and Amani et al., resulting in
a Cmic of 8.24 × 1016 micelles/mL [197, 179].
By rearranging Eq. 17, a particle drift factor, fP D , can be defined as the ratio of
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the effective permeability in the presence and absence of particle drifting species.

fP D =

Pef f,nano
Dmic ⋅ Cmic
≈ (1 +
)
Pef f
Du ⋅ Cu

(4.18)

By combining Eqs. 3, 4, and 18, an equation to model the expected flux advantage
provided by the micelle’s ability to carry drug through the ABL can be defined, as
shown in Eq. 19.

Jef f,nano = fP D (Pef f ⋅ aD,solution ) = fP D ⋅ Jef f
4.5.3

(4.19)

Determination of Thermodynamic Activity in Complex Media

The ABL is a rate-limiting barrier for many BCS class II compounds, which comprise
a vast majority of new chemical entities in the pharmaceutical pipeline [3, 88, 89, 90].
As mentioned previously, the ability for these compounds to permeate across the ABL
may be further complicated by the presence of solution species in-vivo [91, 92, 93]. The
biological gastrointestinal fluid is comprised of many endogenous materials capable of
self-associating or associating with exogenous formulation excipients. The presence
of aggregates, polymer gels, vesicles, or mixed micelle aggregates has been reported
in gastrointestinal fluids or simulations of those fluids after exposure to drug product
formulations [94, 95, 25, 96, 97, 98, 99]. Furthermore, all of these aggregates are
expected to have a diverse set of diffusivities across the ABL, where each species
may distinctly influence the observed flux. The goal of this work was to demonstrate
the ability to correct for permeation differences due to the presence of nano-scale
species capable of carrying API through the ABL. Our simplified “complex media” is
a buffered solution containing 1% v/v PS80, which allows for a concentration greater
than the critical micelle concentration of PS80. Thus, it is expected that micelles
spontaneously form in solution at this concentration, and these micelles are capable
of sequestering molecularly dissolved drug molecules and transporting it through the
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Figure 4.8: E2 flux at various fractions of the amorphous solubility after the incorporation of the effective permeability correction accounting for particle drifting
ABL. The discrepancy between the observed flux and the flux expected at various
supersaturation conditions in the presence of PS80 micelles can be visualized in Figure
8.
The degree of supersaturation induced in the donor compartment of the side-byside diffusion cells is expressed as a fraction of the amorphous solubility determined
for that medium. Describing the degree of supersaturation as a fraction of the amorphous solubilities allows for the comparison of different systems, with varying limits
of supersaturation, at equal unbound drug concentrations.
According to Figure 8, the observed flux is ∼25-50% greater than that predicted
from the traditional flux model based strictly on the supersaturation. In particular, the theoretical flux is determined using the flux vs. supersaturation calibration
curves in Figure S2 and the permeability equation (Eq. 2). This discrepancy between observed and expected flux points to the fact that other phenomena may be
at play. Specifically, micelles may effectively increase the overall permeability by
"drifting" into the ABL. These nano-particulate species may then provide a reservoir for the replenishment of local API concentration within ABL as it is removed
(i.e., as it permeates across the membrane). In the case of the model system stud-
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ied here, when considering the ability of the PS80 micelles to increase the effective
permeability, via particle-drifting, the flux expected with the effective permeability
correction factor can be estimated using Eq. 19. The theoretical flux treated with
the effective permeability correction factor is shown to model the observed flux very
well (Figure 8). There appears to be a tendency for the model to underestimate the
observed flux beyond the amorphous solubility slightly, and this may be a result of
the formation of nano-scale drug-rich colloidal aggregates, which may also serve as a
permeating species through the ABL. Another source of error can be attributed to
the simplification of the model by using a single value for the micelle-associated E2
diffusion coefficient. The micelle-associated E2 diffusion coefficient used in this study
was determined at SR = 2, which served as a midpoint in concentration, where the
maximum concentration is at the amorphous solubility or SR = 3.5. That value for
the diffusion coefficient was selected as it has been observed that Dmic decreases with
increasing supersaturation, as micelles incorporate more molecules of E2 within their
structure[198].
Through the use of the effective permeability correction factor, it becomes possible
to accurately understand the thermodynamic activity of an API in complex media.
By correlating the corrected observed flux to the calibration curve developed, the
unbound drug concentration was determined, and various thermodynamic parameters
were calculated and summarized in Table 3. The presence of micelles in the system
dramatically lowers the API’s activity by approximately two orders of magnitude,
compared to the system devoid of PS80 micelles. With increasing SR, the gamma ratio
is observed to increase until the amorphous solubility limit is reached at SRmax = 3.5.
Past the amorphous solubility limit, the amount of free drug remains constant, and
excess drug forms colloidal drug-rich aggregates, resulting in a decreasing gamma
ratio.
For the calculation of the number of E2 molecules per micelle, an aggregation
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number of 60 was assumed, as reported by de Campo et al. and Amani et al. [197,
179]. As shown in Table 3, the number of E2 molecules contained per PS80 micelle
increases from approximately 1-2 E2 molecules at the crystalline solubility limit to
5-6 E2 molecules at the amorphous solubility limit, which would suggest that the
loading of micelles is a function of the concentration of molecularly-dissolved API in
solution. There have been reports describing the observation of “swollen” micelles,
with a 2-3 fold increase in their hydrodynamic radius at the supersaturated state
[95, 163]. The micro-environment of a micelle in which a solute may reside can be
divided into two regions: hydrophobic core and palisade region, with the latter also
known as the core-corona interface [199]. Saveyn et al. studied the solubilization
capacity of Tween 20 micelles to flurbiprofen using 1 H and

19 F

NMR and found

localization of drug consistent with palisade layer accumulation. In the study, both
chemical shift and NOESY observations confirmed the interaction of the flurbiprofen
aromatic protons with the alkyl side chains rather than the hydrophilic poly(ethylene
oxide) groups[200]. Although the study by Saveyn et al. is conducted at a single
drug concentration, the same phenomenon is expected with our PS80 and E2 system.
γ

), number
Table 4.3: Summary of free drug concentration, E2 gamma ratio ( D,solution
γD,eq
of E2 molecules per micelle, and the observed micellar partition coefficient in the
presence of 1% v/v PS80a .
Molecularly-Dissolved
APIb
SR
(µg/mL)
Gamma Ratio #E2 Molecules/Micelle Km/w
1
3.9
2.8 × 10−2
1.5
14.8
2
7.6
4.3 × 10−2
3.1
14.8
−2
3
11.4
4.8 × 10
4.6
14.8
4
13.9c
4.4 × 10−2
5.6
14.8
c
−2
5.5
13.9
3.5 × 10
5.6
14.8
a Error values indicate standard deviation with n = 3
b Molecularly-dissolved API values were determined by correlating f
AS to
simple buffered systems
c Above SR = 3.5, the amorphous solubility limit is reached, and the system
begins to phase separate
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However, it is suggested that at higher supersaturations where the micelle is saturated
with drug that both the core and palisade regions could be populated [163].
It is important to note that the unbound drug concentration at SR = 1 in the
presence of 1% v/v PS80 was estimated to be 3.9 µg/mL, which is approximately
2-fold greater than the crystalline solubility in the absence of PS80. The unbound
drug concentrations in Table 3 were estimated under the assumption that the amorphous solubility remains constant regardless if PS80 micelles are present or not. The
assumption was shown to be valid, as in Table 1, the unbound drug concentrations
above the amorphous solubility limit were shown to be similar. In cases where the
SR = 1, the fAS values are not equivalent between systems with 1% v/v PS80 and
those devoid of PS80. It was observed that the fAS is greater in the presence of
1% v/v PS80, indicating a potential interaction between PS80 and E2, where the
crystalline solubility is greater than expected. This crystalline solubility difference
is supported by crystalline solubility measurements conducted using ultracentrifugation, where the crystalline solubility was found to be 4.6 µg/mL (Table 1). A similar
phenomenon has been observed by Stewart et al., where the crystalline solubility of
itraconazole in the presence of simulated intestinal fluid was greater than that in pure
buffered media [3]. One potential explanation for the increased crystalline solubility
in our system could be that the micelles or surfactant molecules may inhibit the formation of the hemihydrate polymorphic form of E2, which is the most stable form of
E2 [201]. This hindering of the hemihydrate form would allow for the formation of
the unstable anhydrous form of E2, characterized by a greater crystalline solubility.
The impact of surfactant molecules on polymorphic form transformation has been
reported by several groups [202, 203, 204, 205]. It is also possible that E2 and surfactant molecules may form complexes of sizes less than what is possible to separate
with the ultracentrifugation conditions used.
Interestingly, it was found that the micellar partition coefficient (Km/w ) remained
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constant regardless of the degree of supersaturation in solution. The micellar partition
coefficient is defined as the ratio between the concentrations of the micelle-associated
drug, Cm , and the free or unbound drug, Cu , given by Eq. 20.
Km/w =

Cm (CT − Cu )
=
Cu
Cu

(4.20)

where the micelle-associated drug, Cm , can be defined as the difference between the
total drug concentration, CT , and the unbound drug, Cu .
Elkhabaz et al. conducted a study examining the micellar partitioning of atazanavir
and posaconazole in various simulated gastrointestinal fluids at the crystalline and
amorphous solubilities and found that the partition coefficient of atazanavir and
posaconazole are largely dependent on the degree of supersaturation [54]. In a similar
study, Indulkar et al. found that for atazanavir and sodium dodecyl sulfate systems,
the micellar partition coefficient was also found to be concentration-dependent [163].
It must be noted that partitioning behavior between drugs and micelles may be impacted by ionization, lipophilicity, molecular weight, and micelle concentration. It is
expected that the linear partitioning behavior to deteriorate beyond the saturation of
the micelles. In the systems explored by Elkhabaz and Indulkar, the supersaturation
ratios (SR) went as high as SR = 60 and SR ≈ 20 for their atazanavir and posaconazole systems, respectively [54, 163]. Therefore, they may have saturated the micellar
species in their systems, and non-linear partitioning behavior was observed. However,
care must be taken to ensure that the complete separation of micelles is conducted,
especially when ultracentrifugation is used. In both studies, the speed, the centrifugal
force, and the time of ultracentrifugation would not have been sufficient to completely
separate all of the colloidal species present in fasted state simulated intestinal fluid,
FaSSIF, and fasted human intestinal fluid, FaHIF; according to Stokes’ Law [178].
The size of the colloidal species in FaSSIF and FaHIF can range from about 15-55 nm
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in size[206]. Furthermore, sodium dodecyl sulfate (SDS) micelles have been reported
to be even smaller (1-4 nm), which makes separation of particles via ultracentrifugation more difficult [207, 208, 209]. Therefore, it is possible in either study, the
ultracentrifugation conditions used in either study were not sufficient to completely
separate all colloidal species from solution, leading to an incorrect determination of
the free drug concentration.
4.5.4

Pharmaceutical Implications

The mathematical equations developed in this study provided an accurate determination of the aR and, thus, the driving force for permeability. Although this technique is
not meant to mimic in vivo absorption, it provides a method to understand the impact
of nano-particulate species on the overall resistance to permeability. The model presented herein was successfully applied to E2, a non-ionizable molecule within the gastrointestinal pH. The application of this technique to other drug candidates requires
careful consideration of the membrane selection. As highlighted previously, the use of
a regenerated cellulose dialysis membrane was selected as it sufficiently separated free
drug molecules from both colloidal drug-rich aggregates and micelle-associated drug
molecules. From the physiology standpoint of the oral absorption process, it is only
the free neutral species that drives the absorption across the intestinal membrane
[210]. Thus, in more complex systems containing ionizable compounds, compounds
that may form dimers, inclusion complexes, etc., those systems should be explored
and validated with respect to membrane selection [211, 212]. Also, the approach
developed in this study requires dilute conditions, where the activity coefficients of
the drug in solution and the crystalline drug are unity, as is the case in the buffered
systems in the absence of PS80. Otherwise, in non-dilute cases, as is often the case
in complex media, the true free drug concentration becomes challenging to estimate.
Nevertheless, by comparing the solution flux in complex media to a calibration curve
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correlating flux versus supersaturation as developed in a simple buffered system, formulators may accurately estimate the dynamic changes in the drug thermodynamic
activity. This will allow for a better understanding of the impact of complex species
in solution. Moreover, this approach may enable discriminating dissolution methods
offering a means to optimize formulations in vitro so as maximize oral absorption
in-vivo.
Optimizing the formulation and processing of drug products is expedited when
meaningful discriminating dissolution methods can be developed. That is to say, if
the discriminating methods capture the cause and effect of changes in formulation,
the development scientist can make well informed decisions appropriate for optimizing performance. The impact of nano-speciation is captured and has this end in
mind. Moreover, traditional pharmacokinetic (PK) modeling of the absorption process assumes fluid volumes to be continuously distributed throughout the length of
the GI lumen. However, several groups have reported fluid “pockets” within the GI
lumen [213, 214, 215]. The volume and number of pockets are directly related to GI
motility and the in-vivo fed or fasted conditions [213, 214]. In PK modeling, it is
commonly assumed that the entire GI tract is accessible to the orally dosed product
after dissolution - a plug-flow reactor approach [216]. However, that is often not
the case. For example, Schiller et al. evaluated the fluid volumes surrounding nondisintegrating capsules using magnetic resonance imaging (MRI). Several capsules
were not completely surrounded by fluid in either the stomach or small intestines
[213]. Furthermore, the hydrodynamics in these water pockets may be of concern for
poorly-soluble APIs, as it would be difficult to agitate fluids in such small volumes
locally.
The hydrodynamics of the GI lumen are dynamic and dependent on the amount
of fluid present and the contractile activity of the muscles surrounding the GI lumen
[117, 118]. It is hypothesized that the ABLs surrounding dissolving particles and
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the GI lumen within these water pockets are significant barriers to dissolution and
absorption for certain poorly-soluble APIs. Furthermore, it is expected that the
hydrodynamics of these fluid pockets will vary locally and may yield a distribution
of ABL thicknesses. In a study evaluating the inter-subject variability exposure of
ibuprofen, a BCS Class II drug, Amidon and coworkers have identified the variability
to be a result of motility differences across subjects [117, 118]. It has been suggested
that slower transit times due to lower contractile activity could lead to decreased
agitations of the ABLs surrounding dissolving particles [217]. Therefore, for poorlysoluble drugs whose permeability is limited by the transport through the ABL, it is
expected that the sensitivity to nano-speciation would be significant [87, 218].
Several studies have shown improvements in API permeability and exposure through
the presence of nano-particulate species [219, 220, 221, 85]. One study, in particular,
observed that by varying levels of Vitamin E TPGS in the formulation from 1-10 wt%,
it was possible to control the size of aggregates formed in solution ranging between
50 and 500 nm [85]. Most importantly, in the 10 wt% TPGS system, which generated 48 nm particles, it was found that the benefits of particle-drifting improved the
observed in-vivo permeability of the API 4-fold [85]. Overall, development scientists
may benefit from an understanding of particle-drift and the utilization of formulations
capable of forming nano-particulate species. In some instances, it is possible to improve absorption above what is observed at the amorphous solubility limit by taking
advantage of colloidal species formed from either exogenous or endogenous material.
4.6

Conclusions

The presence of nano-particulate species in solution derived from formulation excipients or endogenous material can significantly alter the supersaturated state by
changing the thermodynamic driving force for drug absorption. Moreover, in cases
where the ABL is a significant barrier to permeating drug molecules, the presence
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of nano-particulate species capable of shuttling drug molecules across the ABL leads
to higher drug activity at the membrane surface. In this study, we demonstrate a
novel approach to accurately measure thermodynamic drug activity in complex media
containing drug distributed into nano-scale species. The results show the influence
of nano-scale speciation on the observed flux values of 17β-Estradiol, an unionized
poorly-soluble drug compound. Specifically, permeability values were increased by
approximately 2-fold with the addition of PS80 micelles. The approach highlighted
in this paper can be used to provide a framework for the development of discriminating dissolution methods to evaluate formulation sensitivity to nano-speciation and
provide an improved correlation between in vitro studies and pre-clinical or clinical
data sets.
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Chapter 5
Mechanistic Investigation of Drug Supersaturation in the Presence of
Solubilizing Additives by Solution NMR Spectroscopy

5.1

Introduction

Year-by-year the proportion of poorly water-soluble drugs (PWSDs) within the pharmaceutical pipeline increases, and it is estimated that 70-90% of novel drug candidates
are currently classified as Biopharmaceutics Classification System (BCS) Class II and
IV compounds, which exhibit poor aqueous solubility in the most stable crystalline
form [222, 10, 223, 11]. Although many novel drug candidates may show promise
in-vitro, there may exist inherent challenges in translating a PWSD candidate to the
clinic and patients as an orally dosed product [224]. In certain cases, the crystalline
solubility may not be sufficient in generating therapeutic concentrations in-vivo as
only molecularly dispersed drug is absorbed across the gastrointestinal (GI) membrane, leading to sub-optimal performance [224, 225]. Several strategies exist to optimize the solubility and dissolution of PWSDs through the manipulation of solid-state
properties to generate solid dispersions [226, 227, 228], higher-energy polymorphs
[229, 230], hydrates [231, 232], salts [233, 234, 235], and cocrystals [236, 237, 16, 17].
However, lipid-based formulations have garnered interest over the years as they avoid
solid-state limitations [225].
Lipid-based formulations can significantly enhance the amount of dissolved drug
in solution, and through a judicious selection of the lipids used, it is possible to design and tune the delivery characteristics of the formulation [238, 239]. Due to this
versatility, lipid-based formulations have become a popular platform to formulate
APIs with a wide range of physicochemical properties. The term “lipid-based formulations” encompasses several delivery systems: oil solutions, emulsions, dispersions,
micelles, self-emulsifying drug delivery systems (SEDDS), and self-microemulsifying
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(a)

(b)

Figure 5.1: (A) Schematic depicting the generic structure of a micelle. (B) Schematic
depicting the structure of a PS80 Micelle
drug delivery systems (SMEDDS) [240]. Among these systems, micelles have drawn
considerable attention as a strategy to improve solubility and dissolution characteristics of PWSDs due to its simplicity, nano-size, and large-scale scalability [241]. In
fact, the presence of colloidal species in-vivo, such as bile salt micelles and phospholipid vesicles, play important roles in the in-vivo dissolution and absorption of poorly
water-soluble drugs [206].
Micelles are nano-to-microscale structures formed by the self-assembly of amphiphilic molecules [1]. In aqueous solutions, amphiphilic molecules orient themselves
to minimize the interaction of their hydrophobic moieties with the aqueous environment. In dilute conditions, amphiphilic molecules tend to localize near the air-liquid
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or container-liquid interfaces. However, in non-dilute conditions, the amphiphilic
molecules will tend to self-assemble into spherical colloidal particles. The concentration at which amphiphilic molecules tend to self-associate is termed as the critical
micelle concentration (CMC). From the micelle surface toward the core of a spherical micelle, the hydrophobicity increases as the interactions between the hydrophobic
moieties and the aqueous environment are minimized. The micelle structure can be
subdivided into three regions [242]: (a) the corona region, which consists of the hydrophilic moieties at the interface between the micelle and the bulk water; (b) the
palisade region, referring to the initial transition between the hydrophilic and hydrophobic moieties; and (c) the core, which forms a very hydrophobic pseudophase
(Figure 1). Micellar solubilization can be defined as the spontaneous dissolution of
a substance, by reversible interaction, to form a thermodynamically stable isotropic
solution [243]. The capacity of micelles to solubilize drugs depends on numerous
factors, such as the chemical structure of both the drug and the amphiphile, temperature, pH, and ionic strength, amongst others [244]. However, a molecular-level
understanding of the interactions between a drug and an amphiphile, as well as a
mechanistic investigation of drug supersaturation, is still lacking due to the dynamic
and complex nature of drug-micelle systems.
In a supersaturated drug solution, the drug concentration is often described in
terms of a supersaturation ratio (SR), which is the ratio between the total drug
concentration, CD,solution and the crystalline equilibrium solubility, Seq , as shown in
Equation (1).

SR =

CD,solution
Seq

(5.1)

However, in a drug absorption model, the total concentration may not represent
the true absorption driving force. To accurately represent the driving force for absorption, the true extent of drug supersaturation should be calculated as the activity
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ratio αR , which is the ratio between the drug solution activity, γD,solution , and the
drug solution activity at the equilibrium crystalline solubility limit, γD,eq in Equation
(2) [91].

αR =

αD,solution γD,solution
=
∗ SR
αD,eq
γD,eq

(5.2)

Where γD,solution and γD,eq represent the drug solution activity coefficient of the
supersaturated drug solution and the drug solution at the crystalline solubility limit,
respectively. To accurately measure αR in complex media containing drug distributed
in nano-particulate species, the drug flux profile needs to be measured, which is
beyond the scope of this manuscript. The authors direct the reader to explore the
following references to learn about the intricacies of quantifying the driving force for
absorption [91, 54, 55]. As no absorption phenomena are explored within this paper,
SR suffices to describe the level of drug supersaturation in the systems explored within
this study.
One-dimensional (1D) and two-dimensional (2D) Nuclear Magnetic Resonance
(NMR) spectroscopy has been utilized as a high-resolution in-situ technique to study
drug-surfactant interactions and quantify drug solubilization in surfactant micelles
[245, 246, 247, 248, 249, 250, 200, 251]. By observing chemical shift changes of
analytes in 1D NMR spectra, the intermolecular interactions in micellar systems can
be studied. Rub et al. explored the interactions of the anionic drug ibuprofen (IBF)
with micelles composed of the non-ionic surfactant Triton X-100 using 1D 1H NMR,
and observed an upfield shift of IBF peaks, suggesting an interaction between IBF and
Triton X-100 surfactant molecules [248]. Furthermore, in a study of the solubilization
of flurbiprofen in non-ionic polysorbate 20 micellar solutions by Saveyn et al., 2D
NOESY experiments revealed the accumulation of flurbiprofen within the palisade
layer of the polysorbate 20 micelles [200]. To understand the dynamic properties of
micelles, Mao and coworkers utilized a combination of 1D chemical shift deviation,
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2D NOESY, diffusion, and relaxation NMR analysis to comprehensively study the
mechanism of mixed micelle formation in binary surfactant aqueous solution systems
[245, 246]. The encapsulation of biomolecules in micelles and reversed micelle systems
also enabled the study of protein structure and membrane protein-lipid interactions
by NMR spectroscopy [250, 252].
This study aims to (1) investigate the potential interactions between surfactant
and drug molecules in a model micelle system and (2) understand the impact of drug
supersaturation on micelle structure, size, and formation. A molecular-level NMR
analysis of drug–micelle (surfactant) interactions was conducted to probe these questions. As a model system in this study, the interactions between 17β-Estradiol (E2),
a non-steroidal drug used in the treatment of menopausal hormone imbalance, and
polysorbate 80 (PS80), a non-ionic poly(ethylene oxide) surfactant, were investigated.
5.2
5.2.1

Experimental Section
Materials

17β-Estradiol (E2) and polysorbate 80 (PS80) (Figure 2A) were purchased from
Sigma-Aldrich (St. Louis, MO). Acetonitrile, potassium dihydrogen phosphate, and
potassium phosphate dibasic were supplied by VWR International (Radnor, PA).
Dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific (Fair Lawn, NJ).
Hydroxypropyl methylcellulose (HPMC) K4M grade was provided by Colorcon (West
Point, PA). Deionized water was obtained from a MilliQ water purification device
(Milli-Q Synthesis, Millipore, Bedford, MA) and filtered through a 0.22 µm filter
(Millipak 40, Millipore, Bedford, MA) before use. Deuterated solvents were purchased from Sigma-Aldrich (St. Louis, MO).
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5.2.2

Crystalline Solubility Measurements

The crystalline solubility of E2 was determined by placing an excess of crystalline E2
into a glass vial containing 50 mM tris maleate buffer and 100 µg/mL of HPMC at pH
7.4 in the absence and presence of 1% v/v PS80. The excipients were pre-dissolved
in the buffer prior to the solubility measurement. The mixture containing excess
crystalline E2 was mixed using a vial rotator in an incubator at 37 °C. After 72 hours,
the equilibrated mixtures were filtered through a 0.22 µm syringe filter. The syringe
filter was saturated by discarding the first 3 mL of the filtrate. Following filtration,
200 µL of the filtrate is diluted with an equivalent volume of the mobile phase used for
high-performance liquid chromatography (HPLC) analysis. The concentration of E2
in the samples was determined using a Waters HPLC system equipped with a Waters
996 photodiode array (Waters, Milford, MA). An injection volume of 10 µL was run
through a Symmetry C18 column (4.6 mm internal diameter, 150 mm length, 5 µm
particle size; Waters, Milford, MA). The mobile phase consisted of methanol and
water in the ratio 70:30 v/v and was pumped isocratically at a 1 mL/min flow rate.
The detection wavelength was set at 280 nm for the quantification of 17β-estradiol.
All solubility measurements were performed in triplicate.
5.2.3

Nuclear Magnetic Resonance (NMR) Sample Preparation

Two buffered solutions containing 50 mM tris maleate at a pH = 7.4 and 100 µg/mL
of HPMC was prepared in D2 O. In one buffered solution, PS80 was introduced to
generate a 1% v/v PS80 solution, which is of greater concentration than the CMC
of PS80 [55, 253, 182, 183]. The formation of PS80 micelles was validated by the
presence of 11 nm particles, as detected via dynamic light scattering analysis [184].
The equilibrium solubility of E2 has been reported to be 2.6 ± 0.1 µg/mL and 62.2
± 0.1 µg/mL for buffered solutions in the absence and presence of 1% v/v PS80,
respectively. Due to the difference in the two media’s solubilizing capacity for E2 at
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equilibrium, different stock solutions were prepared by dissolving E2 in DMSO-d6 to
yield a 1.4 mg/mL and a 19.8 mg/mL solution. Several solutions at an E2 SR of
2, 4, and 6 were prepared by diluting the 1.4 mg/mL stock with the buffered media
without PS80. In addition, solutions at an E2 SR of 1, 2, 3, and 6 were prepared by
diluting the 14.8 mg/mL stock with the buffered media containing 1% v/v PS80. It
is noted that the final concentration of DMSO was less than 1% v/v in all solutions
prepared. Each solution was vortexed for about 15-30 s before transferring a 0.5 mL
sample into an NMR tube for analysis to ensure homogeneity.
5.2.4

Nuclear Magnetic Resonance (NMR) Measurements

All NMR experiments were performed at 37 ± 0.1°C on a Bruker AVANCE III 500
MHz spectrometer (Billerica, MA) with a 5 mm TXI probe in the Biopharmaceutical
NMR Laboratory (BNL) of Preclinical Development at Merck Research Laboratories
(Merck & Co., Inc. West Point, PA). Deuterated sodium trimethylsilyl propionate
(TSP−d4 , Me3 Si−CD2 CD2 −CO2 Na) was used as the external reference to calibrate
frequencies. To ensure complete recovery of the magnetization vector and shorten the
acquisition time, a small flip-angle pulse of 30 degrees was used instead of a 90-degree
pulse in a conventional 1H single pulse sequence. All experiments were performed
within one week of sample preparation. No visual evidence of E2 precipitation was
observed. The spectra were analyzed with the Bruker Topspin 3.5 software package
with reference to TSP protons at 0 ppm.
1D and 2D NOESY experiments were performed with the “noesyesgpph” pulse
sequence (nuclear Overhauser effect spectroscopy using gradients acquired in phasesensitive 2D) that employed excitation sculpting with gradients for water suppression.
The data were collected with eight repeated scans and 2048 data points in the direct
dimension and 256 increments in the indirect dimension. Unless otherwise noted, a
relaxation delay of 3 s was used. The mixing time was set to be 1.5 s.
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Diffusion Ordered Spectroscopy (DOSY) measurement is a well-established method
that reports diffusion coefficients for individual resonance in NMR spectra [254]. For
the past two decades, DOSY has been implemented for the characterization of micelles [246, 247, 255]. DOSY experiments were collected using the “ledbpgp2s” pulse
sequence (longitudinal eddy-current delay experiment using bipolar-pulsed field gradients acquired in pseudo 2D) to measure self-diffusion coefficient D, with a relaxation
delay of 3 s and 32 repeated scans. 2048 t2 points in (F2 dimension) were acquired.
The full magnetic field gradient strength was 6 G/mm for a D2 O standard sample. A
linear gradient ranging from 2% to 95% of the full strength within 16 steps were used
to achieve sufficient signal decay. The diffusion delay (big delta ∆ and gradient pulse
interval (little delta δ used were 300 ms and 2 ms, respectively. Aromatic protons of
E2 and alkene protons of PS80 are chosen for diffusion coefficient fitting due to their
isolated signals.
Longitudinal relaxation time constants (T1 ) were measured using the standard
“t1ir” inversion recovery pulse sequence with a recycle delay (D1) value of 5 s and
16 delay times ranging from 0.001 s to 10 s. T1 values were obtained by fitting the
inversion profiles with an exponential model in Bruker TopSpin software.
5.2.5

Molecular Docking Simulations

Molecular docking simulations were carried out using AutoDock Vina 1.1.2 [256]. In
the simulations, 17β-Estradiol was set as the ligand, and the acyl chain of the PS80
molecule was set as the receptor. The structure files of both 17β-Estradiol and PS80
were obtained from PubChem (compound entry: 5757) and The Inorganic Crystal
Structure Database, respectively. MGLTools 1.5.6 (weblink: http://mgltools.scripps.edu/)
was utilized to prepare the structure files for simulation in AutoDock Vina and aided
in the addition of hydrogen atoms, computing of electrostatic charges, preparing of
grid boxes around the receptor, and defining torsions of the ligand. The docking pa-

127

Table 5.1: E2 Crystalline Solubility Values in Different Media at 37 °C
Media

Apparent Crystalline Solubility (µg/mL)

50 mM tris maleate (pH=7.4)
+ 100 µg/mL HPMC

2.6 ± 0.2

50 mM tris maleate (pH=7.4)
+ 100 µg/mL HPMC + 1 % v/v PS80

62.2 ± 0.2

rameters used for simulations were set as follows: exhaustiveness of 9, an energy range
of 6 kcal/mol , and 20 binding modes. The resulting E2-PS80 acyl chain structures
were visualized in PyMOL 2.3.2 (trial version), and the intermolecular distances were
measured in CCDC Mercury software (weblink: http://www.ccdc.cam.ac.uk/).
5.3
5.3.1

Results
17β-Estradiol Crystalline Solubility

The measured apparent crystalline solubility of E2 at 37°C in 50 mM tris maleate
buffer (pH = 7.4) containing 100 µg/mL of HPMC in the absence and presence of 1%
v/v PS80 is summarized in Table 1. It is to be noted that the distinction of “apparent”
crystalline solubility refers to the total amount of E2 solubilized by the media. Thus
the amount of drug in solution is the sum of the molecularly dispersed drug, micellesolubilized drug, and potentially complexed drug. The apparent crystalline solubility
is found to be 2.6 ± 0.2 and 62.2 ± 0.2 µg/mL in the absence and presence of 1%
v/v PS80, respectively. These values are in accordance with previously reported data
collected in a 20 mM phosphate buffer (pH = 6.8) system containing 1% v/v PS80. It
is observed that, for this instance, buffer type, buffer concentration, and pH did not
significantly impact the observed apparent crystalline solubility values, as Estradiol
is largely unionizable in the physiologically relevant pH ranges. The SR values of
samples discussed below are calculated using these values in Equation (1).
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5.3.2

Site-specific Structure Assignment of Estradiol within Polysorbate
80 Micelles

Both E2 and PS80 contain chemical groups with uniquely identifiable characteristic
1H

chemical shifts and thus allow for the identification of each component when E2 is

solubilized in PS80 micelles. 1D 1 H & 2D 1 H-1 H correlation spectroscopy (COSY) and
1 H-13 C

heteronuclear correlation (HETCOR) spectra were obtained to identify signals

of E2 and PS80 in a supersaturated solution of E2 (SR = 3)in 50 mM tris maleate
buffer (pH = 7.4) containing PS80 micelles. As shown in Figures 2B-D, aromatic
protons H1, H2, and H3 of E2 are found at about 6.6 and 7.2 ppm, isolated from
most aliphatic proton peaks of PS80, and can be used to monitor the drug compound
in 1D 1 H spectra without spectral interference from the surfactant, buffer, or solvent.
The proton signal at 5.6 ppm corresponds to the alkene proton, H8, of the PS80 acyl
chain. The peak at about 2.1 ppm can be assigned to the CH2 group neighboring the
double bond group, H6. H5 and H7 correspond to the protons on the alpha and beta
carbons on the PS80 acyl chain, displaying isolated peaks with chemical shifts of 2.4
and 1.6 ppm, respectively. To further confirm the proton resonance assignments, 1D
1H

and 2D 1 H-13 C HSQC spectra of an E2 reference sample dissolved in DMSO and a

PS80 reference sample dissolved in D2 O are recorded and shown in Figure S1. In both
the mixture and reference spectra, one can identify intramolecular 1 H-1 H correlations
of E2 and PS80, respectively. For example, through-bond connections of H1 & H2
of E2, H6 & H8, and H5 & H7 of PS80 in 2D 1 H-1 H COSY spectra are shown in
Figure 2C and S1. More proton assignments can potentially be made based on 2D
intramolecular 1 H-1 H and 1 H-13 C correlations in Figures 2C and D; however, specific
focus is placed on protons H1-H4 of E2 and H5-H8 of PS80, which exhibit isolated
peaks and can be unambiguously assigned.
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Figure 5.2: Chemical structures of E2 and PS80 with protons of representative chemical shifts numbered (A). (B) 1D 1 H NMR, (C) 2D 1 H-1 H COSY and (D) 2D 1 H-13 C
HSQC spectra of 200 µg/mL E2 solubilized within a 1% v/v PS80 micellar solution
at a supersaturation ratio of 3 (SR= 3).
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Figure 5.3: 1D 1 H spectra of E2 in aqueous solutions of different supersaturation ratios
(SR = 2, 4, 6). The peak intensity of E2 aromatic protons increases in proportion to
the supersaturation ratio.
5.3.3

Estradiol Solubilization in Buffer at Different Supersaturation Ratios

Systems at various values of SR were prepared, SR = 2, 4, and 6, to evaluate the NMR
spectra as a function of the degree of supersaturation. The addition of 100 µg/mL
of HPMC allowed for the physical stability of supersaturated solutions of E2 by
inhibiting crystallization throughout the experimental time. The full recovery times
of longitudinal relaxation (T1 ) of signals of interest and the reference were obtained
using a recycle delay time five times greater than the longest T1 value, which allowed
for reliable quantification. The spectra in Figure 3 were normalized to an internal
reference of TSP of known concentration. As shown in Figure 3, the peak intensity of
E2 protons H1 (7.29 ppm), H2 (6.74 ppm), and H3 (6.69 ppm) increases in proportion
to the E2 concentration (SR = 2, 4, 6). It is worth noting that no proton peaks drift
with an increasing E2 concentration, indicating the absence of interactions between
E2 and buffer components as detected by NMR.
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5.3.4

Estradiol Solubilization in PS80 Micellar Solution at Different Supersaturation Ratios

According to Table 1, the introduction of 1% v/v PS80 in solution increased the
amount of solubilized E2 at equilibrium. The apparent equilibrium solubility value
was measured to be 62.2 ± 0.2 µg/mL in a 1% v/v PS80 buffered solution (pH =
7.4) at 37 °C, containing 100 µg/mL HPMC to inhibit E2 crystallization. To study
the mechanism of E2 solubilization in the presence of 1% v/v PS80, drug-surfactant
solutions were prepared at supersaturated concentrations of E2, SR = 1, 2, 3, and 6.
In these systems, it was possible to evaluate the amount of solubilized E2 using 1D
1H

NMR. As shown in Figure 5, the peak intensity (or integration) of E2 aromatic

proton signals increases linearly with increasing E2 concentrations (SR = 1, 2, 3) after
normalization with respect to the internal reference. In addition, Figure S2 shows
drug supersaturation at SR= 6 presents the same intensity as that of SR= 3, which
indicates that there is no further increase in solubilized E2 in PS80 micelles when
increasing supersaturation from an SR = 3 to an SR = 6. The lack of a difference in
peak intensity between systems at an SR = 3 & 6 may be due to the formation of a
new phase-separated colloidal species above the amorphous solubility limit [162, 52].
The apparent amorphous solubility limit of E2 in the presence of 1% v/v PS80, as
reported by Arce et al., is 220.8 µg/mL, which corresponds to an SR = 3.5 [55]. It
is important to note that the buffer type and pH in the system explored by Arce et
al. are different than what is used in this study; however, E2 is largely unionizable
in the physiological pH range, and PS80 is a nonionic surfactant. Therefore, it is
unexpected that any change in solubility will occur due to differences in buffer type
and pH.
Interestingly, in the presence of PS80 micelles, the aromatic H1 (7.13 ppm) and H2
(6.66 ppm) peaks of E2 are slightly shifted in the SR = 2 system relative to that of the
SR = 1 system. A further shift is observed for the system containing a larger degree
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SR = 1

SR = 2
SR = 3

Figure 5.4: 1D 1 H spectra of aromatic region (left) and aliphatic region (right) of
supersaturated E2 in PS80 solution with different E2 concentrations (SR = 1, 2, 3).
Note the 1 H chemical shift changes at 7.15 ppm.
of supersaturation (SR = 3). However, the aromatic H3 (6.52 ppm) and aliphatic
H4 (2.78 ppm) of E2 show no chemical shift perturbations. These observations may
indicate a predominant site of interaction on the E2 molecule, involved in the drugsurfactant interaction when encapsulated into PS80 micelles. Furthermore, increases
in supersaturation may result in larger degrees of interactions between E2 and PS80
as more E2 is encapsulated within micelles.
5.3.5

Intermolecular Interactions of E2 and PS80 Micelles from 1D and
2D 1 H NMR

To further understand the localization of solubilized E2 molecules with PS80 micelles,
as is suggested by the chemical shifts in Figure 4, a 1D and 2D Nuclear Overhauser
Effect Spectroscopy (NOESY) method is used. 1D and 2D NOESY experiments establish intra- and intermolecular correlations via magnetization transfer among spatially
close atoms. In the 1D 1H selective NOE transfer spectra as shown in Figure 5A, a
highly selective irradiation shape pulse is applied on resonance at 7.13 ppm to excite
the H1 of E2 exclusively. In NOE experiments, the mixing time is a set parameter
of how long the system is allowed to mix before a signal is measured. In the absence
of mixing, only the selected excited peak should be measured, as is shown at the top
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of Figure 5A. After allowing the system to mix for 300 ms, an intra- and intermolecular transfer of magnetization from the H1 proton of E2 is observed. According to
the bottom of Figure 5A, it is observed that the magnetization is transferred to not
only the neighboring H2 of the same molecule but also to the H5 and H7 of PS80
that were assigned in Figure 3 and S1. A hypothetical model of the E2 and PS80
interaction is proposed in Figure 5B, according to the NOE observations in Figure
5A. Since H5 and H7 are proximal to the carbonyl group of PS80 and H1 is located
near a hydroxyl group of E2, a potential intermolecular hydrogen-bonding interaction
between the terminal hydroxyl group of E2 and the carbonyl group of PS80 may exist. This potential hydrogen-bonding interaction suggests the presence of E2 within
the palisade layer rather than the micelle’s hydrophobic core. Further stabilization
would be expected by the hydrophobic interactions between the PS80 acyl chain and
the hydrophobic steroid structure of E2, as evidenced by the chemical shift changes
of H1 and H2 of E2 from 1D spectra (Figure 4).
The localization of E2 molecules within PS80 micelles was examined using 2D
NOESY. A more complete examination of all the potential intermolecular contacts
from the NOE method can be developed by introducing a second dimension into the
analysis. Figure 6A shows the intra-molecular 1H-1H NOESY correlation spectra of
a pure PS80 reference dissolved in D2O. Upon addition of E2 at an SR = 3, several
intramolecular NOE cross-peaks are observed for E2 and PS80 (Figure 6B). More
importantly, a significant number of intermolecular NOE peaks correlating E2 with
PS80 can also be found (black peaks). The observed intermolecular NOE signals
support the proximity of E2 and PS80 molecules due to the solubilization of E2
into PS80 micelles. Specifically, the aromatic H1 proton of E2 have NOE contacts
with the CH2 protons (H5 and H7) neighboring the carboxyl group of the PS80 acyl
chain. The relative intensity of H2-H5 cross-peaks is considerably weaker than that
of H1-H5, suggesting that H2 is further away from PS80 than H1, indicating that
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Figure 5.5: (A) 1D spectra (black) 1 H selective NOE transfer from aromatic protons
of E2 to aliphatic region of PS80 (SR = 3): selective excitation of E2 H1 proton at
7.13 ppm (top); and NOE transfer at 300 ms (bottom); 1D 1 H spectra of E2 dissolved
in DMSO-d6 (red) and PS80 dissolved in D2 O (blue) are shown as references. (B) A
hypothetical interaction model showing the relative location of E2 and PS80. H1 of
E2 is localized close to H5 of PS80.
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Figure 5.6: 2D 1 H-1 H NOESY of E2 dissolved in DMSO (A), PS80 dissolved in D2 O
(B) and E2 within PS80 micelles with an SR of 3 (C). NOE peaks are color coded
according to their origin. Black peaks in panel C indicate correlation peaks between
the aromatic region of E2 and the aliphatic region of PS80.
E2 molecules are not located in parallel with the PS80 acyl chain. The absence of
magnetization transfer between E2 and the olefin group of PS80, such as H6 and H8,
suggests the absence of E2 interaction and localization within the hydrophobic core
of PS80 micelles.
In contrast to H1 and H2, the H3 aromatic proton only exhibits intramolecular
NOE to H4 and lacks any intermolecular NOEs with PS80, suggesting the orientation
of the H1/H2 side of E2 towards the acyl chain. As a result, H3/H4 are positioned
further away from micelle acyl chains. This finding fits with an earlier observation
that H1 and H2 exhibit chemical shift changes, the degree to which is impacted by E2
supersaturation, whereas H3 and H4 did not exhibit the same phenomenon (Figure
4).
5.3.6

Analysis of E2 Supersaturation in PS80 Micelles by Diffusion and
Relaxation NMR

Diffusion is an intrinsic property of sub-micron particles that can be used to assess
their size and molecular weight. DOSY NMR measurements were carried out on

136

E2-PS80 micelle systems at various degrees of supersaturation (SR = 1, 2, 3, and 6)
to determine the impact of drug incorporation on the size of the micelles and their
motion. Figure 7A shows the self-diffusion coefficients of E2 at four drug concentrations. In this zoomed-in plot, both H1 & H2 of E2 show a shift of 0.05 ppm at each
successive increase of SR, up to an SR = 3, consistent with the 1D analysis in Figure
4. Furthermore, the diffusion coefficients of micelle-associated E2 are equivalent to
the values obtained for PS80 micelles, confirming drug association within the micelle.
When the drug supersaturation increases from SR = 1 to 3, the self-diffusion coefficient of E2 drops from -9.97 to -10.15 log(m2·s-1), which suggests increased micellar
sizes according to the Stokes-Einstein equation. Table 2 summarizes the size of PS80
micelles with increasing degrees of E2 supersaturation calculated from the diffusion
coefficients using the Stokes-Einstein equation.
The increase of E2 incorporation at an SR= 3 leads to an approximate 150%
increase in micelle volume compared to the micelles in the SR = 1 system. This
difference in micellar size potentially indicates an increasing number of drug and
surfactant molecules in the micelle’s structure. A longer proton T1 relaxation time of
the E2 H1 & H2 nuclei in PS80 micelles at SR= 3 was observed compared to that of SR
= 1 (shown in Figure 7B). The increase in relaxation time indicates the decreasing
mobility of E2 at higher degrees of supersaturation. It is hypothesized that the
increased incorporation of E2 at higher SR values imbues a greater degree of rigidity
to the micellar structure, resulting in the observed difference in T1 relaxation times.
The diffusion and relaxation measurements, taken together, may provide a glimpse
into the solubilization mechanisms of E2 in PS80 micelles. At an increasing SR, the
volume of micelles increases to accommodate more drug molecules. Furthermore, the
number of solubilized E2 molecules saturates when each micelle contains 5-6 drug
molecules according to previous work citeRN367.
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Table 5.2: Summary of Hydrodynamic Radius of E2-encapsulated PS80 Micelles
Supersaturation
Ratio (SR)

Number of E2
Molecules per Micelle

Diffusion
Coefficient (cm2 /s)

Hydrodynamic
Radius (nm)

1

1.5

1.07 × 10−6

2.83

2

3.1

8.65 × 10−7

3.51

3

4.6

6.97 × 10−7

4.35

6

5.6

6.97 × 10−7

4.35

SR = 6
SR = 3
SR = 2
SR = 1

SR = 3

1.2 s –n–

SR = 1

0.8 s –l–

Figure 5.7: 1 H diffusion (A) and T1 relaxation (B) measurements for E2 in PS80
micelles at different SR values.
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5.3.7

Molecular docking of E2 with PS80 hydrophobic chain

Computational docking is widely used to study drug-excipient interactions and has
been applied in structure-based drug discovery and virtual drug screening [257]. Docking simulations of a drug molecule with a biomolecule or certain excipients can be used
to predict bound conformations and free energies for the binding of small-molecule
ligands to targets. The acyl chain structure of PS80 was used as the target molecule
rather than the complete structure of PS80 to simplify computation and reduce the
simulation time. AutoDock Vina [256] was used to predict the bound conformations
and calculate the binding energy of interactions between E2 and the acyl chain of
PS80. Docking simulations indicate the presence of the E2 molecule along the PS80
acyl chain, in a similar fashion to what was hypothesized from the 1D & 2D NOESY
NMR experiments (Figure 5B). A model summarizing the docking simulations is presented in Figure 8 According to Figure 8, the hydroxyl group of E2 is positioned close
to the carbonyl group of PS80, also suggesting a hydrogen-bonding interaction. The
H1 and H2 atoms of E2 were estimated to be 3.5-4.5 Åfrom the H5 and H7 atoms of
PS80 in the model. Docking simulations estimated a binding affinity of -3.9 kcal/mol,
which is within the 2-10 kcal/mol range of typical hydrogen-bonding binding energies
[258]. Overall, as estimated from docking simulations, the proximity of these protons
agrees well with the presence of strong cross-peaks in the NOE-based experiments.
Both molecular docking and experimental results support the presence of E2 within
the palisade region of PS80 micelles and the interaction between the E2 hydroxyl
group and the carbonyl group of the PS80 acyl chain.
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Figure 5.8: A docking model of E2 with PS80 acyl chain. The molecular structures
are shown in stick and ball. A representative intermolecular distance of protons in
proximity between E2 and PS80 acyl chain are labeled.
5.4
5.4.1

Discussion
Solubilization of Poorly Aqueous Soluble Drugs in Surfactant Micelles

Micellar solubilization is a powerful approach for improving the dissolution rate and
bioavailability of poorly water-soluble drugs [259]. The effectiveness of surfactant
micelles on drug solubilization have been widely reported for a variety of surfactants
[259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274]. Many
studies report the effects of surfactant and drug chemical structure, electrolyte, pH on
the micellar solubilization of hydrophobic drugs [261, 262, 263, 264, 265, 266, 267, 268,
269, 270, 271, 272, 274]. Generally, for hydrophobic drugs, surfactants with nonionic
headgroups are better solubilizing agents than ionic surfactants [259]. Moreover, drug
solubilization increases almost linearly with the increase of hydrophobic chain length
for both neutral and charged surfactant types [274]. However, for polar drugs, the
solubilization power of surfactants depends on possible interactions between the drug
and hydrophilic headgroup at the micelle-water interface and the incorporation into
the micellar interior [259]. Krishna et al. showed that ionic surfactants had significant higher solubilizing capability than non-ionic surfactants for a polar antimalarial
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drug [270]. The location of the solubilized molecule inside the surfactant micelles
plays an important role in determining the micellar solubilization capacity. Van der
Meeren and coworkers utilized 2D NOESY experiments to determine that flurbiprofen is accumulated within the palisade layer of the PS20 micelles [200]. Vinarov et
al. identified the locus of drug solubilization in the micelle by using UV absorption
spectroscopy [274]. By determining the polarity of drug surroundings in micelles,
fenofibrate is found to locate in the anhydrous hydrophobic core in the nonionic PS20
micelles, whereas the drug is located in the palisade layer of the ionic surfactant micelles [274]. The driving force for drug encapsulation and the intermolecular binding
site is yet to be explored. We need a molecular understanding of the interaction
between drug and surfactant, e.g. relative location and type of interaction. Highresolution 1D and 2D NMR spectroscopy has become a powerful approach to study
the solubilization and interactions between surfactant and drug molecules [200, 255].
A combination of proton NMR, 2D DOSY and NOESY provides insights into the
solubilization states, dynamics, interaction site of thymol, a poorly soluble drug, in
PS80 micelles as recently reported by Chen and coworkers [255]. In this study, the interaction of E2 and PS80 was first monitored by chemical shift changes of H1 and H2
of E1 with an increasing SR, whereas chemical shifts of E2 remain unchanged when
solubilized in buffer. The comparison of E2 in buffer (Figure 3) and in PS80 micelle
solutions (Figure 4) demonstrated that the chemical environment of E2 changes when
entrapped within PS80 micelles possibly due to intermolecular interactions. To probe
the molecular level interactions between the drug and surfactant, 1D 1 H selective
NOE transfer (Figure 5) and a 2D NOESY (Figure 6) were utilized to identify the
PS80 protons in proximity to H1 and H2 of E2. These results suggest the presence
of a hydrogen-bonding interaction between the E2 hydroxyl group and a carbonyl
group found on the acyl chain within PS80 molecules as proposed in Figure 5B. As
a result of the drug-surfactant interaction, the drug-surfactant micelles are stabilized
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due to decrease of the free energy and result in enhanced solubilization. Due to the
mismatch of drug and surfactant molecular structures, which hinders the close packing of the molecules in the micelle, the incorporation of drug molecules into micelles
increases the size of micelles and results in a slower diffusion rate. Relaxation measurements shown in Figure 7 show restricted mobility of E2 when interacting with
PS80 micelles. In addition, diffusion NMR analysis in Figure 7 and Table 2 suggests
the micelle volume is increased by 150% when supersaturation level increases from
1 to 3. The values reported in Table 2 for the hydrodynamic radii of PS80 micelles
at varying degrees suggest smaller particles than the 11nm size measured using DLS
[184]. This may be a result of the assumptions made in the estimated values of the
dynamic viscosity of the solutions within the Stokes-Einstein equation. Regardless,
the two values obtained show close agreement and suggest PS80 micelles range from
5-11 nm in size. A proposed model is shown in Figure 9 summarizing the findings
of E2 solubilization in PS80 micelles. The number of drug molecules encapsulated
PS80 micelles increases as the supersaturation level increases. At a low drug concentration, i.e., within crystalline solubility limit, the drug molecule may interact with
the micelle at the micelle-water interface. As the supersaturation ratio increases,
E2 molecules preferably reside in the palisade region of PS80 micelles. The size of
micelles increases as more drug molecules are packed inside the micelles. When the
supersaturation level reaches the amorphous solubility limit, i.e., SR = 3.5 in this
case, no further increase of E2 solubilization in PS80 micelles is observed. In previous
work, the theoretically predicted number of E2 molecules per PS80 micelle increases
from 1-2 at the crystalline solubility limit up to 5-6 at the maximum supersaturation
level of SR = 3.5. This theoretical calculation is based on the assumption of a selfassembly of sixty PS80 molecules per micelle, as reported in literature [253, 275]. No
evidence of E2 in the hydrophobic core is seen even at high supersaturation levels,
and it is unlikely to be found in the hydrophobic core due to its polar characteris-
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Increasing SR

Figure 5.9: (A) Interaction model of Estradiol supersaturation in PS80 where Estradiol is encapsulated in the palisade layer of PS80 micelles. (B) Schematic representation showing an increase in micellar size at a higher supersaturation level.
tics. A previous study has suggested that polar drug danazol may be predominantly
solubilized in the palisade layer of ionic surfactant micelles [274]. Flurbiprofen was
also found to accumulate within the palisade layer of the PS20 micelles. Indulkar
et al. observed that drug molecule atazanavir is mostly solubilized in the palisade
region of micelles when the concentration is between the crystalline solubility limit
and low levels of supersaturation, whereas at high supersaturation these molecules
occupy both the core and palisade [276].
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5.5

Pharmaceutical Implications

The spectroscopic techniques developed in this paper serve as an accurate determination of the interactions between a model API and an encapsulating species. The
insights gained from the analysis of interactions between the API and the encapsulating species can glean some information on the stability and release of the therapeutic
payload. For a large degree of encapsulating formulations (i.e., micelles [277, 278, 279],
cyclodextrins [280, 281], flash nanoprecipitates [282, 283]), a large emphasis placed
on selecting appropriate amphiphilic molecules to stabilize the therapeutic payload.
Often, selecting an appropriate amphiphile is an art rather than a deliberate selection due to known interactions between the API and the amphiphilic molecule. The
stability and release of the API are dependent on the drug-carrier interactions [284].
Therefore, NMR provides a high-resolution technique to understand, at a molecular level, what types of interactions may be occurring and how to potentially tune
those interaction sites to achieve a more desirable stability and release profile. More
specifically, through this work, a greater understanding of an API’s encapsulation
effects on the overall structure of a model micelle was explored. This work highlights
a directly proportional effect of API encapsulation to micelle size. In cases where
the API is a poorly water-soluble drug, the systemic absorption of the API is often
limited by its diffusion through the aqueous boundary layer (ABL) within the small
intestinal lumen. Several papers have reported the benefits in permeability gained
from the encapsulation of the API in nano-scale encapsulating species due to the
combined diffusivity of freely-solubilized drug and encapsulated drugs in nano-scale
species [86, 84, 3, 80]. However, it is important to note that the benefits on the
permeability of ABL-limited APIs due to particle-drifting are largely seen when the
encapsulating species are smaller than 50 nm. Therefore, small changes in size (1-5
nm) will significantly impact the particle drifting observed. In the system explored
within this paper, diffusion measurements indicated an increase in micelle size of
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4nm, which corresponds to an increase of approximately 150 % relative to the size of
the micelle at the lowest encapsulation observed. Therefore, in cases where the ABL
may be a limiting barrier, it is important to consider the effects of the API encapsulation on the structure of micelles and how that may impact the absorption observed.
Overall, development scientists may benefit from an understanding between the API
and the encapsulating species. These interactions will dictate the stability, release,
and overall absorption of the API in-vivo. Although the work demonstrated in this
study was conducted using a small molecule API, one could also extend the methods
described in this paper to biologic therapeutics and other large molecules.
5.6

Conclusions

The interaction of hydrophobic drugs and surfactant micelles is particularly important
to the solubilizing capacity of surfactants. In this study, the intermolecular interactions, location, and kinetic properties of E2 in PS80 micelles were investigated using
high-resolution NMR methods to probe solubilization mechanisms at a molecular
level. It was found that PS80 micelles can solubilize E2 up to its amorphous solubility limit. Beyond this limit, it is expected that a spinodal decomposition occurs
leading to the formation of phase-separated colloidal particles. Using 1D 1H NMR,
chemical shift differences of E2 upon encapsulation were identified and the extent of
shifting was found to be proportional to the degree of supersaturation. Moreover, a
molecular-level analysis of the locus and the solubilizing mechanism of E2 in PS80
micelles was probed using 1D and 2D NOESY NMR measurements. NOE measurements suggested that E2 is localized within the palisade layer of PS80 micelles due to
the formation of hydrogen-bonding interactions between the terminal hydroxyl group
of E2 and the carbonyl group of PS80. Furthermore, using diffusion NMR methods,
it was observed that PS80 micelles increase in size with increasing amounts of E2
encapsulation. Relaxation measurements suggested a decrease in E2 mobility within
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micelles as more E2 molecules are incorporated into the micelle’s palisade layer. The
observations from this study provides a molecular-level understanding of the solubilizing mechanism of a model hydrophobic drug within a model micelles system. The
high-resolution NMR methods demonstrated within this paper can be adapted and
translated to different systems for the evaluation of drug solubilization and supersaturation in complex media where solubilizing materials are present.
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Chapter 6
Probing the Influence of Mucin on the Thermodynamic Activity of
Several Poorly Water-Soluble Compounds

6.1

Introduction

With the looming prevalence of poorly-soluble and highly lipophilic compounds classified as Biopharmaceutics Classification System (BCS) Class II compounds emerging as novel therapeutic entities [6, 7], the generation of supersaturated concentrations of drug in the gastrointestinal (GI) tract to increase drug absorption has garnered significant interest. Formulation techniques such as the use of solid dispersions [24, 25, 26] and lipid-based drug-delivery systems [285, 286, 287] have become
common avenues to generate supersaturated concentrations of active pharmaceutical
ingredients (APIs) into the GI fluid. However, the generation of drug concentrations
that exceeds the equilibrium solubility (i.e., supersaturation) is thermodynamically
unfavored, and one risks precipitation which can lead to compromised absorption
[24, 288]. Often, polymeric precipitation inhibitors such as hydroxypropyl methylcellulose (HPMC) and polyvinylpyrrolidone (PVP) are employed to stabilize drug
supersaturation in the GI tract such that the driving force for absorption is maximized [289, 290, 68, 67, 291, 285]. Although polymers have been well known to
stabilize supersaturated solutions, the mechanisms of action of such polymers are not
fully understood. Several studies have highlighted the ability of several polymers to
alter the surface tension and viscosity of aqueous media, which in turn impact the
rate of nucleation [63, 64]. More recent studies have highlighted the ability of several
polymers to adsorb onto growing crystal surfaces and consequently block the available
sites of integration within the crystal lattice [68, 69, 292]. Furthermore, several polymers have been observed to form complexes with drug molecules in solution, reducing
thermodynamic drug activity and, consequently, the driving force for and permeation
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[293, 294]. Many authors suggest that the formation of intermolecular interactions is
critical for stabilizing supersaturation[295, 296, 297].
Considering these polymers’ proposed mechanisms of action, it is possible that
mucin, the main component of mucus lining the length of the gastrointestinal (GI)
tract, may also stabilize drug supersaturation. Figure 6.1 highlights a schematic
for the structure of a generic mucin glycoprotein molecule. Mucin is defined as a
long polymeric glycoprotein containing heavily O-glycosylated proline, threonine, and
serine-rich tandem repeats (PTS domains)[155]. The presence of negatively charged
glycosylated functional groups such as sialic acid and sulfonate groups have led some
to suggest mucin may interact with ionic molecules or molecules with hydrogenbond donor characteristics via electrostatic or hydrogen-bonding interactions [298,
299, 76]. Furthermore, within the mucin protein backbone exists non-glycosylated
domains, which in turn results in exposed hydrophobic residues which may interact
with hydrophobic molecules via hydrophobic interactions [4].
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Figure 6.1: Generic structure of the mucin glycoprotein with the types of interactions
possible with specific residues on the mucin structure. Adapted from Ref. [4]
Although mucin is commonly localized to the gastrointestinal walls and other sur148

faces exposed to the environment, it is argued that a significant amount of mucin
can be found in the intestinal fluids due to the high turnover rate of the intestinal
mucus lining (47-270 minutes) as determined in rats [156]. In a study evaluating the
retention times of a series of 25 drug compounds through a covalently-immobilized
mucin chromatographic column, a quantitative structure-property relationship was
developed highlighting the critical characteristics of compounds that were retained
for longer times within the column. The authors found that the compounds retained longer in the mucin-immobilized column were those with more hydrophobic
and hydrogen-bond donor characteristics [300]. This result poses interesting implications for specific drug products in which the active pharmaceutical ingredient is
poorly soluble, as the results suggest that poorly soluble compounds are more likely
to interact with mucin. Interestingly, Yeap et al. examined the desupersaturation
profiles of carvedilol and piroxicam in the presence of mucin and observed that mucin
significantly prolongs the supersaturation of both drugs [157].
There has been a shortage of literature evaluating the interactions of mucin with
poorly soluble compounds. Only recently have researchers begun to explore the properties of mucin as a crystallization inhibitor. Similar to polymers, the mechanism by
which mucin stabilizes supersaturation is poorly understood. However, Butnarasu
et al. identified the complexation of mucin with several model lipophilic compounds
using fluorescence and UV-vis spectroscopic techniques. Their results found, through
the examination of binding energies, that the lipophilic molecules established weak
intermolecular interactions with mucin [4]. These results suggest that the ability of
mucin to stabilize supersaturated solutions may stem from mucin’s ability to form
complexes in solution. As a result of complexation, the thermodynamic activity of
the supersaturated solute is decreased, effectively reducing the driving force for crystallization. Although supersaturation may be stabilized, the reduction of thermodynamic drug activity may negatively impact drug absorption across the GI epithelium,
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as the thermodynamic activity drives the flux across a membrane [91]. Therefore,
it becomes crucial to understand how mucin may stabilize supersaturated solutions
against crystallization and whether or not that may impact the in-vivo absorption.
By understanding the underlying mechanisms, formulators can take advantage of the
naturally abundant mucin and accurately predict the in-vivo performance of orally
dosed drug products.
This study aims to examine the impact of mucin on the thermodynamic activity
of several model drug compounds in solution. This examination is conducted using
diffusion cells to indirectly evaluate thermodynamic activity through the observed
flux profiles across an artificial membrane. The model drug compounds used within
this study are structurally diverse and represent a range of lipophilicity.
6.2
6.2.1

Materials and Methods
Materials

17β-Estradiol (E2) and Mucin from porcine stomach (PGM type III, 0.5-1.5 % bound
sialic acid, partially purified powder) were purchased from Sigma-Aldrich (St. Louis,
MO). Acetonitrile, methanol, potassium dihydrogen phosphate, and potassium phosphate dibasic were supplied by VWR International (Radnor, PA). Nifedipine was
obtained from TCI America (Shirley, NY). Bicalutamide was purchased from BOC
Sciences (Portland, OR) Dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific (Fair Lawn, NJ). Hydroxypropyl methylcellulose (HPMC) K4M grade was
provided by Colorcon (West Point, PA). Deionized water was obtained from a MilliQ
water purification device (Milli-Q Synthesis, Millipore, Bedford, MA) and filtered
through a 0.22 µm filter (Millipak 40, Millipore, Bedford, MA) before use. Polytetrafluoroethylene (PTFE) syringe filters with a diameter of 13 mm (0.22 µm pore
size) were purchased from Tisch Scientific (Cleves, OH). Regenerated cellulose dialysis membrane with 6-8 kDa molecular weight cutoff (MWCO) and 70 µm thickness
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was obtained from Spectrum Laboratories (Rancho Dominguez, CA). Membranes
were soaked in deionized water overnight, prior to use in flux experiments. All other
materials were used as received.
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Figure 6.2: Molecular structures of (a) 17β-estradiol, (b) nifedipine, (c) bicalutamide,
and (d) Hydroxypropyl methylcellulose (HPMC)

6.2.2

Crystalline Solubility Measurements

The crystalline solubilities of the model drug compounds 17β-estradiol, nifedipine,
and bicalutamide were determined by placing an excess of crystalline drug into a glass
vial containing 20 mM potassium phosphate buffer at pH = 6.8. The mixtures were
agitated using a vial rotator in an incubator at 37°C for 72 hours. The equilibrated
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suspensions were filtered through a 0.22 µm syringe filter to remove excess undissolved
crystalline material. The syringe filter was saturated by discarding the first 3 mL of
the filtrate, and samples were collected following filter saturation. 200µL of the filtrate
was diluted with an equal volume of the mobile phase to minimize any crystallization
post-sampling.
The concentration of the drugs in samples was determined using a Dionex Ultimate 3000 high-performance liquid chromatography (HPLC) system equipped with a
photodiode array (Thermo Fisher Scientific, Waltham, MA). An ODS-2 Hypersil C18
column (4.6 mm internal diameter, 150 mm length, 5 µm particle size; Thermo Fisher
Scientific, Waltham, MA) equilibrated at 25 °C was used for all compounds. The determination of drug concentrations was conducted utilizing different chromatographic
methods. 17β-estradiol concentrations were determined using a mobile phase composed of acetonitrile and water in a 55:45 v/v ratio was pumped isocratically at a flow
rate of 1 mL/min following the injection of 20 µL of sample. Peaks associated with
17β-estradiol were detected using a 224 nm detection wavelength at a retention time
of approximately 3 minutes. A calibration curve (R2 = 0.999) between 0.25 µg/mL
and 30 µg/mL was developed to determine 17β-estradiol concentration in solution.
Quantification of nifedipine concentrations was conducted with a mobile phase composed of acetonitrile, methanol and water in a 25:25:50 v/v ratio. The mobile phase
was pumped isocratically at a 1 mL/min flow rate following the injection of 10 µL of
sample. Nifedipine detection was conducted at 254 nm, and peaks were observed at
about 6.5 min. A calibration curve (R2 = 0.998) between 0.625 µg/mL and 10 µg/mL
was developed for nifedipine quantification. The concentrations of bicalutamide in
solution were quantified using a mobile phase composed of acetonitrile and water in
a 70:30 v/v ratio. Bicalutamide detection was conducted using a 254 nm detection
wavelength, and peaks were observed at 2.8 min. A calibration curve (R2 = 0.990)
between 0.25 µg/mL and 100 µg/mL was developed for bicalutamide quantification.
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All solubility measurements were performed in triplicate.
6.2.3

Amorphous Solubility Determination

The experimental amorphous solubility of 17β-estradiol was determined using extinction measurements at a non-absorbing wavelength. A concentrated stock solution of
17β-estradiol was prepared by dissolving 17β-estradiol in DMSO. A Cole-Parmer 96well plate (Vernon Hills, IL) was utilized to develop an amorphous solubility assay. A
horizontal group of 12 wells were filled with 20 mM potassium phosphate buffer (pH
= 6.8) containing 100 µg/mL of HPMC. Estradiol was introduced via solvent-shift
using a concentrated stock solution to yield a gradient of concentration across the 96well plate ranging from 0 to 27.5 µg/mL of 17β-estradiol. The 96-well plate was then
placed into a Synergy H1 Hybrid Multi-Mode plate reader (BioTek, Winooski, VT)
and equilibrated at 37 °/C for 5 min. Following thermal equilibration, the absorbance
is evaluated at 700 nm.
The experimental amorphous solubility of bicalutamide was evaluated using fluorescence spectroscopy. Both pyrene and 4-Di-2-ASP were used as fluorescent dyes for
the detection of phases separation of bicalutamide from solution. Stock solutions of
the dyes were prepared in methanol and added to 20 mM potassium phosphate buffer
(pH = 6.8) containing 100 µg/mL of HPMC to yield 0.4 µg/mL solutions of the dyes.
Similar to the amorphous solubility determination of 17β-estradiol, an amorphous
solubility assay was developed using Corning™ 96-Well solid black polystyrene microplates (Corning, NY). The buffer solutions containing fluorescent dyes were placed
in wells, and aliquots of a concentrated stock solution of bicalutamide in DMSO were
added to wells to generate a gradient of bicalutamide concentration ranging from 0 to
100 µg/mL. The 96-well plate was then placed into the plate reader and equilibrated
at 37 °C for 5 min. Following thermal equilibration, the fluorescence spectrum was
obtained at each well. Excitation wavelengths of 332 and 488 nm were used for pyrene
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and 4-Di-2-ASP, respectively. A shift in the maximum emission wavelength (λmax ) in
the case of the 4-Di-2-ASP dye systems indicates the formation of a lipophilic phase
within the media. In the case of pyrene dyes, a change in the peak ratio between the
first (I1 at 373 nm) and third ( I3 at 383 nm) emission peaks indicate the formation
of a lipophilic phase in the media. All solubility measurements were performed in
triplicate.
6.2.4

Nuclear Magnetic Resonance (NMR) Sample Preparation

Monitoring molecularly dissolved drug is complex, especially in the presence of particulate matter. Particulate matter may scatter light in traditional concentration
monitoring techniques such as UV spectroscopy, giving erroneous results [301]. Ionselective electrodes have been used to monitor concentration in the presence of particulates [157, 302, 303]. Still, it requires an ionizable analyte with a pKa near the
physiological pH range, limiting its applicability. Recently, 1 H NMR, coupled with
modern instrumentation and analysis techniques, has been used to quantify molecularly dissolved drug in aqueous buffers in the presence of particulates [304, 305],
which allows for a broader range of compounds to be analyzed as well as additional
information regarding the physical interactions between solution components.
Solutions containing 90% 20 mM potassium phosphate buffer at a pH = 6.8 and
10% D2 O were prepared as media for supersaturation studies. The presence of 10%
D2 O allows for the NMR spectrometer to achieve a deuterium lock which allows for
the compensation of any drift in the strength of the superconducting magnet’s field.
For the preparation of nifedipine calibration standards, 100 µg/mL was dissolved in
the 90:10 buffer and D2 O media. The addition of HPMC allowed for the inhibition
of crystallization and allowed for the analysis of stable supersaturated solutions of
nifedipine. Nifedipine calibration standards were prepared using a concentrated 10
mg/mL stock solution of nifedipine dissolved in DMSO using a solvent-shift method.
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The concentrations of the prepared calibration standards were 10, 25, 50, and 75
µg/mL, and in all standards, the concentration of the organic solvent, DMSO, was
less than 1%. 0.5 mL of the calibration samples were placed in Wilmad Precision
NMR tubes (Vineland, NJ) for evaluation via NMR.
Supersaturation experiments were evaluated in the 90:10 buffer and D2 O media.
Mucin was introduced to the media and sonicated for 2-5 min to yield opaque solutions containing 1 mg/mL and 4 mg/mL of mucin. The media was placed in 18 mL
glass vials and thermally equilibrated to 37 °C using a mineral oil bath. The desupersaturation experiment commenced following the addition of the stock solution to the
buffer to yield a 75 µg/mL solution of nifedipine. 0.5 mL samples were taken at 15,
30, 45, 60, 75, 90, 150, 175, 190, and 250 min and placed into NMR tubes and rapidly
analyzed via NMR. All desupersaturation experiments were performed in triplicate.
6.2.5

Quantification of Nifedipine Supersaturation via 1 H NMR

NMR experiments were performed on an Agilent DD2 14.1 Tesla NMR spectrometer
(Agilent Technologies, CA) equipped with a 3 mm inverse triple resonance HCN
cryoprobe. 1D 1 H spectra with water excitation sculpting were acquired at 37 °C
with double pulsed field gradient spin-echoes on the HOD resonance frequency to
suppress water signal. A total of 9 ppm spectral width corresponding to 10776 data
points were acquired with 2 s acquisition time, 196 transients, and 1 s recycle delay
time. The spectra were analyzed with the MNova software package(ver. 12.0.4,
Mestrelab Research, S.L., Spain) with reference to TSP protons at 0 ppm.
The quantification of NMR concentrations was achieved by evaluating areas of
peaks at 7.6 ppm corresponding to two aromatic protons on the substituted benzene
ring of nifedipine. A calibration curve (R2 = 0.9898) was developed and used to
quantify nifedipine in supersaturated solutions by comparing the area of the peak at
7.6 ppm. The peak areas were determined using the MNova software package.
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6.2.6

In-situ UV Spectroscopy

The desupersaturation profiles of nifedipine in the absence of mucin were evaluated
using a microDiss Profiler (Pion Inc., Billerica, MA). Fiber optic ultraviolet (UV)
probes were placed in glass vials containing 18 mL of 20 mM Phosphate buffer (pH
= 6.8) and stirred with cross stir bars. Nifedipine was introduced via solvent-shift
using a 10 mg/mL stock solution containing nifedipine dissolved in DMSO. Quantification of nifedipine was conducted at an absorbing wavelength of 224nm, where a
calibration curve (R2 = 0.998) ranging from 0 to 75 µg/mL was developed using the
sequential addition of the stock solution up until the amorphous solubility limit. The
desupersaturation experiment commenced following the addition of the stock solution
to the buffer to yield a 75 µg/mL solution of nifedipine. The desupersaturation of
nifedipine was monitored for 4 hours, and triplicate experiments were performed.
6.2.7

Diffusion Cell Experiments

The flux of model compounds across a model membrane was evaluated using a horizontal diffusion cell setup (PermeGear, Inc., Hellertown, PA) of 30 mL volume (each
compartment) and a 32 mm orifice diameter. A regenerated cellulose membrane
(MWCO 6-8 kDa) was inserted between the two diffusion cells, coupled with two
Teflon spacer rings on either side of the membrane to ensure adequate sealing of the
system. The surface area of the exposed membrane was 8.042 cm2 . The donor and
acceptor compartments were filled with 30 mL of 20 mM phosphate-buffered media
(pH=6.8). The media within each cell was stirred using a Double Spinfin® alnico stir
bar at 300 RPM and maintained at 37°C. The aqueous boundary layer (ABL) is not
expected to be a significant permeation barrier as the 300 RPM stirring condition
has been shown to sufficiently reduce any impact the ABL may have on Pef f . All
media used for flux experiments in standard conditions contained 100 µg/mL HPMC
to stabilize against crystallization throughout the time-course of the experiment. For
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experiments at SR = 1 (i.e., suspension), the donor compartment contained an excess of crystalline drug, whereas the acceptor compartment was filled with a blank
buffered solution. In experiments evaluating the impact of mucin on flux, the donor
compartment was filled with 30 mL of 20 mM phosphate-buffered media (pH=6.8)
containing 1 mg/mL mucin. Mucin is added only in the donor compartment to avoid
any potential complexation in the acceptor compartment, complicating sample preparation and concentration determinations. A solvent shift approach, where an aliquot
of a highly concentrated stock solution of the drug of interest was transferred to the
aqueous buffered solution at t = 0, was used to generate different supersaturation ratios (SR) conditions. The DMSO content in the donor compartment was kept below
1% v/v.
A 200 µL sample was taken from the acceptor compartment of the side-by-side
diffusion cells every 30 min after the start of the experiment for 6 hours and then
diluted with an equal volume of mobile phase to minimize crystallization after sampling. Samples were then analyzed via HPLC using the same method described for
crystalline solubility determination. All diffusion cell experiments were done in triplicate.
6.3

Results and Discussion

6.3.1

Crystalline and Amorphous Solubilities of Model Drug Compounds

The measured crystalline solubility values of 17β-estradiol, nifedpine, and bicalutamide determined at 37 °C in 20 mM phosphate buffer (pH = 6.8) were found to be
2.20 ± 0.03, 8.76 ± 0.05, and 5.9 ± 0.4 µg/mL, respectively.
Liquid-liquid phase separation was evaluated for 17β-estradiol by examining the
scattering of light due to the formation of colloidal particles as a result of spinodal decomposition at high degrees of supersaturation. Figure 6.3 is a plot of the absorbance
of 700 nm light as a function of 17β-estradiol concentration. Previous work from this
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group has shown the amorphous solubility limit to be approximately 14 µg/mL [55].
However, that was conducted by continuously adding aliquots of a concentrated stock
solution into a single vial. As utilized in this work, the use of a 96-well plate aids
in the acceleration of amorphous solubility determination and reduces the times in
which a solution remains in a thermodynamically unstable supersaturated state. The
amorphous solubility determined from the profile in Figure 6.3 is 12.5 ± 1.1 µg/mL,
which is derived from the onset of a sharp increase in absorbance due to the scattering
of light by colloidal particles formed from the spinodal decomposition of the solution
into drug rich and drug-lean phases.
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Figure 6.3: Extinction measurements evaluating the evolution of drug-rich particles
in solution with increasing concentrations of 17β-estradiol. Absorbance was measured
at a 700 nm wavelength. The solid lines are added as visual aids in the detection of
the sharp increase in absorbance. The vertical dotted line is added to represent the
start of sharp increase of absorbance.
The onset of spinodal decomposition for bicalutamide was evaluated with the use
of fluorescent dyes. The emission spectra of fluorescent dyes can change depending
on the local environment in which the dyes are found [306]. Solvent polarity has been
shown to significantly impact the energy gaps between the excited and ground states
of fluorophores due to dipole interactions [307]. Dipole interactions in polar solvents,
such as aqueous media can reduce the energy gap between the excited and ground
states of a fluorophore [308]. Therefore, if the fluorophore were to partition into a
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lipophilic environment that is less polar than the aqueous media, a blue shift in the
emission spectra is observed as dipole interactions no longer stabilize the excited state.
This phenomenon is true for 4-Di-2-ASP; however, the emission spectrum of pyrene
is more complex. In pyrene systems, polarity is probed by measuring changes in the
ratio of the intensities of the first (I1 at 373 nm) and the third peaks (I3 at 383 nm)
of the emission spectra, where the partitioning of pyrene into lipophilic environments
leads to a decrease in the ratio of the intensities of the two peaks [309].
Figures 6.4a & 6.4b show the results of the experiments evaluating the evolution
of drug-rich phases as a result of spinodal decomposition. Figure 6.4a shows the
maximum emission wavelength (λM ax ) of 4-Di-2-ASP as a function of bicalutamide
concentration. The onset of phase separation is marked by a blue-shift of λM ax
towards smaller wavelengths. The amorphous solubility of bicalutamide in the 4-Di2-ASP/ bicalutamide system was 50.4 ± 5.8. Figure 6.4b shows a plot of the ratio of
the intensities of the first and third peaks of the pyrene emission spectra ( II13 ) as a
function of bicalutamide concentration. The evolution of a drug-rich phase is marked
by a sharp decrease in ( II13 ), which was observed to be at 42.5 ± 6.1. The amorphous
solubility limits determined for bicalutamide in the 4-Di-2-ASP and pyrene systems
are within error and agree.
The amorphous solubility limit of nifedipine is taken from literature, where it was
determined to be 72.86±5.66 at 37 °C in 50 mM phosphate buffer (pH=6.8) [310]. The
determination of nifedipine phase separation was performed using a similar method
as that used for 17β-estradiol.
The crystalline and amorphous solubilities of the model drug compounds used
within this study are highlighted in Table 6.1. Table 6.1 also highlights the maximum
supersaturation possible (SRM ax ), which is described as the ratio of the amorphous
and crystalline solubilities. The characterization of the crystalline and amorphous
solubilities allows for identifying the ranges of supersaturation possible within the
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Figure 6.4: Fluorescence measurements evaluating the changes of the a) maximum
emission wavelength (λM ax ) in the 4-Di-2-ASP system and b) the II31 ratio in the
pyrene containing system. The solid lines are added as visual aids in the detection
of the sharp decreases in either λM ax or II13 . The vertical dotted lines are added to
represent the onset of phase separation.
media.
Table 6.1: Measured crystalline and amorphous solubility values of model drug compounds in 20 mM potassium phosphate buffer (pH = 6.8) at 37 °C

API

Crystalline Solubility
(µg/mL)

Amorphous Solubility
(µg/mL)

SRM ax

17β-Estradiol

2.20 ± 0.03

12.5 ± 1.1

5.7

Nifedipine

8.76 ± 0.05

72.85 ± 5.66a

8.3

Bicalutamide

5.9 ± 0.4

50.4 ± 5.8

8.54

Error indicates one standard deviation (n = 3)
a Value obtained from Ref. [310]

6.3.2

NMR Evaluation of Supersaturation Stability

The use of solution 1 H NMR as a quantification technique of drug concentrations in
solutions containing mucin aggregates was explored with nifedipine as a model drug
compound. The large supersaturation window of nifedipine, ranging from 10 - 75
µg/mL, made nifedipine an ideal model compound for quantification via NMR. Due
to the poor-solubility characteristics of BCS Class II compounds, the NMR detection
160

of drug molecules in such dilute conditions becomes difficult even with some of the
higher resolution spectrometers. Fortunately, peaks attributed to nifedipine were
detected within its supersaturation range in aqueous media.
The desupersaturation profiles of nifedipine following the introduction of an aliquot
of a highly concentrated stock solution yielding a 75 µg/mL solution of nifedipine are
shown in Figure 6.5. The desupersaturation profiles in the presence of 1 and 4 mg/mL
of mucin were collected using NMR spectroscopy, while the desupersaturation profile in buffer was collected using in-situ fiber-optic UV probes. According to Figure
6.5, the desupersaturation of nifedipine in the absence of mucin was very rapid, occurring within 6 minutes. In contrast, mucin’s presence in solution helped stabilize
the supersaturated solution for approximately 60 minutes before a rapid decrease
in nifedipine concentration was observed. When comparing the times to which this
rapid decrease in concentration occurs, a 10-fold increase in supersaturation stability
time is observed in the presence of mucin. An increase in mucin concentration from
1 to 4 mg/mL did not serve to prolong supersaturation. However, a decrease in the
initial concentrations before the steep decline in concentration is observed when increasing mucin concentration. Although the cause of this discrepancy is unknown,
it may result from the binding of free nifedipine molecules with mucin, which can
effectively reduce the amount of nifedipine detected via NMR spectroscopy. Another
explanation for the difference in profiles between the 1 and 4 mg/mL mucin systems
could be the error caused by precipitation within the NMR vial during the collection
of spectra. The collection of spectra using 196 transients with a 2 s acquisition time
and a 1 s recycle delay resulted in data being collected over a 10 min period for each
sample. This time would allow for the crystallization of the supersaturated solutions
within the NMR tubes, reducing nifedipine concentration in solution.
It is also worth noting that in all systems in Figure 6.5, the concentration reaches
a slightly greater plateau than nifedipine’s crystal solubility. This phenomenon has
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been reported in the literature previously, and it is believed to be a result of the rapid
crystallization process. Some high-energy sites are still present on crystal surfaces,
and over time through redissolution and recrystallization, the system will equilibrate
at the crystalline solubility.
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Figure 6.5: Desupersaturation profile of nifedipine in buffer ( ), 1 mg/mL mucin ( ),
and 4 mg/mL mucin ( ). The desupersaturation profile in buffer is measured using
in-situ UV probes, while the other two datasets are measured using 1 H NMR. The
amorphous solubility limit is represented by the horizontal line ( ). The crystalline
solubility limit is represented by the horizontal line ( ).
The results highlighted in Figure 6.5 indicate the presence of an interaction between nifedipine and mucin in solution, which can inhibit crystallization. This result
agrees with observations by Yeap et al. where the supersaturation of carvedilol and
piroxicam is prolonged in the presence of mucin relative to buffer. A concentrationdependent effect on supersaturation stability is observed with mucin, which was not
observed in the nifedipine study observed in Figure 6.5. There is limited literature
examining the mechanism for the stability of supersaturated solutions in the presence
of mucin. As suggested by the data in Figure 6.5, it is possible that binding of free
nifedipine molecules to mucin may help to stabilize supersaturation by reducing the
thermodynamic activity of nifedipine in solution. With the reduction of the thermo162

dynamic activity, the driving force for crystallization is diminished, and the kinetics
for nucleation is reduced.
6.3.3

Flux Measurements

To probe the effects of mucin on the thermodynamic activity on several model drug
compounds, a flux analysis is conducted. The use of diffusion cells as a model to
describe the permeation phenomenon requires adherence to the following assumptions
[3]:
1. Drug transport through the aqueous boundary layer (ABL) and the membrane
is described by Fick’s laws of diffusion.
2. The diffusion coefficient of the drug is not a function of concentration in the
medium explored.
3. Drug transport via convection (i.e., bulk fluid flow) across the membrane can
be neglected for the hydrodynamic conditions studied.
4. The ABL is a theoretical boundary representing the development of a concentration gradient near the membrane surface due to fast membrane transport
relative to solution transport.
5. The flux observed is characterized by unidirectional transport across each barrier in series from the well-mixed, bulk aqueous donor medium to the receiver
medium.
6. The instantaneous concentration profile within each diffusion layer resembles a
steady-state (pseudo steady-state approximation).
7. The thickness of each diffusion layer is constant with time for a given experiment.
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8. The partitioning of drug into the membrane is unaffected by medium components.
9. The concentration of drug in the receiver medium is much less than that in the
donor medium, leading to a constant concentration gradient throughout the
course of the experiment.
10. Colloid-associated drug is in equilibrium with the unbound drug in solution.
11. The integrity of the membrane is conserved for the duration of the experiment.
If the listed assumptions are valid, the absorption profiles of model active pharmaceutical ingredients (APIs) can be mathematically described by the following version
of Fick’s first law (Eq. 2).

J=

V dC
∗
= Pef f ∗ αD,solution
A dt

(6.1)

The rate of drug absorption, represented as flux (J), is expressed as a product of the
effective permeability (Pef f ) and the thermodynamic activity of the drug in solution
(aD,solution ). The volume (V), membrane surface area (A), and the change in drug
concentration as a function of time ( dC
dt ) can be controlled or measured experimentally
to calculate the flux across a membrane.
The flux behavior of an API can be collected in standard conditions, where the
activity of the drug is equivalent to the concentration of the API in solution (i.e.,
αAP I = CAP I ). By characterizing the flux at a series of donor compartment concentrations, a calibration curve can be developed correlating flux to the drug concentration
in the donor compartment. Once the flux in standard conditions is characterized,
it is possible to compare the flux of API in solutions containing an additive. If the
additive binds to the API, the activity of the API decreases, and a lower than expected flux would be observed for a given amount dosed in the donor compartment
164

of the diffusion cell setup. The concentrations of mucin used within the study are
sufficiently dilute and should not significantly impact the hydrodynamic conditions
within the horizontal diffusion cells.
The mass transport rates of the API across the cellulosic membranes were calculated from the slopes of the linear regions of the concentration profiles of the API
in the acceptor compartment. The mass transport rates are volume-corrected due to
decreases in the receiver compartment volume due to sampling. The flux values are
calculated through the normalization of mass transport rates with the surface area of
the membrane to give values of units (µg/min/cm2 ).
The concentration profiles of the model drug compounds are highlighted in Figures
6.6-6.8. For all of the concentration profiles in Figures 6.6-6.8, the concentration of
API in the donor compartment is reported as a supersaturation ratio (SR). The
supersaturation ratio term is defined as the ratio between the crystalline solubility of
the API over the concentration of API in solution.

SR =

CAP I
CAP I,eq

(6.2)

Figure 6.6 highlights the dependence of the mass transport rates on the concentration of 17β-estradiol in the donor compartment. A linear increase in mass transport
is observed with increasing 17β-estradiol in the donor compartment. A maximum
mass transport rate is observed at an SR value of 6, where equivalent slopes in the
concentration profiles are observed in the SR = 6 & SR = 10 systems. This maximum
corresponds well to the SRM ax value calculated in Table 6.1 using the experimentally
determined crystalline and amorphous solubilities. It is important to note that 100
µg/mL of HPMC is added to inhibit crystallization of the supersaturated solutions
throughout the time course of the experiment. A linear flux profile is observed when
the flux of 17β-estradiol at an SR = 10 is evaluated in the presence of mucin and the
absence of HPMC. The linearity of the flux profile indicates the lack of crystalliza165

tion throughout the 6-hour time course of the experiment and the ability of mucin
to stabilize supersaturated solutions of 17β-estradiol. The flux of 17β-estradiol was
also evaluated in the presence of both mucin and HPMC, and a linear flux profile was
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Figure 6.6: Concentration profiles of 17β-estradiol in the acceptor compartments
following the generation of different degrees of supersaturation (SR) in the donor
compartment of horizontal diffusion cells.
The concentration profiles of nifedipine in the acceptor compartment of the diffusion cell setup are shown in Figure 6.7. A linear increase in mass transport is
observed with increasing nifedipine concentration in the donor compartment. The
loss of linearity of the concentration profiles is observed at the higher SR values of
nifedipine. Similar to the 17β-estradiol systems, HPMC was used as a crystallization
inhibitor; however, in the SR = 8 systems, deviations from linearity are observed at
the 3-hour mark, indicating the strong propensity of nifedipine to crystallize from
supersaturated solutions. In the system evaluating flux of nifedipine at an SR = 8
in the presence of mucin and absence of HPMC, mucin was unable to stabilize the
supersaturated solution of nifedipine for the time course of the experiment, as the
concentration deviated from linearity at approximately 1 hour following dosing. This
observation corresponds well to the desupersaturation profile in Figure 6.5, which was
conducted at a similar SR value. The loss of linearity is attributed to the crystallization of nifedipine in the donor compartment at higher degrees of supersaturation. In
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the systems where linearity is lost, the donor compartments were visually observed

Nifedipine Concentration (ug/mL)

to be opaque, and as time progressed, solid particles were visibly observed.
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Figure 6.7: Concentration profiles of nifedipine in the acceptor compartments following the generation of different degrees of supersaturation (SR) in the donor compartment of horizontal diffusion cells.
Figure 6.8 highlights the concentration profiles of bicalutamide, at various SR
values, in the acceptor compartment of the diffusion cell setup. The concentration
profiles were observed to be linear in all systems, and a linear increase in the mass
transport rates was observed with increasing SR values up to an SR = 10, where
no difference in the mass transport rate is observed between the SR = 10 & SR =
15 systems. Mucin was shown to sufficiently stabilize supersaturated solutions of

Bicalutamide Concentration (ug/mL)

bicalutamide at the amorphous solubility limit for the time course of the experiment.
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Figure 6.8: Concentration profiles of bicalutamide in the acceptor compartments
following the generation of different degrees of supersaturation (SR) in the donor
compartment of horizontal diffusion cells.
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The flux of the concentration profiles highlighted in Figures 6.6-6.8 were calculated
and plotted in Figures 6.9-6.11 as a function of concentration. The flux values were
calculated from the linear regions of the concentration profiles, and volume corrected
for decreasing donor compartment concentrations due to sampling.
The impact of mucin on the flux of 17β-estradiol can be visualized in Figure
6.9. The black plots highlight the expected linear relationship between observed
flux and the concentration within the donor compartment. The flux observed at the
amorphous solubility limit can not be exceeded. The inclusion of more API leads
to the enrichment of the drug-rich phase and does not lead to more solubilized drug
capable of crossing the membrane. This phenomenon is evident in the observation
that the flux in the SR = 10 condition is statistically equivalent to that observed at
the amorphous solubility limit. In the SR = 10 systems containing mucin, there is
no observable change in the flux and is within the range of error. The simultaneous
presence of mucin and HPMC also did not have an impact on the observed flux.
In Figure 6.10, the impact of mucin on the flux of nifedipine is highlighted. A
linear relationship between the supersaturation induced in the donor compartment is
observed from an SR of 1 to an SR of 8. Due to the deviation from linearity of the mass
transport rates, the flux was calculated from the linear portions of the concentration
profiles at earlier time points. A significant error in the flux is observed in the system
in the absence of HPMC and the presence of mucin. Therefore, it is difficult to
conclude whether or not mucin reduced the thermodynamic activity of nifedipine.
However, the flux is statistically equivalent in the SR = 8 system containing HPMC
and mucin to what is expected for the SR explored. The results in Figure 6.10 suggest
that mucin does not significantly impact the thermodynamic activity of nifedipine.
Similar to 17β-estradiol and nifedipine, the thermodynamic activity of bicalutamide is not significantly impacted by the presence of mucin in solution. According
to Figure 6.11, a linear relationship between the measured flux and SR is observed.
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Figure 6.9: Plot of the measured flux of 17β-estradiol versus the concentrations
generated in the donor compartment of the horizontal diffusion cells. The black
plots ( ) represent the flux calibration curve developed in standard conditions (i.e.
αAP I = CAP I ). The solid line ( ) represents the linear fit of the flux in standard
conditions, where the dashed line ( ) represents the 95% confidence intervals of the
linear fit. The colored plots represent the flux observed at an SR = 10 in the presence of HPMC ( ), the presence of mucin ( ), and the presence of mucin and HPMC
( ). The dotted horizontal line ( ) represents the maximum flux observable at the
amorphous solubility limit.
Beyond the amorphous solubility, the flux is expected to remain constant, which is
observed in the SR = 10 and SR = 15 systems. The presence of mucin in the SR = 10
and SR = 15 systems does not significantly reduce the observed flux. Therefore, it is
not expected that mucin reduces the thermodynamic activity of bicalutamide.
Overall, with the model compounds explored within this study, the presence of
mucin is not expected to significantly reduce the thermodynamic activities as the observed flux in the presence of mucin is similar to that observed in the absence of mucin.
The model compounds used in this study exhibit different chemical structures and
lipophilic character. All model compounds seemed to interact with mucin to stabilize
their respective supersaturated solutions, indicating the presence of some intermolecular interaction. Although mucin’s ability to stabilize supersaturated solutions does
not appear to result from reducing the thermodynamic drug activity via the forma169
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Figure 6.10: Plot of the measured flux of nifedipine versus the concentrations
generated in the donor compartment of the horizontal diffusion cells. The black
plots ( ) represent the flux calibration curve developed in standard conditions (i.e.
αAP I = CAP I ). The solid line ( ) represents the linear fit of the flux in standard
conditions, where the dashed line ( ) represents the 95% confidence intervals of the
linear fit. The colored plots represent the flux observed at an SR = 8 in the presence
of mucin ( ), and the presence of both mucin and HPMC ( ).
tion of mucin-API complexes, mucin may stabilize supersaturation through another
mechanism. Mucin may function as a nucleation inhibitor, stabilizing concentrated
drug-rich clusters against the organization of molecules into a crystal lattice. Another
possible explanation could be that mucin may adsorb onto growing crystal surfaces,
thereby inhibiting the integration of further molecules within the crystal lattice and
slowing down the kinetics for crystallization.
6.3.4

Pharmaceutical Implications

As oral administration is the most preferred dosing route for many drug products
[311], the potential interactions between mucin and APIs present an interesting phenomenon that must be accounted for to understand the in-vivo performance of products where supersaturation in the gastrointestinal (GI) fluids is generated. The entirety of the GI tract is lined with mucus which is consistently replaced reportedly
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Figure 6.11: Plot of the measured flux of bicalutamide versus the concentrations
generated in the donor compartment of the horizontal diffusion cells. The black
plots ( ) represent the flux calibration curve developed in standard conditions (i.e.
αAP I = CAP I ). The solid line ( ) represents the linear fit of the flux in standard
conditions, where the dashed line ( ) represents the 95% confidence intervals of the
linear fit. The colored plots represent the flux observed at an SR = 10 in the presence
of HPMC ( ) and presence of both HPMC and mucin ( ). The flux of bicalutamide
was also evaluated at an SR = 15 in the presence of HPMC ( ) and presence of both
HPMC and mucin ( ). The dotted horizontal line ( ) represents the maximum flux
observable at the amorphous solubility limit.
every 4-6 h [157, 312], indicating a significant quantity of mucin can be found within
GI fluids. Attempts to predict product performance utilizing in-vitro precipitation
methods often result in contradicting observations [115, 135], where the crystallization kinetics in in-vitro studies often significantly overestimates what is observed in
in-vivo systems. The apparent disconnect between in-vitro and in-vivo precipitation suggests the failure to account for a factor within in-vitro models which may
play a significant role within the in-vivo system. Studies have shown that the dissolution of supersaturating formulations can be highly dependent on the media used
[140, 141, 142]. The implications of endogenous materials such as bile acids and
phospholipids [143, 144, 74, 145, 66, 75], found natively in the intestinal fluids have
been studied and accounted for in commercial formulations of simulated GI fluids
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[146]. However, studies examining the impact of mucin on the performance of orally
dosed products are limited. By understanding how mucin may stabilize supersaturated solutions against crystallization, formulators can begin to use mucin, which is
found naturally within the GI tract, and accurately predict the in-vivo performance
of orally dose drug products.
6.4

Conclusions

This study demonstrates the lack of a significant impact of mucin on the solution
thermodynamic activity of several model drugs with varying chemical structures and
lipophilic character. Mucin was observed to stabilize supersaturation of all the model
drugs explored within this study; however, the mechanism by which mucin stabilizes
supersaturation has yet to be determined. An in-depth understanding of the potential impact of mucin on the stabilization of supersaturation may be necessary for the
prediction and interpretation of the in-vivo performance of supersaturating drug delivery systems. This study also highlights the use of 1 H NMR, coupled with modern
techniques such as solvent suppression and shimming, as an effective tool to monitor
concentrations of molecularly dissolved drug molecules in solution in the presence of
particulates and endogenous material. Compared to traditional techniques such as
UV spectroscopy, 1 H NMR avoids the scattering effects of sub-micron particles, which
can lead to artificial increases in concentration.
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